| Drug Name |
Drug Class |
Is Cardiotoxic |
Up/Down |
Pathway |
Enrichment p-value |
Enrichment rank |
Pathway F1 score AUC rank |
Cardiotoxicity Pathway |
Pathway Genes |
| verapamil |
Antiarrhythmic |
Yes |
Down |
Actin filament bundling and crosslinking |
0.04714737 |
22 |
NaN |
|
ACTN2;SYNPO;TAGLN |
| verapamil |
Antiarrhythmic |
Yes |
Down |
Actin polymerization |
0.042319189 |
20 |
NaN |
|
ABRA;ACTA1;ENAH;HSPB1 |
| verapamil |
Antiarrhythmic |
Yes |
Up |
Alternative complement pathway |
0.001694401 |
2 |
NaN |
|
C1S;C3 |
| verapamil |
Antiarrhythmic |
Yes |
Down |
Antigen presentation via MHC class I molecules |
0.037654174 |
17 |
NaN |
|
HLA-A;HLA-C |
| verapamil |
Antiarrhythmic |
Yes |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.014260416 |
10 |
NaN |
|
KCNIP2;KCNJ2 |
| verapamil |
Antiarrhythmic |
Yes |
Up |
Cellular cholesterol uptake and efflux |
0.012329314 |
7 |
NaN |
|
ABCA1;ABCG1 |
| verapamil |
Antiarrhythmic |
Yes |
Down |
Cholesterol synthesis |
0.023724425 |
13 |
NaN |
|
DHCR24;DHCR7;MSMO1 |
| verapamil |
Antiarrhythmic |
Yes |
Up |
Classical complement pathway |
0.003496783 |
3.5 |
NaN |
|
C1R;C1S |
| verapamil |
Antiarrhythmic |
Yes |
Down |
Collagen fibril organization by fibril-associated bridges |
0.013640012 |
10.5 |
NaN |
|
COL12A1;COL9A2 |
| verapamil |
Antiarrhythmic |
Yes |
Down |
Connection of muscle sarcomere to plasma membrane |
0.003151618 |
6 |
NaN |
|
DES;ILK;SYNM |
| verapamil |
Antiarrhythmic |
Yes |
Up |
Decorin synthesis |
0.013232181 |
8.5 |
NaN |
|
DCN |
| verapamil |
Antiarrhythmic |
Yes |
Down |
Epithelial intermediate filament dynamics |
0.001541535 |
5 |
NaN |
|
KRT19;KRT7;KRT8 |
| verapamil |
Antiarrhythmic |
Yes |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.003748527 |
5 |
NaN |
|
ADAMTS14;ADAMTS5;ADAMTS6 |
| verapamil |
Antiarrhythmic |
Yes |
Down |
Glycolysis and Gluconeogenesis |
2.90E-07 |
2 |
NaN |
|
ALDOA;ENO1;HK2;LDHA;PFKP;PGAM1;PGK1;TPI1 |
| verapamil |
Antiarrhythmic |
Yes |
Up |
G-protein coupled receptor signaling pathway |
0.028275372 |
12 |
NaN |
|
GRK5;RGS6 |
| verapamil |
Antiarrhythmic |
Yes |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.000989092 |
4 |
NaN |
|
JAK2;JUND |
| verapamil |
Antiarrhythmic |
Yes |
Down |
Growth differentiation factor receptor signaling |
0.024421416 |
14 |
NaN |
|
GDF11;GDF2 |
| verapamil |
Antiarrhythmic |
Yes |
Up |
Hemoglobin and myoglobin synthesis |
0.039176997 |
13.5 |
NaN |
|
MB |
| verapamil |
Antiarrhythmic |
Yes |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.039176997 |
13.5 |
NaN |
|
MME |
| verapamil |
Antiarrhythmic |
Yes |
Down |
Microtubule crosslinking and bundling |
0.013640012 |
10.5 |
NaN |
|
MAP2;MTCL1 |
| verapamil |
Antiarrhythmic |
Yes |
Down |
Microtubule polymerization |
0.013640012 |
10.5 |
NaN |
|
MAP4;TUBA1A |
| verapamil |
Antiarrhythmic |
Yes |
Down |
Myofibril formation |
0.037654174 |
17 |
NaN |
|
DES;XIRP1 |
| verapamil |
Antiarrhythmic |
Yes |
Down |
Natriuretic peptide receptor signaling |
0.013640012 |
10.5 |
NaN |
|
NPPA;NPPB |
| verapamil |
Antiarrhythmic |
Yes |
Up |
Platelet-derived growth factor receptor signaling |
0.008845574 |
6 |
NaN |
|
PDGFD;PDGFRA |
| verapamil |
Antiarrhythmic |
Yes |
Down |
Potassium transmembrane transport |
0.038420172 |
19 |
NaN |
|
ATP1A2;ATP1A3;FXYD1 |
| verapamil |
Antiarrhythmic |
Yes |
Down |
Progesterone receptor signaling |
0.03149259 |
15 |
NaN |
|
PGR |
| verapamil |
Antiarrhythmic |
Yes |
Down |
Restriction point |
0.037654174 |
17 |
NaN |
|
CCND2;CDKN1A |
| verapamil |
Antiarrhythmic |
Yes |
Up |
Roundabout signaling |
0.003496783 |
3.5 |
NaN |
|
ROBO1;ROBO2 |
| verapamil |
Antiarrhythmic |
Yes |
Up |
Semaphorin signaling |
0.001002962 |
1 |
NaN |
|
NRP2;PLXNC1;SEMA6A;SEMA6D |
| verapamil |
Antiarrhythmic |
Yes |
Down |
Serine and glycine metabolism |
0.045081089 |
21 |
NaN |
|
SHMT2;SLC1A5 |
| verapamil |
Antiarrhythmic |
Yes |
Up |
Serotonin inactivation |
0.026290423 |
11 |
NaN |
|
MAOA |
| verapamil |
Antiarrhythmic |
Yes |
Down |
Syndecan receptor signaling |
0.009285718 |
8 |
NaN |
|
SDC3;SDC4 |
| verapamil |
Antiarrhythmic |
Yes |
Down |
Thin myofilament organization |
0.000986426 |
3 |
NaN |
|
ACTA1;TNNI3;TPM2 |
| verapamil |
Antiarrhythmic |
Yes |
Down |
Thrombospondin receptor signaling |
0.005689617 |
7 |
NaN |
|
THBS2;THBS4 |
| verapamil |
Antiarrhythmic |
Yes |
Up |
Tropoelastin synthesis |
0.013232181 |
8.5 |
NaN |
|
ELN |
| verapamil |
Antiarrhythmic |
Yes |
Down |
Z-disc organization |
9.24E-09 |
1 |
NaN |
|
ACTN2;CSRP3;DES;DYSF;MYPN;NEXN;PDLIM3;TCAP |
| vemurafenib |
Kinase inhibitor |
No |
Down |
Adenylyl cyclase signaling pathway |
0.007461589 |
12 |
NaN |
|
ADCY1;PDE4D;RAPGEF4 |
| vemurafenib |
Kinase inhibitor |
No |
Down |
Adrenergic receptor signaling |
0.02079651 |
17 |
NaN |
|
GRK5;PDE4D;RAPGEF4 |
| vemurafenib |
Kinase inhibitor |
No |
Up |
Albumin mediated blood protein transport |
0.021877205 |
9.5 |
NaN |
|
ALB |
| vemurafenib |
Kinase inhibitor |
No |
Down |
Aspartate and arginine metabolism |
0.020733699 |
15.5 |
NaN |
|
ASS1;SLC7A1 |
| vemurafenib |
Kinase inhibitor |
No |
Up |
Axonal intermediate filament dynamics |
0.009309998 |
5.5 |
NaN |
|
NEFM;NES |
| vemurafenib |
Kinase inhibitor |
No |
Up |
Biglycan synthesis |
0.021877205 |
9.5 |
NaN |
|
BGN |
| vemurafenib |
Kinase inhibitor |
No |
Down |
Calcitonin receptor signaling |
0.045175089 |
20.5 |
NaN |
|
RAMP1 |
| vemurafenib |
Kinase inhibitor |
No |
Down |
CCN intercellular signaling protein family receptor signaling |
0.004968548 |
8 |
NaN |
|
CTGF;CYR61 |
| vemurafenib |
Kinase inhibitor |
No |
Up |
Cellular cholesterol uptake and efflux |
0.031721823 |
13 |
NaN |
|
ABCA1;ABCG1 |
| vemurafenib |
Kinase inhibitor |
No |
Down |
Cholesterol synthesis |
4.93E-12 |
1 |
NaN |
|
CYP51A1;DHCR7;FDFT1;FDPS;HMGCR;HMGCS1;MSMO1;MVD;MVK;SQLE |
| vemurafenib |
Kinase inhibitor |
No |
Down |
Cholesterol-sensitive control of SREBP activation |
0.007340787 |
10.5 |
NaN |
|
INSIG1;SREBF1 |
| vemurafenib |
Kinase inhibitor |
No |
Up |
Collagen fibril organization by fibril-associated bridges |
0.006746931 |
4 |
NaN |
|
COL12A1;COL9A3 |
| vemurafenib |
Kinase inhibitor |
No |
Up |
Decorin synthesis |
0.021877205 |
9.5 |
NaN |
|
DCN |
| vemurafenib |
Kinase inhibitor |
No |
Down |
Desaturation of fatty acids |
0.010122903 |
13 |
NaN |
|
FADS2;SCD |
| vemurafenib |
Kinase inhibitor |
No |
Down |
Epithelial intermediate filament dynamics |
0.013295073 |
14 |
NaN |
|
KRT19;KRT7 |
| vemurafenib |
Kinase inhibitor |
No |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.001973052 |
6 |
NaN |
|
ADAMTS14;ADAMTS15;ADAMTS17;ADAMTS8 |
| vemurafenib |
Kinase inhibitor |
No |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.015505928 |
7 |
NaN |
|
MMP14;MMP2 |
| vemurafenib |
Kinase inhibitor |
No |
Up |
Extracellular matrix breakdown by serine proteases |
0.009309998 |
5.5 |
NaN |
|
KLK5;PRSS8 |
| vemurafenib |
Kinase inhibitor |
No |
Up |
Fibrillar collagen core structure organization |
1.11E-06 |
1 |
NaN |
|
COL11A2;COL1A1;COL1A2;COL5A1;COL5A2 |
| vemurafenib |
Kinase inhibitor |
No |
Down |
Fibrillar collagen core structure organization |
0.001256016 |
3 |
NaN |
|
COL11A1;COL2A1;COL5A3 |
| vemurafenib |
Kinase inhibitor |
No |
Up |
Hepatocyte growth factor receptor signaling |
0.043277686 |
15.5 |
NaN |
|
MET |
| vemurafenib |
Kinase inhibitor |
No |
Down |
Hepatocyte growth factor receptor signaling |
0.045175089 |
20.5 |
NaN |
|
HGF |
| vemurafenib |
Kinase inhibitor |
No |
Down |
Hyaluronan synthesis |
0.001536541 |
4.5 |
NaN |
|
HAS2;HAS3 |
| vemurafenib |
Kinase inhibitor |
No |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001536541 |
4.5 |
NaN |
|
A2M;MME |
| vemurafenib |
Kinase inhibitor |
No |
Down |
Lipogenesis |
0.045175089 |
20.5 |
NaN |
|
FASN |
| vemurafenib |
Kinase inhibitor |
No |
Up |
Methionine cycle |
0.043277686 |
15.5 |
NaN |
|
BHMT |
| vemurafenib |
Kinase inhibitor |
No |
Up |
Osteonectin receptor signaling |
0.00277824 |
3 |
NaN |
|
SMOC2;SPOCK1 |
| vemurafenib |
Kinase inhibitor |
No |
Up |
Osteopontin receptor signaling |
0.021877205 |
9.5 |
NaN |
|
SPP1 |
| vemurafenib |
Kinase inhibitor |
No |
Down |
Prostaglandin E2 receptor signaling |
0.007340787 |
10.5 |
NaN |
|
PTGER3;RAPGEF4 |
| vemurafenib |
Kinase inhibitor |
No |
Down |
Restriction point |
0.020733699 |
15.5 |
NaN |
|
CDK6;PFKFB3 |
| vemurafenib |
Kinase inhibitor |
No |
Down |
Retinol metabolism |
0.002845211 |
7 |
NaN |
|
RDH10;RPE65;TTR |
| vemurafenib |
Kinase inhibitor |
No |
Down |
Semaphorin signaling |
0.007204299 |
9 |
NaN |
|
DPYSL3;NRP2;PLXNC1;SEMA3C |
| vemurafenib |
Kinase inhibitor |
No |
Up |
Serine and glycine metabolism |
0.023018072 |
12 |
NaN |
|
PHGDH;PSAT1 |
| vemurafenib |
Kinase inhibitor |
No |
Down |
Serotonin inactivation |
0.000520042 |
2 |
NaN |
|
MAOA;MAOB |
| vemurafenib |
Kinase inhibitor |
No |
Up |
Sister chromatid attachment to mitotic spindle |
0.043277686 |
15.5 |
NaN |
|
NUF2 |
| vemurafenib |
Kinase inhibitor |
No |
Up |
Thrombospondin receptor signaling |
4.07E-05 |
2 |
NaN |
|
CD47;THBS2;THBS4 |
| vemurafenib |
Kinase inhibitor |
No |
Down |
Tropoelastin synthesis |
0.022847565 |
18 |
NaN |
|
ELN |
| vemurafenib |
Kinase inhibitor |
No |
Up |
Vasoactive intestinal peptide receptor signaling |
0.043277686 |
15.5 |
NaN |
|
VIPR2 |
| vemurafenib |
Kinase inhibitor |
No |
Down |
Vasoactive intestinal peptide receptor signaling |
0.045175089 |
20.5 |
NaN |
|
VIPR1 |
| vemurafenib |
Kinase inhibitor |
No |
Up |
Z-disc organization |
0.046759314 |
18 |
NaN |
|
CSRP3;DYSF |
| vandetanib |
Kinase inhibitor |
Yes |
Up |
Albumin mediated blood protein transport |
0.021083275 |
12 |
NaN |
|
ALB |
| vandetanib |
Kinase inhibitor |
Yes |
Up |
Alternative complement pathway |
0.004244577 |
3.5 |
NaN |
|
C1S;CFH |
| vandetanib |
Kinase inhibitor |
Yes |
Down |
Biglycan synthesis |
0.022759351 |
8 |
18 |
Down by cardiotoxic TKIs |
BGN |
| vandetanib |
Kinase inhibitor |
Yes |
Down |
Cardiomyocyte pacemaker current generation |
0.000599569 |
1 |
NaN |
|
CACNA1G;HCN4;KCNK2 |
| vandetanib |
Kinase inhibitor |
Yes |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.002836212 |
2 |
NaN |
|
KCNA5;KCNIP2;KCNJ2 |
| vandetanib |
Kinase inhibitor |
Yes |
Up |
CD44-Mediated leukocyte rolling |
0.041723865 |
19 |
NaN |
|
CD44 |
| vandetanib |
Kinase inhibitor |
Yes |
Down |
Chloride transmembrane transport |
0.034116484 |
13.5 |
17 |
Down by cardiotoxic TKIs |
SLC12A7;SLC26A1 |
| vandetanib |
Kinase inhibitor |
Yes |
Up |
Cholesterol synthesis |
0.008092624 |
6 |
22 |
Up by cardiotoxic TKIs |
HMGCR;HMGCS1;MSMO1 |
| vandetanib |
Kinase inhibitor |
Yes |
Up |
Classical complement pathway |
0.008668292 |
7.5 |
NaN |
|
C1R;C1S |
| vandetanib |
Kinase inhibitor |
Yes |
Up |
Collagen fibril organization by fibril-associated bridges |
0.006278564 |
5 |
NaN |
|
COL14A1;COL9A1 |
| vandetanib |
Kinase inhibitor |
Yes |
Up |
Decorin synthesis |
0.021083275 |
12 |
NaN |
|
DCN |
| vandetanib |
Kinase inhibitor |
Yes |
Down |
Eicosanoid metabolism |
0.044582774 |
16 |
NaN |
|
CYP2J2;PTGS2 |
| vandetanib |
Kinase inhibitor |
Yes |
Up |
Endogenous control of complement activity |
0.004244577 |
3.5 |
NaN |
|
CFH;CFI |
| vandetanib |
Kinase inhibitor |
Yes |
Down |
Eukaryotic axoneme organization |
0.032767128 |
12 |
NaN |
|
DNAH11;GAS8;SERPINE2 |
| vandetanib |
Kinase inhibitor |
Yes |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.014452362 |
10 |
NaN |
|
MMP1;MMP2 |
| vandetanib |
Kinase inhibitor |
Yes |
Up |
Fibrillar collagen core structure organization |
9.24E-07 |
1 |
NaN |
|
COL11A1;COL1A1;COL1A2;COL2A1;COL3A1 |
| vandetanib |
Kinase inhibitor |
Yes |
Down |
Fibulin receptor signaling |
0.045002676 |
18 |
NaN |
|
FBLN1 |
| vandetanib |
Kinase inhibitor |
Yes |
Up |
G2 M transition checkpoint |
0.025418115 |
15 |
NaN |
|
CCNG1;WEE1 |
| vandetanib |
Kinase inhibitor |
Yes |
Down |
GABA metabolism |
0.007285832 |
3.5 |
NaN |
|
ABAT;SLC6A1 |
| vandetanib |
Kinase inhibitor |
Yes |
Down |
Gap junction organization |
0.039215592 |
15 |
24 |
Down by cardiotoxic TKIs |
GJA5;GJD2 |
| vandetanib |
Kinase inhibitor |
Yes |
Up |
Inhibin receptor signaling |
0.011397983 |
9 |
NaN |
|
INHA;INHBA |
| vandetanib |
Kinase inhibitor |
Yes |
Down |
Inhibition of apoptosis |
0.029300737 |
11 |
NaN |
|
BIRC5;BIRC7 |
| vandetanib |
Kinase inhibitor |
Yes |
Up |
JAK-STAT signaling pathway |
0.034093361 |
17 |
NaN |
|
STAT3;STAT4 |
| vandetanib |
Kinase inhibitor |
Yes |
Down |
Natriuretic peptide receptor signaling |
0.007285832 |
3.5 |
NaN |
|
NPR1;NPR3 |
| vandetanib |
Kinase inhibitor |
Yes |
Down |
Notch receptor signaling |
0.009974492 |
5 |
NaN |
|
DLK1;JAG1;LFNG |
| vandetanib |
Kinase inhibitor |
Yes |
Up |
Osteopontin receptor signaling |
0.021083275 |
12 |
NaN |
|
SPP1 |
| vandetanib |
Kinase inhibitor |
Yes |
Down |
Perlecan synthesis |
0.022759351 |
8 |
NaN |
|
HSPG2 |
| vandetanib |
Kinase inhibitor |
Yes |
Down |
Platelet-derived growth factor receptor signaling |
0.024784198 |
10 |
14 |
Down by cardiotoxic TKIs |
PDGFD;PDGFRB |
| vandetanib |
Kinase inhibitor |
Yes |
Down |
Prostacycline receptor signaling |
0.045002676 |
18 |
NaN |
|
PTGIR |
| vandetanib |
Kinase inhibitor |
Yes |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.045002676 |
18 |
NaN |
|
PTGFR |
| vandetanib |
Kinase inhibitor |
Yes |
Up |
Retinol metabolism |
0.029628054 |
16 |
NaN |
|
ALDH1A1;ALDH1A3 |
| vandetanib |
Kinase inhibitor |
Yes |
Down |
Retinol metabolism |
0.034116484 |
13.5 |
NaN |
|
DHRS3;RLBP1 |
| vandetanib |
Kinase inhibitor |
Yes |
Down |
Roundabout signaling |
0.010047711 |
6 |
NaN |
|
ROBO1;ROBO2 |
| vandetanib |
Kinase inhibitor |
Yes |
Up |
Serine and glycine metabolism |
0.02147651 |
14 |
19 |
Up by cardiotoxic TKIs |
PSAT1;SLC1A5 |
| vandetanib |
Kinase inhibitor |
Yes |
Up |
Serotonin inactivation |
0.041723865 |
19 |
NaN |
|
MAOA |
| vandetanib |
Kinase inhibitor |
Yes |
Up |
Thin myofilament organization |
0.008668292 |
7.5 |
NaN |
|
ACTA1;LMOD3 |
| vandetanib |
Kinase inhibitor |
Yes |
Down |
Thrombospondin receptor signaling |
0.003003699 |
2 |
NaN |
|
THBS2;THBS4 |
| vandetanib |
Kinase inhibitor |
Yes |
Down |
Tropoelastin synthesis |
0.022759351 |
8 |
NaN |
|
ELN |
| vandetanib |
Kinase inhibitor |
Yes |
Up |
Vasoactive intestinal peptide receptor signaling |
0.041723865 |
19 |
NaN |
|
VIPR2 |
| trastuzumab |
Monoclonal antibody |
Yes |
Up |
Aggrecan synthesis |
0.023288638 |
11.5 |
NaN |
|
ACAN |
| trastuzumab |
Monoclonal antibody |
Yes |
Up |
Albumin mediated blood protein transport |
0.023288638 |
11.5 |
NaN |
|
ALB |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
Biglycan synthesis |
0.021083275 |
16 |
18 |
Down by cardiotoxic TKIs |
BGN |
| trastuzumab |
Monoclonal antibody |
Yes |
Up |
Cardiomyocyte depolarization during action potential |
0.023288638 |
11.5 |
NaN |
|
SCN5A |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
CCN intercellular signaling protein family receptor signaling |
0.004244577 |
7 |
NaN |
|
CTGF;CYR61 |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
CD44-Mediated leukocyte rolling |
0.041723865 |
22.5 |
NaN |
|
CD44 |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
Centrosome separation |
0.000995243 |
2 |
NaN |
|
CCNB1;CDK1;ESPL1 |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
Cholesterol synthesis |
0.008092624 |
12 |
NaN |
|
DHCR24;DHCR7;MVK |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
Cholesterol-sensitive control of SREBP activation |
0.006278564 |
9.5 |
NaN |
|
INSIG1;SREBF1 |
| trastuzumab |
Monoclonal antibody |
Yes |
Up |
Collagen fiber crosslinking |
0.005158008 |
3 |
NaN |
|
LOX;PXDN |
| trastuzumab |
Monoclonal antibody |
Yes |
Up |
Collagen fibril organization by fibril-associated bridges |
0.007618457 |
4 |
NaN |
|
COL14A1;COL9A2 |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
Decorin synthesis |
0.021083275 |
16 |
NaN |
|
DCN |
| trastuzumab |
Monoclonal antibody |
Yes |
Up |
Epithelial intermediate filament dynamics |
0.013789873 |
5 |
NaN |
|
KRT7;TCHH |
| trastuzumab |
Monoclonal antibody |
Yes |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.017608297 |
7 |
NaN |
|
ADAM33;ADAMTS2;ADAMTS8 |
| trastuzumab |
Monoclonal antibody |
Yes |
Up |
Extracellular matrix breakdown by cathepsins |
0.021492826 |
8.5 |
NaN |
|
CTSH;CTSV |
| trastuzumab |
Monoclonal antibody |
Yes |
Up |
Fibrillar collagen core structure organization |
0.021492826 |
8.5 |
NaN |
|
COL11A1;COL2A1 |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
Fibrillar collagen core structure organization |
3.66E-05 |
1 |
NaN |
|
COL1A1;COL1A2;COL3A1;COL5A2 |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
G2 M transition checkpoint |
0.025418115 |
19 |
NaN |
|
CCNB1;CDK1 |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
GABA metabolism |
0.006278564 |
9.5 |
NaN |
|
ABAT;SLC6A1 |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
Glycolysis and Gluconeogenesis |
0.012002569 |
13 |
NaN |
|
ENO1;HK2;LDHA |
| trastuzumab |
Monoclonal antibody |
Yes |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.046036922 |
16 |
NaN |
|
JAK2 |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001309537 |
3 |
NaN |
|
A2M;PLAT |
| trastuzumab |
Monoclonal antibody |
Yes |
Up |
Inhibition of apoptosis |
0.030574288 |
14 |
NaN |
|
IFI6;XAF1 |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
Insulin receptor signaling |
0.038801493 |
20 |
NaN |
|
IRS1;IRS2 |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
Lipogenesis |
0.041723865 |
22.5 |
NaN |
|
FASN |
| trastuzumab |
Monoclonal antibody |
Yes |
Up |
Methionine cycle |
0.046036922 |
16 |
NaN |
|
BHMT |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
Microfibril scaffold organization |
0.041723865 |
22.5 |
NaN |
|
FBN1 |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
Mitotic spindle disassembly |
0.021083275 |
16 |
NaN |
|
CDK1 |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
Natriuretic peptide receptor signaling |
0.006278564 |
9.5 |
NaN |
|
NPPA;NPPB |
| trastuzumab |
Monoclonal antibody |
Yes |
Up |
Osteopontin receptor signaling |
0.023288638 |
11.5 |
NaN |
|
SPP1 |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
Platelet-derived growth factor receptor signaling |
0.001347236 |
4.5 |
14 |
Down by cardiotoxic TKIs |
PDGFRA;PDGFRB;TNK2 |
| trastuzumab |
Monoclonal antibody |
Yes |
Up |
Removal of caspase inhibition |
0.046036922 |
16 |
NaN |
|
XAF1 |
| trastuzumab |
Monoclonal antibody |
Yes |
Up |
Retinol metabolism |
0.003003835 |
2 |
NaN |
|
ALDH1A1;ALDH1A2;ALDH1A3 |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
Serine and glycine metabolism |
0.001347236 |
4.5 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
Sister chromatid segregation |
0.006278564 |
9.5 |
NaN |
|
ESPL1;TOP2A |
| trastuzumab |
Monoclonal antibody |
Yes |
Up |
Thick myofilament organization |
0.00159608 |
1 |
NaN |
|
MYBPC3;MYH7 |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
Thrombospondin receptor signaling |
0.002582626 |
6 |
NaN |
|
THBS1;THBS4 |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
Tropoelastin synthesis |
0.021083275 |
16 |
NaN |
|
ELN |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
Versican receptor signaling |
0.041723865 |
22.5 |
NaN |
|
VCAN |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
Versican synthesis |
0.021083275 |
16 |
NaN |
|
VCAN |
| trastuzumab |
Monoclonal antibody |
Yes |
Up |
WNT-Beta-catenin signaling pathway |
0.016465738 |
6 |
NaN |
|
CTHRC1;FZD2;SFRP4;SFRP5;WNT2 |
| trastuzumab |
Monoclonal antibody |
Yes |
Down |
WNT-Beta-catenin signaling pathway |
0.045815603 |
25 |
NaN |
|
DACT1;FZD7;SFRP2;WNT1 |
| trametinib |
Kinase inhibitor |
Yes |
Up |
Aggrecan synthesis |
0.015878617 |
4.5 |
NaN |
|
ACAN |
| trametinib |
Kinase inhibitor |
Yes |
Up |
Androgen receptor signaling |
0.031506482 |
9 |
NaN |
|
AR |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Axonal intermediate filament dynamics |
0.017816684 |
25.5 |
NaN |
|
NEFL;NES |
| trametinib |
Kinase inhibitor |
Yes |
Down |
CCN intercellular signaling protein family receptor signaling |
0.008837033 |
20.5 |
NaN |
|
CTGF;CYR61 |
| trametinib |
Kinase inhibitor |
Yes |
Up |
Cellular iron storage |
0.046887533 |
10.5 |
NaN |
|
FTL |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Centrosome maturation |
0.005133558 |
16.5 |
NaN |
|
AURKA;PLK1;TPX2 |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Centrosome organization |
0.004701563 |
15 |
NaN |
|
ASPM;NEK2;PLK4;POC1A;STIL;TACC3;WDR62 |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Centrosome separation |
3.11E-11 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;NEK6;SPAG5 |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Cholesterol synthesis |
0.022193047 |
27 |
NaN |
|
DHCR24;DHCR7;MVK |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Collagen fibril organization by fibril-associated bridges |
0.012987834 |
23 |
NaN |
|
COL9A1;COL9A2 |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Contractile ring constriction |
0.000273952 |
7.5 |
NaN |
|
ANLN;ECT2;MYLK |
| trametinib |
Kinase inhibitor |
Yes |
Up |
Decorin synthesis |
0.015878617 |
4.5 |
NaN |
|
DCN |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Desaturation of fatty acids |
0.017816684 |
25.5 |
NaN |
|
FADS2;SCD |
| trametinib |
Kinase inhibitor |
Yes |
Down |
DNA replication elongation |
0.008837033 |
20.5 |
NaN |
|
MCM5;MCM7 |
| trametinib |
Kinase inhibitor |
Yes |
Down |
DNA replication initiation |
7.21E-06 |
4 |
NaN |
|
CDC45;CDC6;GINS1;GINS2;MCM10;MCM5;MCM7 |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Equatorial RhoA activation |
0.005411801 |
18.5 |
NaN |
|
ECT2;KIF23 |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Eukaryotic kinetochore dynamics |
7.66E-10 |
2 |
NaN |
|
BUB1;CENPE;CENPF;CENPI;CENPU;MAD2L1;NDC80;NUF2;SKA3;SPC24;TTK;ZWINT |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Extracellular matrix breakdown by heparanases and sulfatases |
0.005411801 |
18.5 |
NaN |
|
SULF1;SULF2 |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Fanconi anemia interstrand cross-link repair pathway |
0.001023657 |
13 |
NaN |
|
BRIP1;FANCA;FANCD2;FANCI;UBE2T |
| trametinib |
Kinase inhibitor |
Yes |
Up |
Fibrillar collagen core structure organization |
1.20E-05 |
1 |
NaN |
|
COL1A1;COL1A2;COL3A1;COL5A1 |
| trametinib |
Kinase inhibitor |
Yes |
Down |
G2 M transition checkpoint |
0.005133558 |
16.5 |
NaN |
|
CCNB1;CDC25C;CDK1 |
| trametinib |
Kinase inhibitor |
Yes |
Up |
Hemoglobin and myoglobin synthesis |
0.046887533 |
10.5 |
NaN |
|
MB |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Intracellular bridge assembly |
0.002761969 |
14 |
NaN |
|
INCENP;KIF23 |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Metaphase to anaphase checkpoint |
6.57E-06 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;PTTG1;TTK |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Mitotic chromosome condensation |
0.000915708 |
11 |
NaN |
|
INCENP;NCAPG2;SMC4 |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.000273952 |
7.5 |
NaN |
|
AURKB;CCNA2;INCENP |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Mitotic spindle assembly |
2.78E-05 |
5 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Natriuretic peptide receptor signaling |
0.012987834 |
23 |
NaN |
|
NPPA;NPPB |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Nuclear intermediate filaments |
0.012987834 |
23 |
NaN |
|
LMNB1;LMNB2 |
| trametinib |
Kinase inhibitor |
Yes |
Up |
Potassium transmembrane transport |
0.000509517 |
2 |
7 |
Up by cardiotoxic TKIs |
ABCC9;ATP1A2;FXYD1;SLC12A6 |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Pyrimidine synthesis and salvage |
0.023278285 |
28 |
NaN |
|
TK1;TYMS |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Retinol metabolism |
0.000500941 |
9 |
NaN |
|
ALDH1A1;ALDH1A3;DHRS3;RDH10 |
| trametinib |
Kinase inhibitor |
Yes |
Up |
Semaphorin signaling |
0.016421671 |
6 |
NaN |
|
NRP2;SEMA6A;SEMA6D |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Sister chromatid attachment to mitotic spindle |
0.000939783 |
12 |
NaN |
|
NUF2;TACC3 |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Sister chromatid segregation |
0.000535432 |
10 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| trametinib |
Kinase inhibitor |
Yes |
Up |
Thin myofilament organization |
0.004996504 |
3 |
NaN |
|
ACTA1;LMOD3 |
| trametinib |
Kinase inhibitor |
Yes |
Down |
Thrombospondin receptor signaling |
0.000112137 |
6 |
NaN |
|
THBS1;THBS2;THBS4 |
| trametinib |
Kinase inhibitor |
Yes |
Up |
WNT-Beta-catenin signaling pathway |
0.018655736 |
7 |
NaN |
|
AMER1;FZD1;SFRP1;SFRP2 |
| trametinib |
Kinase inhibitor |
Yes |
Up |
Z-disc organization |
0.025999312 |
8 |
NaN |
|
CSRP3;TCAP |
| tofacitinib |
Kinase inhibitor |
No |
Down |
Aggrecan synthesis |
0.026199718 |
12.5 |
NaN |
|
ACAN |
| tofacitinib |
Kinase inhibitor |
No |
Up |
Albumin mediated blood protein transport |
0.018966126 |
9 |
NaN |
|
ALB |
| tofacitinib |
Kinase inhibitor |
No |
Up |
Androgen receptor signaling |
0.037574179 |
14 |
NaN |
|
AR |
| tofacitinib |
Kinase inhibitor |
No |
Down |
Antigen presentation via MHC class I molecules |
0.026793335 |
14 |
NaN |
|
HLA-B;HLA-C |
| tofacitinib |
Kinase inhibitor |
No |
Up |
Biglycan synthesis |
0.018966126 |
9 |
NaN |
|
BGN |
| tofacitinib |
Kinase inhibitor |
No |
Up |
CCN intercellular signaling protein family receptor signaling |
6.54E-05 |
4 |
NaN |
|
CTGF;CYR61;WISP1 |
| tofacitinib |
Kinase inhibitor |
No |
Up |
Cellular fatty acid uptake |
0.037574179 |
14 |
NaN |
|
CD36 |
| tofacitinib |
Kinase inhibitor |
No |
Up |
Chaperone-mediated autophagy |
0.037574179 |
14 |
NaN |
|
HSPA8 |
| tofacitinib |
Kinase inhibitor |
No |
Down |
Cholesterol synthesis |
1.94E-08 |
1 |
NaN |
|
CYP51A1;DHCR7;HMGCR;HMGCS1;MSMO1;MVD;SC5D;SQLE |
| tofacitinib |
Kinase inhibitor |
No |
Down |
Cholesterol-sensitive control of SREBP activation |
0.009570814 |
7.5 |
NaN |
|
INSIG1;SREBF1 |
| tofacitinib |
Kinase inhibitor |
No |
Down |
Classical complement pathway |
0.013168643 |
9 |
NaN |
|
C1QA;C1R |
| tofacitinib |
Kinase inhibitor |
No |
Up |
Coagulation cascade |
0.02085161 |
11 |
NaN |
|
F2RL1;TFPI |
| tofacitinib |
Kinase inhibitor |
No |
Up |
Collagen fibril organization by fibril-associated bridges |
0.005107525 |
5 |
NaN |
|
COL14A1;COL9A1 |
| tofacitinib |
Kinase inhibitor |
No |
Down |
Collagen fibril organization by fibril-associated bridges |
0.009570814 |
7.5 |
NaN |
|
COL9A2;COL9A3 |
| tofacitinib |
Kinase inhibitor |
No |
Up |
Decorin synthesis |
0.018966126 |
9 |
NaN |
|
DCN |
| tofacitinib |
Kinase inhibitor |
No |
Up |
DNA replication elongation |
6.20E-07 |
3 |
NaN |
|
MCM4;MCM5;MCM7;PCNA |
| tofacitinib |
Kinase inhibitor |
No |
Up |
DNA replication initiation |
2.88E-07 |
1 |
NaN |
|
CDC45;CDC6;MCM3;MCM4;MCM5;MCM6;MCM7 |
| tofacitinib |
Kinase inhibitor |
No |
Down |
Epithelial intermediate filament dynamics |
0.01725681 |
10 |
NaN |
|
KRT19;KRT8 |
| tofacitinib |
Kinase inhibitor |
No |
Up |
Extracellular matrix breakdown by cathepsins |
0.014575224 |
6.5 |
NaN |
|
CTSF;CTSV |
| tofacitinib |
Kinase inhibitor |
No |
Up |
Fibrillar collagen core structure organization |
5.46E-07 |
2 |
NaN |
|
COL11A1;COL1A1;COL1A2;COL2A1;COL3A1 |
| tofacitinib |
Kinase inhibitor |
No |
Down |
Glutamate and glutamine metabolism |
0.044111632 |
16.5 |
NaN |
|
SLC1A5;SLC7A5 |
| tofacitinib |
Kinase inhibitor |
No |
Down |
Granulocyte-colony stimulating factor receptor signaling |
0.021807329 |
11 |
NaN |
|
SOCS3;STAT3 |
| tofacitinib |
Kinase inhibitor |
No |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.002016908 |
4 |
NaN |
|
A2M;MME |
| tofacitinib |
Kinase inhibitor |
No |
Down |
Leptin receptor signaling |
0.003963971 |
5 |
NaN |
|
SOCS3;STAT3 |
| tofacitinib |
Kinase inhibitor |
No |
Up |
Microfibril scaffold organization |
0.037574179 |
14 |
NaN |
|
FBN1 |
| tofacitinib |
Kinase inhibitor |
No |
Up |
Myofibril formation |
0.014575224 |
6.5 |
NaN |
|
KLHL41;XIRP1 |
| tofacitinib |
Kinase inhibitor |
No |
Down |
Oncostatin-M receptor signaling |
0.006492473 |
6 |
NaN |
|
OSMR;STAT3 |
| tofacitinib |
Kinase inhibitor |
No |
Down |
Retinol metabolism |
0.044111632 |
16.5 |
NaN |
|
DHRS3;RDH10 |
| tofacitinib |
Kinase inhibitor |
No |
Down |
Serine and glycine metabolism |
0.032189046 |
15 |
NaN |
|
PHGDH;SLC1A5 |
| tofacitinib |
Kinase inhibitor |
No |
Up |
Serotonin inactivation |
0.037574179 |
14 |
NaN |
|
MAOA |
| tofacitinib |
Kinase inhibitor |
No |
Down |
Thin myofilament organization |
0.000576244 |
2 |
NaN |
|
ACTA1;NEBL;TNNI3 |
| tofacitinib |
Kinase inhibitor |
No |
Down |
Tropoelastin synthesis |
0.026199718 |
12.5 |
NaN |
|
ELN |
| tofacitinib |
Kinase inhibitor |
No |
Down |
Z-disc organization |
0.000655008 |
3 |
NaN |
|
CSRP3;DES;NEBL;PDLIM3 |
| tnf-alpha |
Cytokine |
|
Up |
Albumin mediated blood protein transport |
0.017025406 |
8.5 |
NaN |
|
ALB |
| tnf-alpha |
Cytokine |
|
Up |
Antigen presentation via MHC class I molecules |
0.011861068 |
5.5 |
NaN |
|
B2M;HLA-B |
| tnf-alpha |
Cytokine |
|
Down |
Biglycan synthesis |
0.028140438 |
18 |
NaN |
|
BGN |
| tnf-alpha |
Cytokine |
|
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.022939425 |
11.5 |
NaN |
|
KCNIP2;KCNQ5 |
| tnf-alpha |
Cytokine |
|
Up |
Cellular fatty acid uptake |
0.033762424 |
14 |
NaN |
|
CD36 |
| tnf-alpha |
Cytokine |
|
Down |
Centrosome maturation |
0.043251813 |
22 |
NaN |
|
PLK1;TPX2 |
| tnf-alpha |
Cytokine |
|
Down |
Centrosome separation |
0.002286708 |
6 |
NaN |
|
CCNB1;KIF11;SPAG5 |
| tnf-alpha |
Cytokine |
|
Down |
Cholesterol synthesis |
1.26E-09 |
1 |
NaN |
|
CYP51A1;DHCR7;HMGCR;HMGCS1;MSMO1;MVD;MVK;NSDHL;SQLE |
| tnf-alpha |
Cytokine |
|
Up |
Collagen fibril organization by fibril-associated bridges |
9.36E-05 |
1 |
NaN |
|
COL14A1;COL19A1;COL9A3 |
| tnf-alpha |
Cytokine |
|
Down |
Contractile ring constriction |
0.007462268 |
10.5 |
NaN |
|
ANLN;MYLK |
| tnf-alpha |
Cytokine |
|
Up |
Decorin synthesis |
0.017025406 |
8.5 |
NaN |
|
DCN |
| tnf-alpha |
Cytokine |
|
Down |
Desaturation of fatty acids |
0.000710301 |
5 |
NaN |
|
FADS2;FADS3;SCD |
| tnf-alpha |
Cytokine |
|
Down |
Epithelial intermediate filament dynamics |
0.01975769 |
16 |
NaN |
|
KRT7;KRT8 |
| tnf-alpha |
Cytokine |
|
Down |
Eukaryotic kinetochore dynamics |
0.000611459 |
4 |
NaN |
|
BUB1;CENPF;NDC80;SPC24;TTK;ZWINT |
| tnf-alpha |
Cytokine |
|
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.000662661 |
2 |
NaN |
|
ADAM12;ADAMTS1;ADAMTS5;ADAMTS6 |
| tnf-alpha |
Cytokine |
|
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.028853674 |
20 |
NaN |
|
ADAM19;ADAMTS15;ADAMTS8 |
| tnf-alpha |
Cytokine |
|
Up |
Fibrillar collagen core structure organization |
0.011861068 |
5.5 |
NaN |
|
COL11A2;COL3A1 |
| tnf-alpha |
Cytokine |
|
Down |
Gluthatione conjugation |
0.028140438 |
18 |
NaN |
|
GSTP1 |
| tnf-alpha |
Cytokine |
|
Down |
Glycolysis and Gluconeogenesis |
0.003568606 |
8 |
NaN |
|
ALDOA;ENO1;LDHA;TPI1 |
| tnf-alpha |
Cytokine |
|
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.033762424 |
14 |
NaN |
|
JAK2 |
| tnf-alpha |
Cytokine |
|
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.009595627 |
4 |
NaN |
|
SOCS3;STAT3 |
| tnf-alpha |
Cytokine |
|
Up |
JAK-STAT signaling pathway |
0.022939425 |
11.5 |
NaN |
|
SOCS3;STAT3 |
| tnf-alpha |
Cytokine |
|
Up |
Leptin receptor signaling |
0.001691693 |
3 |
NaN |
|
SOCS3;STAT3 |
| tnf-alpha |
Cytokine |
|
Down |
Metaphase to anaphase checkpoint |
0.002433212 |
7 |
NaN |
|
BUB1;CCNB2;CDC20;PTTG1;TTK |
| tnf-alpha |
Cytokine |
|
Up |
Methionine cycle |
0.033762424 |
14 |
NaN |
|
BHMT |
| tnf-alpha |
Cytokine |
|
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.007462268 |
10.5 |
NaN |
|
AURKB;CCNA2 |
| tnf-alpha |
Cytokine |
|
Down |
Mitotic spindle assembly |
0.000359811 |
3 |
NaN |
|
DLGAP5;TACC3;TPX2;TTK |
| tnf-alpha |
Cytokine |
|
Down |
Natriuretic peptide receptor signaling |
0.010986142 |
13.5 |
NaN |
|
NPPA;NPPB |
| tnf-alpha |
Cytokine |
|
Up |
Neuregulin receptor signaling |
0.014335775 |
7 |
NaN |
|
ERBB3;SH3TC2 |
| tnf-alpha |
Cytokine |
|
Down |
Platelet-derived growth factor receptor signaling |
0.036713271 |
21 |
NaN |
|
PDGFB;TNK2 |
| tnf-alpha |
Cytokine |
|
Down |
Protein polyubiquitination |
0.009416278 |
12 |
NaN |
|
ISG15;UBE2S;UCHL1 |
| tnf-alpha |
Cytokine |
|
Down |
Retinol metabolism |
0.005118789 |
9 |
NaN |
|
DHRS3;RBP1;RDH10 |
| tnf-alpha |
Cytokine |
|
Up |
Semaphorin signaling |
0.019739244 |
10 |
NaN |
|
SEMA3D;SEMA6A;SEMA6D |
| tnf-alpha |
Cytokine |
|
Down |
Serine and glycine metabolism |
0.000173654 |
2 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| tnf-alpha |
Cytokine |
|
Down |
Sister chromatid segregation |
0.010986142 |
13.5 |
NaN |
|
PTTG1;TOP2A |
| tnf-alpha |
Cytokine |
|
Down |
Thin myofilament organization |
0.015096478 |
15 |
NaN |
|
ACTA1;TPM4 |
| tnf-alpha |
Cytokine |
|
Down |
Tropoelastin synthesis |
0.028140438 |
18 |
NaN |
|
ELN |
| sunitinib |
Kinase inhibitor |
Yes |
Down |
Aggrecan synthesis |
0.023023994 |
9.5 |
NaN |
|
ACAN |
| sunitinib |
Kinase inhibitor |
Yes |
Up |
Albumin mediated blood protein transport |
0.019936486 |
9 |
NaN |
|
ALB |
| sunitinib |
Kinase inhibitor |
Yes |
Up |
Biglycan synthesis |
0.019936486 |
9 |
NaN |
|
BGN |
| sunitinib |
Kinase inhibitor |
Yes |
Down |
CCN intercellular signaling protein family receptor signaling |
0.0001166 |
2 |
NaN |
|
CTGF;CYR61;WISP1 |
| sunitinib |
Kinase inhibitor |
Yes |
Down |
CD44-Mediated leukocyte rolling |
0.045519869 |
15 |
NaN |
|
CD44 |
| sunitinib |
Kinase inhibitor |
Yes |
Down |
Cellular cholesterol uptake and efflux |
0.034848653 |
11.5 |
23 |
Down by cardiotoxic TKIs |
ABCA1;ARL4C |
| sunitinib |
Kinase inhibitor |
Yes |
Down |
Centrosome separation |
0.021035933 |
8 |
NaN |
|
ESPL1;SPAG5 |
| sunitinib |
Kinase inhibitor |
Yes |
Down |
Classical complement pathway |
0.000394321 |
4.5 |
NaN |
|
C1QB;C1QC;C1R |
| sunitinib |
Kinase inhibitor |
Yes |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.001194517 |
4 |
NaN |
|
ADAM33;ADAMTS15;ADAMTS5;ADAMTS8 |
| sunitinib |
Kinase inhibitor |
Yes |
Up |
Extracellular matrix breakdown by cathepsins |
0.016025171 |
6.5 |
NaN |
|
CTSF;CTSV |
| sunitinib |
Kinase inhibitor |
Yes |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.000601039 |
3 |
NaN |
|
MMP12;MMP2;MMP3 |
| sunitinib |
Kinase inhibitor |
Yes |
Up |
Fibrillar collagen core structure organization |
7.00E-07 |
1 |
NaN |
|
COL11A2;COL1A1;COL1A2;COL2A1;COL3A1 |
| sunitinib |
Kinase inhibitor |
Yes |
Down |
Fibulin receptor signaling |
0.045519869 |
15 |
NaN |
|
FBLN1 |
| sunitinib |
Kinase inhibitor |
Yes |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.039477231 |
12.5 |
NaN |
|
JUND |
| sunitinib |
Kinase inhibitor |
Yes |
Down |
Hepatocyte growth factor receptor signaling |
0.00052812 |
6 |
NaN |
|
HGF;MET |
| sunitinib |
Kinase inhibitor |
Yes |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
1.21E-05 |
1 |
NaN |
|
A2M;MME;PLAT |
| sunitinib |
Kinase inhibitor |
Yes |
Down |
Methionine cycle |
0.045519869 |
15 |
NaN |
|
BHMT |
| sunitinib |
Kinase inhibitor |
Yes |
Up |
Microfibril scaffold organization |
0.039477231 |
12.5 |
NaN |
|
FBN1 |
| sunitinib |
Kinase inhibitor |
Yes |
Down |
Mineralocorticoid receptor signaling |
0.045519869 |
15 |
NaN |
|
GPER1 |
| sunitinib |
Kinase inhibitor |
Yes |
Up |
Osteonectin receptor signaling |
3.08E-05 |
2 |
NaN |
|
SMOC2;SPARC;SPOCK1 |
| sunitinib |
Kinase inhibitor |
Yes |
Down |
Progesterone receptor signaling |
0.023023994 |
9.5 |
NaN |
|
PGR |
| sunitinib |
Kinase inhibitor |
Yes |
Up |
Prostaglandin PGF2 alpha receptor signaling |
0.039477231 |
12.5 |
NaN |
|
PTGFR |
| sunitinib |
Kinase inhibitor |
Yes |
Up |
Protein polyubiquitination |
0.039518883 |
15 |
NaN |
|
ISG15;UCHL1 |
| sunitinib |
Kinase inhibitor |
Yes |
Up |
Restriction point |
0.016025171 |
6.5 |
3 |
Up by cardiotoxic TKIs |
CCND2;CDKN1A |
| sunitinib |
Kinase inhibitor |
Yes |
Down |
Retinol metabolism |
0.034848653 |
11.5 |
NaN |
|
ALDH1A3;DHRS3 |
| sunitinib |
Kinase inhibitor |
Yes |
Up |
Serotonin inactivation |
0.039477231 |
12.5 |
NaN |
|
MAOA |
| sunitinib |
Kinase inhibitor |
Yes |
Down |
Serotonin inactivation |
0.045519869 |
15 |
NaN |
|
MAOB |
| sunitinib |
Kinase inhibitor |
Yes |
Down |
Sister chromatid segregation |
0.000229227 |
3 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| sunitinib |
Kinase inhibitor |
Yes |
Down |
Thin myofilament organization |
0.000394321 |
4.5 |
21 |
Down by cardiotoxic TKIs |
ACTA1;LMOD3;TNNI3 |
| sunitinib |
Kinase inhibitor |
Yes |
Up |
Tropoelastin synthesis |
0.019936486 |
9 |
NaN |
|
ELN |
| sunitinib |
Kinase inhibitor |
Yes |
Up |
WNT-Beta-catenin signaling pathway |
0.008849032 |
5 |
NaN |
|
AXIN2;FZD2;FZD8;PAX6;WNT5A |
| sunitinib |
Kinase inhibitor |
Yes |
Down |
Z-disc organization |
0.005410758 |
7 |
NaN |
|
DYSF;PDLIM3;TCAP |
| sorafenib |
Kinase inhibitor |
Yes |
Down |
Albumin mediated blood protein transport |
0.019848271 |
9.5 |
NaN |
|
ALB |
| sorafenib |
Kinase inhibitor |
Yes |
Down |
Antigen presentation via MHC class I molecules |
0.015890842 |
5 |
NaN |
|
HLA-B;HLA-C |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
CD44-Mediated leukocyte rolling |
0.048447984 |
24.5 |
NaN |
|
CD44 |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Centrosome maturation |
0.002723606 |
10 |
NaN |
|
AURKA;PLK1;TPX2 |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Centrosome organization |
0.00632086 |
13 |
NaN |
|
ASPM;ATF5;NEK2;PLK3;TACC3;WDR62 |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Centrosome separation |
5.58E-10 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Cholesterol synthesis |
0.012211764 |
15 |
22 |
Up by cardiotoxic TKIs |
DHCR7;MVD;MVK |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Collagen fiber crosslinking |
0.005706386 |
12 |
NaN |
|
LOXL1;PXDN |
| sorafenib |
Kinase inhibitor |
Yes |
Down |
Decorin synthesis |
0.019848271 |
9.5 |
NaN |
|
DCN |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Desaturation of fatty acids |
0.011600172 |
14 |
11 |
Up by cardiotoxic TKIs |
FADS2;SCD |
| sorafenib |
Kinase inhibitor |
Yes |
Down |
Epithelial intermediate filament dynamics |
0.010149397 |
2.5 |
NaN |
|
KRT19;KRT7 |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Eukaryotic kinetochore dynamics |
3.05E-06 |
3 |
NaN |
|
BUB1;CENPE;CENPF;NDC80;NUF2;SPC24;TTK;ZWINT |
| sorafenib |
Kinase inhibitor |
Yes |
Down |
Extracellular matrix breakdown by cathepsins |
0.015890842 |
5 |
NaN |
|
CTSF;CTSV |
| sorafenib |
Kinase inhibitor |
Yes |
Down |
Fibrillar collagen core structure organization |
0.015890842 |
5 |
NaN |
|
COL1A2;COL3A1 |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Fibulin receptor signaling |
0.048447984 |
24.5 |
NaN |
|
FBLN1 |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
G2 M transition checkpoint |
0.0336321 |
20.5 |
NaN |
|
CCNB1;CDK1 |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Gap junction organization |
0.004345619 |
11 |
NaN |
|
GJA1;GJA5;GJB2 |
| sorafenib |
Kinase inhibitor |
Yes |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.039304304 |
17.5 |
NaN |
|
JAK2 |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Hepatocyte growth factor receptor signaling |
0.048447984 |
24.5 |
NaN |
|
HGF |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Hyaluronan-mediated motility receptor signaling |
0.024523641 |
17 |
NaN |
|
HMMR |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Inhibition of apoptosis |
0.0336321 |
20.5 |
NaN |
|
BIRC5;XAF1 |
| sorafenib |
Kinase inhibitor |
Yes |
Down |
Interferon alpha receptor signaling |
0.010149397 |
2.5 |
NaN |
|
IRF9;STAT1 |
| sorafenib |
Kinase inhibitor |
Yes |
Down |
Interferon beta receptor signaling |
0.007712399 |
1 |
NaN |
|
IFIT2;IRF9 |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Intracellular bridge assembly |
0.001768708 |
8 |
NaN |
|
INCENP;KIF23 |
| sorafenib |
Kinase inhibitor |
Yes |
Down |
JAK-STAT signaling pathway |
0.030506558 |
13 |
NaN |
|
SOCS2;STAT1 |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Lipogenesis |
0.048447984 |
24.5 |
NaN |
|
FASN |
| sorafenib |
Kinase inhibitor |
Yes |
Down |
Mammalian target of rapamycin signaling pathway |
0.043858476 |
20 |
NaN |
|
PIK3R1;RICTOR |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Metaphase to anaphase checkpoint |
8.64E-08 |
2 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MXD3;PLK3;PTTG1;TTK |
| sorafenib |
Kinase inhibitor |
Yes |
Down |
Methionine cycle |
0.039304304 |
17.5 |
NaN |
|
BHMT |
| sorafenib |
Kinase inhibitor |
Yes |
Down |
Microfibril scaffold organization |
0.039304304 |
17.5 |
NaN |
|
FBN1 |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
0.000140678 |
5 |
NaN |
|
AURKB;CCNA2;INCENP |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Mitotic spindle assembly |
9.37E-06 |
4 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Mitotic spindle disassembly |
0.024523641 |
17 |
NaN |
|
CDK1 |
| sorafenib |
Kinase inhibitor |
Yes |
Down |
Osteopontin receptor signaling |
0.019848271 |
9.5 |
NaN |
|
SPP1 |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Platelet-derived growth factor receptor signaling |
0.028480684 |
19 |
NaN |
|
FOSL1;TNK2 |
| sorafenib |
Kinase inhibitor |
Yes |
Down |
Platelet-derived growth factor receptor signaling |
0.019170669 |
7 |
14 |
Down by cardiotoxic TKIs |
PDGFRA;RGS5 |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Removal of caspase inhibition |
0.048447984 |
24.5 |
NaN |
|
XAF1 |
| sorafenib |
Kinase inhibitor |
Yes |
Down |
Retinol metabolism |
0.02648975 |
12 |
NaN |
|
ALDH1A1;ALDH1A3 |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Semaphorin signaling |
0.049939927 |
28 |
NaN |
|
PLXNA2;PLXNA4;RND1 |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Serine and glycine metabolism |
0.002080203 |
9 |
19 |
Up by cardiotoxic TKIs |
PHGDH;PSAT1;SHMT2 |
| sorafenib |
Kinase inhibitor |
Yes |
Down |
Serotonin inactivation |
0.039304304 |
17.5 |
NaN |
|
MAOA |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Sister chromatid attachment to mitotic spindle |
0.000599299 |
7 |
NaN |
|
NUF2;TACC3 |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Sister chromatid segregation |
0.000276247 |
6 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| sorafenib |
Kinase inhibitor |
Yes |
Down |
Tropoelastin synthesis |
0.019848271 |
9.5 |
NaN |
|
ELN |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Versican receptor signaling |
0.048447984 |
24.5 |
NaN |
|
VCAN |
| sorafenib |
Kinase inhibitor |
Yes |
Up |
Versican synthesis |
0.024523641 |
17 |
NaN |
|
VCAN |
| sorafenib |
Kinase inhibitor |
Yes |
Down |
WNT-Beta-catenin signaling pathway |
0.03806357 |
14 |
NaN |
|
FRZB;PAX6;SFRP2;WNT9A |
| sorafenib |
Kinase inhibitor |
Yes |
Down |
Z-disc organization |
0.039201142 |
15 |
NaN |
|
CSRP3;PDLIM3 |
| saxagliptin |
Antidiabetic |
No |
Down |
Actin filament bundling and crosslinking |
0.019555227 |
13 |
NaN |
|
SYNPO;SYNPO2;USH1C |
| saxagliptin |
Antidiabetic |
No |
Up |
Actin filament severing and depolymerization |
0.03363188 |
13.5 |
NaN |
|
SCIN;TAGLN2 |
| saxagliptin |
Antidiabetic |
No |
Up |
Aggrecan synthesis |
0.022582922 |
11.5 |
NaN |
|
ACAN |
| saxagliptin |
Antidiabetic |
No |
Down |
Albumin mediated blood protein transport |
0.022318278 |
16 |
NaN |
|
ALB |
| saxagliptin |
Antidiabetic |
No |
Down |
Biglycan synthesis |
0.022318278 |
16 |
NaN |
|
BGN |
| saxagliptin |
Antidiabetic |
No |
Down |
Cellular cholesterol uptake and efflux |
0.000147809 |
2 |
NaN |
|
ABCA1;ABCA12;ABCG1;SCARA3 |
| saxagliptin |
Antidiabetic |
No |
Down |
Centrosome separation |
0.001173699 |
4.5 |
NaN |
|
CCNB1;CDK1;NEK2 |
| saxagliptin |
Antidiabetic |
No |
Up |
Chloride transmembrane transport |
0.03363188 |
13.5 |
NaN |
|
ANO1;SLC12A6 |
| saxagliptin |
Antidiabetic |
No |
Up |
Classical complement pathway |
0.000372505 |
1 |
NaN |
|
C1QA;C1QB;C1QC |
| saxagliptin |
Antidiabetic |
No |
Down |
Collagen fibril organization by fibril-associated bridges |
0.000209049 |
3 |
NaN |
|
COL12A1;COL14A1;COL9A1 |
| saxagliptin |
Antidiabetic |
No |
Up |
Decorin synthesis |
0.022582922 |
11.5 |
NaN |
|
DCN |
| saxagliptin |
Antidiabetic |
No |
Up |
DNA replication initiation |
0.002211379 |
4 |
NaN |
|
CDC6;MCM10;MCM5;MCM6 |
| saxagliptin |
Antidiabetic |
No |
Down |
Epithelial intermediate filament dynamics |
0.012712092 |
9 |
NaN |
|
KRT19;KRT8 |
| saxagliptin |
Antidiabetic |
No |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.01622804 |
9 |
NaN |
|
ADAMTS2;ADAMTS5;ADAMTS9 |
| saxagliptin |
Antidiabetic |
No |
Down |
Extracellular matrix breakdown by serine proteases |
0.009675618 |
8 |
NaN |
|
KLK5;PRSS12 |
| saxagliptin |
Antidiabetic |
No |
Up |
Fibrillar collagen core structure organization |
0.001214412 |
2 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| saxagliptin |
Antidiabetic |
No |
Down |
Fibrillar collagen core structure organization |
0.001173699 |
4.5 |
NaN |
|
COL11A1;COL2A1;COL5A2 |
| saxagliptin |
Antidiabetic |
No |
Down |
Fibronectin synthesis and extracellular assembly |
0.000106279 |
1 |
NaN |
|
FN1;ITGA5;ITGB3 |
| saxagliptin |
Antidiabetic |
No |
Down |
G2 M transition checkpoint |
0.028256676 |
19 |
NaN |
|
CCNB1;CDK1 |
| saxagliptin |
Antidiabetic |
No |
Up |
Glutamate and glutamine metabolism |
0.002752604 |
5 |
NaN |
|
GLS;SLC1A5;SLC7A5 |
| saxagliptin |
Antidiabetic |
No |
Down |
Granulocyte-colony stimulating factor receptor signaling |
0.016105455 |
12 |
NaN |
|
SOCS3;STAT3 |
| saxagliptin |
Antidiabetic |
No |
Up |
Hepatocyte growth factor receptor signaling |
0.044657802 |
15.5 |
NaN |
|
HGF |
| saxagliptin |
Antidiabetic |
No |
Up |
HIF-1 receptor signaling pathway |
0.016470005 |
10 |
NaN |
|
CITED2;EGLN3 |
| saxagliptin |
Antidiabetic |
No |
Up |
Inhibin receptor signaling |
0.013002108 |
8 |
NaN |
|
INHBB;INHBE |
| saxagliptin |
Antidiabetic |
No |
Down |
JAK-STAT signaling pathway |
0.037839911 |
20 |
NaN |
|
SOCS3;STAT3 |
| saxagliptin |
Antidiabetic |
No |
Down |
Leptin receptor signaling |
0.002889904 |
7 |
NaN |
|
SOCS3;STAT3 |
| saxagliptin |
Antidiabetic |
No |
Down |
Microfibril scaffold organization |
0.044140376 |
21 |
NaN |
|
FBN1 |
| saxagliptin |
Antidiabetic |
No |
Down |
Mitotic spindle assembly |
0.002661905 |
6 |
NaN |
|
DLGAP5;NUSAP1;TPX2 |
| saxagliptin |
Antidiabetic |
No |
Down |
Mitotic spindle disassembly |
0.022318278 |
16 |
NaN |
|
CDK1 |
| saxagliptin |
Antidiabetic |
No |
Up |
Natriuretic peptide receptor signaling |
0.007176501 |
7 |
NaN |
|
NPPB;NPR3 |
| saxagliptin |
Antidiabetic |
No |
Down |
Osteopontin receptor signaling |
0.022318278 |
16 |
NaN |
|
SPP1 |
| saxagliptin |
Antidiabetic |
No |
Down |
Potassium transmembrane transport |
0.015726997 |
11 |
NaN |
|
ABCC9;ATP1A2;ATP1A3 |
| saxagliptin |
Antidiabetic |
No |
Up |
Protein polyubiquitination |
0.049507089 |
17 |
NaN |
|
ISG15;UCHL1 |
| saxagliptin |
Antidiabetic |
No |
Up |
Serine and glycine metabolism |
0.00164207 |
3 |
NaN |
|
GLDC;PSAT1;SLC1A5 |
| saxagliptin |
Antidiabetic |
No |
Up |
Serotonin inactivation |
0.044657802 |
15.5 |
NaN |
|
MAOA |
| saxagliptin |
Antidiabetic |
No |
Up |
Tight junction organization |
0.006917983 |
6 |
NaN |
|
CGN;CLDN19;EMP1;MYLK |
| saxagliptin |
Antidiabetic |
No |
Down |
Tropoelastin synthesis |
0.022318278 |
16 |
NaN |
|
ELN |
| saxagliptin |
Antidiabetic |
No |
Down |
WNT-Beta-catenin signaling pathway |
0.013926759 |
10 |
NaN |
|
DACT1;DKK2;FRZB;WNT2;WNT9A |
| ruxolitinib |
Kinase inhibitor |
No |
Down |
Actin polymerization |
0.026886169 |
16 |
NaN |
|
ACTA1;ENAH;FMNL2;GAS7 |
| ruxolitinib |
Kinase inhibitor |
No |
Down |
Aggrecan synthesis |
0.027258292 |
18 |
NaN |
|
ACAN |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
Albumin mediated blood protein transport |
0.018877911 |
14 |
NaN |
|
ALB |
| ruxolitinib |
Kinase inhibitor |
No |
Down |
Antigen presentation via MHC class I molecules |
0.028842387 |
20.5 |
NaN |
|
HLA-B;HLA-C |
| ruxolitinib |
Kinase inhibitor |
No |
Down |
Aspartate and arginine metabolism |
9.99E-05 |
2 |
NaN |
|
ARG2;ASS1;SLC7A1;SLC7A2 |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
Biglycan synthesis |
0.018877911 |
14 |
NaN |
|
BGN |
| ruxolitinib |
Kinase inhibitor |
No |
Down |
CCN intercellular signaling protein family receptor signaling |
0.007013572 |
8 |
NaN |
|
CTGF;NOV |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
Centrosome maturation |
0.001286823 |
6 |
NaN |
|
AURKA;PLK1;TPX2 |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
Centrosome separation |
5.34E-07 |
2 |
NaN |
|
AURKA;CCNB1;CDK1;NEK2;SPAG5 |
| ruxolitinib |
Kinase inhibitor |
No |
Down |
Chloride transmembrane transport |
0.047387116 |
22.5 |
NaN |
|
ANO1;BEST1 |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
Cholesterol synthesis |
2.82E-05 |
3 |
NaN |
|
DHCR24;FDFT1;FDPS;HMGCS1;MVK |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
Collagen fibril organization by fibril-associated bridges |
0.005061213 |
9 |
NaN |
|
COL14A1;COL9A1 |
| ruxolitinib |
Kinase inhibitor |
No |
Down |
Collagen fibril organization by fibril-associated bridges |
0.010331661 |
9.5 |
NaN |
|
COL12A1;COL9A2 |
| ruxolitinib |
Kinase inhibitor |
No |
Down |
Connection of muscle sarcomere to plasma membrane |
0.028842387 |
20.5 |
NaN |
|
DES;SYNM |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
Decorin synthesis |
0.018877911 |
14 |
NaN |
|
DCN |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
Eukaryotic kinetochore dynamics |
0.005514636 |
11 |
NaN |
|
BUB1;CENPE;CENPF;NUF2 |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.000512369 |
5 |
NaN |
|
MMP12;MMP2;MMP3 |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
Fibrillar collagen core structure organization |
8.32E-09 |
1 |
NaN |
|
COL11A2;COL1A1;COL1A2;COL2A1;COL3A1;COL5A1 |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
Fibulin receptor signaling |
0.037401081 |
22.5 |
NaN |
|
FBLN1 |
| ruxolitinib |
Kinase inhibitor |
No |
Down |
Filopodium organization |
0.026579947 |
15 |
NaN |
|
ENAH;FMNL2;GAP43 |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
G2 M transition checkpoint |
0.020669774 |
17.5 |
NaN |
|
CCNB1;CDK1 |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
GABA metabolism |
0.005061213 |
9 |
NaN |
|
ABAT;SLC6A1 |
| ruxolitinib |
Kinase inhibitor |
No |
Down |
Glutamate and glutamine metabolism |
0.004682035 |
7 |
NaN |
|
SLC1A5;SLC38A2;SLC7A5 |
| ruxolitinib |
Kinase inhibitor |
No |
Down |
Granulocyte-colony stimulating factor receptor signaling |
0.023491402 |
14 |
NaN |
|
SOCS3;STAT3 |
| ruxolitinib |
Kinase inhibitor |
No |
Down |
Hepatocyte growth factor receptor signaling |
0.000740675 |
4 |
NaN |
|
HGF;MET |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
Inhibition of apoptosis |
0.020669774 |
17.5 |
NaN |
|
BIRC5;IFI6 |
| ruxolitinib |
Kinase inhibitor |
No |
Down |
Leptin receptor signaling |
0.004285177 |
5.5 |
NaN |
|
SOCS3;STAT3 |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
Lipogenesis |
0.037401081 |
22.5 |
NaN |
|
FASN |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
Metaphase to anaphase checkpoint |
3.65E-05 |
4 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;PTTG1 |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
Microfibril scaffold organization |
0.037401081 |
22.5 |
NaN |
|
FBN1 |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
Microtubule destabilization |
0.005061213 |
9 |
NaN |
|
KIF2C;STMN1 |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
Mitotic spindle assembly |
0.001649697 |
7 |
NaN |
|
DLGAP5;NUSAP1;TPX2 |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
Mitotic spindle disassembly |
0.018877911 |
14 |
NaN |
|
CDK1 |
| ruxolitinib |
Kinase inhibitor |
No |
Down |
Notch receptor signaling |
0.01621364 |
12 |
NaN |
|
DLK1;LFNG;NOTCH3 |
| ruxolitinib |
Kinase inhibitor |
No |
Down |
Osteonectin receptor signaling |
0.004285177 |
5.5 |
NaN |
|
SMOC2;SPOCK1 |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
Osteopontin receptor signaling |
0.018877911 |
14 |
NaN |
|
SPP1 |
| ruxolitinib |
Kinase inhibitor |
No |
Down |
Progesterone receptor signaling |
0.027258292 |
18 |
NaN |
|
PGR |
| ruxolitinib |
Kinase inhibitor |
No |
Down |
Retinoic acid receptor signaling |
0.047387116 |
22.5 |
NaN |
|
NR4A1;TBL1XR1 |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
Retinol metabolism |
0.024127969 |
19 |
NaN |
|
ALDH1A1;RDH10 |
| ruxolitinib |
Kinase inhibitor |
No |
Down |
Sarcoplasmic reticulum organization |
0.018602463 |
13 |
NaN |
|
PLN;TRDN |
| ruxolitinib |
Kinase inhibitor |
No |
Down |
Serine and glycine metabolism |
0.000153557 |
3 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
Sister chromatid attachment to mitotic spindle |
0.037401081 |
22.5 |
NaN |
|
NUF2 |
| ruxolitinib |
Kinase inhibitor |
No |
Down |
Thin myofilament organization |
0.014205479 |
11 |
NaN |
|
ACTA1;TNNI3 |
| ruxolitinib |
Kinase inhibitor |
No |
Down |
Tropoelastin synthesis |
0.027258292 |
18 |
NaN |
|
ELN |
| ruxolitinib |
Kinase inhibitor |
No |
Down |
Urea cycle |
0.010331661 |
9.5 |
NaN |
|
ARG2;ASS1 |
| ruxolitinib |
Kinase inhibitor |
No |
Up |
WNT-Beta-catenin signaling pathway |
0.03254987 |
20 |
NaN |
|
APCDD1;FRZB;SFRP2;SFRP5 |
| ruxolitinib |
Kinase inhibitor |
No |
Down |
Z-disc organization |
4.97E-05 |
1 |
NaN |
|
CSRP3;DES;LDB3;PDLIM3;TCAP |
| rosiglitazone |
Antidiabetic |
No |
Down |
Adherens junction organization |
0.007969333 |
8 |
NaN |
|
CDH1;CDH3;CGNL1;MYO1D |
| rosiglitazone |
Antidiabetic |
No |
Down |
Albumin mediated blood protein transport |
0.019407198 |
14.5 |
NaN |
|
ALB |
| rosiglitazone |
Antidiabetic |
No |
Up |
Alternative complement pathway |
0.00628096 |
8 |
NaN |
|
C3;CFH |
| rosiglitazone |
Antidiabetic |
No |
Down |
Amyloid plaque organization |
0.018374809 |
11.5 |
NaN |
|
COL25A1;HSPB6 |
| rosiglitazone |
Antidiabetic |
No |
Up |
Aspartate and arginine metabolism |
0.025958406 |
19 |
NaN |
|
ARG2;DDAH1 |
| rosiglitazone |
Antidiabetic |
No |
Down |
Biglycan synthesis |
0.019407198 |
14.5 |
NaN |
|
BGN |
| rosiglitazone |
Antidiabetic |
No |
Down |
Cellular cholesterol uptake and efflux |
0.0254047 |
17 |
NaN |
|
ABCA1;ABCG1 |
| rosiglitazone |
Antidiabetic |
No |
Up |
Cellular iron uptake and export |
0.042773869 |
21 |
NaN |
|
CP;TFRC |
| rosiglitazone |
Antidiabetic |
No |
Up |
Collagen fiber crosslinking |
0.00628096 |
8 |
NaN |
|
LOXL1;PXDN |
| rosiglitazone |
Antidiabetic |
No |
Down |
Collagen fibril organization by fibril-associated bridges |
0.005342076 |
4 |
NaN |
|
COL12A1;COL14A1 |
| rosiglitazone |
Antidiabetic |
No |
Up |
Decorin synthesis |
0.025758645 |
17.5 |
NaN |
|
DCN |
| rosiglitazone |
Antidiabetic |
No |
Up |
DNA replication initiation |
0.0255927 |
16 |
NaN |
|
CDC45;CDC6;MCM5 |
| rosiglitazone |
Antidiabetic |
No |
Up |
Endogenous control of complement activity |
0.00628096 |
8 |
NaN |
|
CFH;CFI |
| rosiglitazone |
Antidiabetic |
No |
Down |
Endothelin receptor signaling |
0.007383606 |
6.5 |
NaN |
|
ECE1;EDN1 |
| rosiglitazone |
Antidiabetic |
No |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
2.53E-05 |
1 |
NaN |
|
ADAM19;ADAM33;ADAMTS1;ADAMTS2;ADAMTS5;ADAMTS9 |
| rosiglitazone |
Antidiabetic |
No |
Down |
Extracellular matrix breakdown by cathepsins |
0.000782324 |
1 |
NaN |
|
CTSB;CTSF;CTSZ |
| rosiglitazone |
Antidiabetic |
No |
Down |
Extracellular matrix breakdown by serine proteases |
0.007383606 |
6.5 |
NaN |
|
KLK5;PRSS12 |
| rosiglitazone |
Antidiabetic |
No |
Up |
Fibrillar collagen core structure organization |
0.001774618 |
4 |
NaN |
|
COL11A2;COL1A2;COL3A1 |
| rosiglitazone |
Antidiabetic |
No |
Down |
Fibrillar collagen core structure organization |
0.015226725 |
10 |
NaN |
|
COL1A1;COL5A2 |
| rosiglitazone |
Antidiabetic |
No |
Down |
GABA metabolism |
0.005342076 |
4 |
NaN |
|
ABAT;SLC6A1 |
| rosiglitazone |
Antidiabetic |
No |
Up |
Gap junction organization |
0.04907168 |
23 |
NaN |
|
GJA5;GJA8 |
| rosiglitazone |
Antidiabetic |
No |
Up |
Glutamate and glutamine metabolism |
0.042773869 |
21 |
NaN |
|
SLC1A5;SLC7A5 |
| rosiglitazone |
Antidiabetic |
No |
Up |
Glycolysis and Gluconeogenesis |
0.020461275 |
14 |
NaN |
|
ENO1;HK2;PCK2 |
| rosiglitazone |
Antidiabetic |
No |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.021121648 |
15 |
NaN |
|
SOCS3;STAT3 |
| rosiglitazone |
Antidiabetic |
No |
Down |
Growth differentiation factor receptor signaling |
0.009719559 |
9 |
NaN |
|
GDF2;GDF6 |
| rosiglitazone |
Antidiabetic |
No |
Up |
Inhibin receptor signaling |
0.000860536 |
3 |
NaN |
|
INHBB;INHBE;TGFBR3 |
| rosiglitazone |
Antidiabetic |
No |
Up |
Interferon alpha receptor signaling |
0.016709342 |
13 |
NaN |
|
IRF9;STAT1 |
| rosiglitazone |
Antidiabetic |
No |
Up |
JAK-STAT signaling pathway |
0.000351975 |
2 |
NaN |
|
SOCS2;SOCS3;STAT1;STAT3 |
| rosiglitazone |
Antidiabetic |
No |
Up |
Leptin receptor signaling |
0.003833695 |
6 |
NaN |
|
SOCS3;STAT3 |
| rosiglitazone |
Antidiabetic |
No |
Down |
Microfibril scaffold organization |
0.038439436 |
19.5 |
NaN |
|
FBN1 |
| rosiglitazone |
Antidiabetic |
No |
Up |
Mitotic chromosome condensation |
0.01274714 |
11 |
NaN |
|
INCENP;NCAPG2 |
| rosiglitazone |
Antidiabetic |
No |
Up |
Natriuretic peptide receptor signaling |
0.009261749 |
10 |
NaN |
|
NPPA;NPPB |
| rosiglitazone |
Antidiabetic |
No |
Up |
Notch receptor signaling |
0.013937761 |
12 |
NaN |
|
DLK1;LFNG;NOTCH3 |
| rosiglitazone |
Antidiabetic |
No |
Down |
Osteopontin receptor signaling |
0.019407198 |
14.5 |
NaN |
|
SPP1 |
| rosiglitazone |
Antidiabetic |
No |
Down |
Platelet-derived growth factor receptor signaling |
0.018374809 |
11.5 |
NaN |
|
PDGFRA;TNK2 |
| rosiglitazone |
Antidiabetic |
No |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.038439436 |
19.5 |
NaN |
|
PTGFR |
| rosiglitazone |
Antidiabetic |
No |
Down |
Removal of caspase inhibition |
0.038439436 |
19.5 |
NaN |
|
XAF1 |
| rosiglitazone |
Antidiabetic |
No |
Up |
Retinol metabolism |
0.042773869 |
21 |
NaN |
|
DHRS3;RLBP1 |
| rosiglitazone |
Antidiabetic |
No |
Down |
Selectin-mediated Leukocyte rolling |
0.005342076 |
4 |
NaN |
|
SELP;VCAM1 |
| rosiglitazone |
Antidiabetic |
No |
Up |
Serine and glycine metabolism |
0.002393839 |
5 |
NaN |
|
GLDC;PSAT1;SLC1A5 |
| rosiglitazone |
Antidiabetic |
No |
Down |
Thrombospondin receptor signaling |
0.00219248 |
2 |
NaN |
|
THBS2;THBS4 |
| rosiglitazone |
Antidiabetic |
No |
Up |
Tropoelastin synthesis |
0.025758645 |
17.5 |
NaN |
|
ELN |
| rosiglitazone |
Antidiabetic |
No |
Down |
Versican receptor signaling |
0.038439436 |
19.5 |
NaN |
|
VCAN |
| rosiglitazone |
Antidiabetic |
No |
Down |
Versican synthesis |
0.019407198 |
14.5 |
NaN |
|
VCAN |
| rituximab |
Monoclonal antibody |
No |
Down |
Adrenergic receptor signaling |
0.019352519 |
8 |
NaN |
|
ADCY2;RAPGEF4;RGS4 |
| rituximab |
Monoclonal antibody |
No |
Down |
Aggrecan synthesis |
0.022230064 |
11 |
NaN |
|
ACAN |
| rituximab |
Monoclonal antibody |
No |
Up |
Antigen presentation via MHC class I molecules |
0.019397192 |
8 |
NaN |
|
HLA-B;HLA-C |
| rituximab |
Monoclonal antibody |
No |
Up |
Basement membrane assembly and organization |
0.019397192 |
8 |
NaN |
|
COL4A4;HSPG2 |
| rituximab |
Monoclonal antibody |
No |
Up |
Biglycan synthesis |
0.022053634 |
11 |
NaN |
|
BGN |
| rituximab |
Monoclonal antibody |
No |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.037023918 |
16 |
NaN |
|
KCNIP2;KCNJ2 |
| rituximab |
Monoclonal antibody |
No |
Down |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.037567125 |
14 |
NaN |
|
KCNA1;KCNQ1 |
| rituximab |
Monoclonal antibody |
No |
Down |
CCN intercellular signaling protein family receptor signaling |
0.000105033 |
1 |
NaN |
|
CTGF;NOV;WISP1 |
| rituximab |
Monoclonal antibody |
No |
Down |
Cellular cholesterol uptake and efflux |
0.032671153 |
13 |
NaN |
|
ABCA1;ABCG1 |
| rituximab |
Monoclonal antibody |
No |
Down |
Cholesterol-sensitive control of SREBP activation |
0.006960163 |
5.5 |
NaN |
|
INSIG1;SREBF1 |
| rituximab |
Monoclonal antibody |
No |
Up |
Collagen fibril organization by fibril-associated bridges |
0.000201793 |
4 |
NaN |
|
COL9A1;COL9A2;COL9A3 |
| rituximab |
Monoclonal antibody |
No |
Down |
Decorin synthesis |
0.022230064 |
11 |
NaN |
|
DCN |
| rituximab |
Monoclonal antibody |
No |
Down |
Electron transport chain |
0.002058279 |
4 |
NaN |
|
COX7A1;NDUFS4;NDUFV2 |
| rituximab |
Monoclonal antibody |
No |
Up |
Epithelial intermediate filament dynamics |
0.012425035 |
6 |
NaN |
|
KRT19;KRT4 |
| rituximab |
Monoclonal antibody |
No |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
1.04E-05 |
1 |
NaN |
|
ADAM15;ADAMTS1;ADAMTS12;ADAMTS14;ADAMTS17;ADAMTS9 |
| rituximab |
Monoclonal antibody |
No |
Up |
Extracellular matrix breakdown by cathepsins |
0.019397192 |
8 |
NaN |
|
CTSD;CTSV |
| rituximab |
Monoclonal antibody |
No |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
2.67E-05 |
2 |
NaN |
|
MMP12;MMP14;MMP2;MMP3 |
| rituximab |
Monoclonal antibody |
No |
Up |
Fibrillar collagen core structure organization |
4.37E-05 |
3 |
NaN |
|
COL11A2;COL2A1;COL3A1;COL5A2 |
| rituximab |
Monoclonal antibody |
No |
Down |
Fibrillar collagen core structure organization |
0.019690847 |
9 |
NaN |
|
COL11A1;COL1A2 |
| rituximab |
Monoclonal antibody |
No |
Down |
Glucuronidation |
0.022230064 |
11 |
NaN |
|
UGT2B4 |
| rituximab |
Monoclonal antibody |
No |
Up |
Glutamate and glutamine metabolism |
0.032195057 |
14.5 |
NaN |
|
SLC1A5;SLC7A5 |
| rituximab |
Monoclonal antibody |
No |
Down |
Glycolysis and Gluconeogenesis |
0.0015134 |
2 |
NaN |
|
LDHA;PCK2;PGK1;TPI1 |
| rituximab |
Monoclonal antibody |
No |
Down |
Hepatocyte growth factor receptor signaling |
0.043967869 |
16.5 |
NaN |
|
MET |
| rituximab |
Monoclonal antibody |
No |
Up |
Lipogenesis |
0.043622809 |
18 |
NaN |
|
FASN |
| rituximab |
Monoclonal antibody |
No |
Down |
Microfibril scaffold organization |
0.043967869 |
16.5 |
NaN |
|
FBN1 |
| rituximab |
Monoclonal antibody |
No |
Down |
Microtubule polymerization |
0.006960163 |
5.5 |
NaN |
|
DCLK1;TUBA1A |
| rituximab |
Monoclonal antibody |
No |
Up |
Perlecan synthesis |
0.022053634 |
11 |
NaN |
|
HSPG2 |
| rituximab |
Monoclonal antibody |
No |
Up |
Platelet-derived growth factor receptor signaling |
0.023366841 |
13 |
NaN |
|
FOSL1;TNK2 |
| rituximab |
Monoclonal antibody |
No |
Down |
Removal of caspase inhibition |
0.043967869 |
16.5 |
NaN |
|
XAF1 |
| rituximab |
Monoclonal antibody |
No |
Up |
Retinol metabolism |
0.032195057 |
14.5 |
NaN |
|
ALDH1A2;STRA6 |
| rituximab |
Monoclonal antibody |
No |
Up |
Semaphorin signaling |
0.038375695 |
17 |
NaN |
|
CRMP1;PLXNA4;PLXND1 |
| rituximab |
Monoclonal antibody |
No |
Down |
Serine and glycine metabolism |
0.00156935 |
3 |
NaN |
|
PHGDH;SHMT2;SLC1A4 |
| rituximab |
Monoclonal antibody |
No |
Down |
Serotonin inactivation |
0.043967869 |
16.5 |
NaN |
|
MAOA |
| rituximab |
Monoclonal antibody |
No |
Up |
Sulfonation |
0.004636036 |
5 |
NaN |
|
SULT1A1;SULT1E1 |
| rituximab |
Monoclonal antibody |
No |
Down |
Transamination pathways |
0.009601976 |
7 |
NaN |
|
BCAT1;GOT1 |
| rituximab |
Monoclonal antibody |
No |
Up |
Tropoelastin synthesis |
0.022053634 |
11 |
NaN |
|
ELN |
| rituximab |
Monoclonal antibody |
No |
Down |
Z-disc organization |
0.048125749 |
19 |
NaN |
|
CSRP3;TCAP |
| regorafenib |
Kinase inhibitor |
No |
Up |
Aggrecan synthesis |
0.024964714 |
24 |
NaN |
|
ACAN |
| regorafenib |
Kinase inhibitor |
No |
Down |
Antigen presentation via MHC class I molecules |
0.017535602 |
7.5 |
NaN |
|
HLA-B;HLA-C |
| regorafenib |
Kinase inhibitor |
No |
Up |
Centrosome maturation |
0.002865155 |
11 |
NaN |
|
AURKA;PLK1;TPX2 |
| regorafenib |
Kinase inhibitor |
No |
Up |
Centrosome separation |
6.32E-10 |
2 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| regorafenib |
Kinase inhibitor |
No |
Up |
Chaperone-mediated autophagy |
0.049308339 |
30 |
NaN |
|
HSPA8 |
| regorafenib |
Kinase inhibitor |
No |
Up |
Cholesterol synthesis |
4.90E-15 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;FDFT1;FDPS;HMGCR;HMGCS1;LSS;MSMO1;MVD;NSDHL;SQLE |
| regorafenib |
Kinase inhibitor |
No |
Up |
Collagen fibril organization by fibril-associated bridges |
0.0087173 |
17 |
NaN |
|
COL9A2;COL9A3 |
| regorafenib |
Kinase inhibitor |
No |
Up |
Contractile ring constriction |
0.000148334 |
6 |
NaN |
|
ANLN;ECT2;MYH14 |
| regorafenib |
Kinase inhibitor |
No |
Up |
Contractile ring formation |
0.005908595 |
14.5 |
NaN |
|
MYH14;RACGAP1 |
| regorafenib |
Kinase inhibitor |
No |
Up |
Decorin synthesis |
0.024964714 |
24 |
NaN |
|
DCN |
| regorafenib |
Kinase inhibitor |
No |
Up |
Desaturation of fatty acids |
0.012004155 |
19.5 |
NaN |
|
FADS2;SCD |
| regorafenib |
Kinase inhibitor |
No |
Up |
Equatorial RhoA activation |
0.003604491 |
12.5 |
NaN |
|
ECT2;KIF23 |
| regorafenib |
Kinase inhibitor |
No |
Down |
ER unfolded protein response pathway |
0.011215577 |
6 |
NaN |
|
ATF4;HERPUD1 |
| regorafenib |
Kinase inhibitor |
No |
Up |
Eukaryotic kinetochore dynamics |
3.49E-06 |
3 |
NaN |
|
BUB1;CENPE;CENPF;MTUS2;NDC80;NUF2;SPC24;TTK |
| regorafenib |
Kinase inhibitor |
No |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.021145298 |
21 |
NaN |
|
ADAM33;ADAMTS15;ADAMTS2 |
| regorafenib |
Kinase inhibitor |
No |
Up |
Fibrillar collagen core structure organization |
7.09E-05 |
5 |
NaN |
|
COL11A1;COL2A1;COL5A1;COL5A2 |
| regorafenib |
Kinase inhibitor |
No |
Down |
Fibrillar collagen core structure organization |
0.000971271 |
2 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| regorafenib |
Kinase inhibitor |
No |
Up |
G2 M transition checkpoint |
0.034752905 |
27 |
NaN |
|
CCNB1;CDK1 |
| regorafenib |
Kinase inhibitor |
No |
Down |
Gap junction organization |
0.033571046 |
12 |
NaN |
|
GJA3;GJA5 |
| regorafenib |
Kinase inhibitor |
No |
Down |
Glutamate and glutamine metabolism |
0.029170805 |
10.5 |
NaN |
|
SLC38A2;SLC7A5 |
| regorafenib |
Kinase inhibitor |
No |
Up |
Hyaluronan-mediated motility receptor signaling |
0.024964714 |
24 |
NaN |
|
HMMR |
| regorafenib |
Kinase inhibitor |
No |
Up |
Lipogenesis |
0.049308339 |
30 |
NaN |
|
FASN |
| regorafenib |
Kinase inhibitor |
No |
Up |
MAPK signaling pathway |
0.038039913 |
28 |
NaN |
|
FOXM1;MAP2K3;MAP2K6 |
| regorafenib |
Kinase inhibitor |
No |
Up |
Metaphase to anaphase checkpoint |
1.69E-05 |
4 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;PTTG1;TTK |
| regorafenib |
Kinase inhibitor |
No |
Down |
Methionine cycle |
0.041378401 |
14.5 |
NaN |
|
BHMT |
| regorafenib |
Kinase inhibitor |
No |
Up |
Microtubule destabilization |
0.0087173 |
17 |
NaN |
|
KIF2C;STMN1 |
| regorafenib |
Kinase inhibitor |
No |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
0.005908595 |
14.5 |
NaN |
|
AURKB;CCNA2 |
| regorafenib |
Kinase inhibitor |
No |
Up |
Mitotic spindle assembly |
0.000227554 |
7 |
NaN |
|
DLGAP5;NUSAP1;TPX2;TTK |
| regorafenib |
Kinase inhibitor |
No |
Up |
Mitotic spindle disassembly |
0.024964714 |
24 |
NaN |
|
CDK1 |
| regorafenib |
Kinase inhibitor |
No |
Up |
Muscarinic receptor signaling |
0.0087173 |
17 |
NaN |
|
CHRM4;RGS5 |
| regorafenib |
Kinase inhibitor |
No |
Down |
Myofibril formation |
0.017535602 |
7.5 |
NaN |
|
DES;MYOZ1 |
| regorafenib |
Kinase inhibitor |
No |
Down |
Natriuretic peptide receptor signaling |
0.006176635 |
5 |
NaN |
|
NPPA;NPPB |
| regorafenib |
Kinase inhibitor |
No |
Down |
Osteonectin receptor signaling |
0.002540098 |
4 |
NaN |
|
SPARC;SPOCK1 |
| regorafenib |
Kinase inhibitor |
No |
Up |
Osteopontin receptor signaling |
0.024964714 |
24 |
NaN |
|
SPP1 |
| regorafenib |
Kinase inhibitor |
No |
Up |
Platelet-derived growth factor receptor signaling |
0.002189037 |
10 |
NaN |
|
PDGFRA;PDGFRB;RGS5 |
| regorafenib |
Kinase inhibitor |
No |
Up |
Polyol pathway |
0.003604491 |
12.5 |
NaN |
|
AKR1A1;SORD |
| regorafenib |
Kinase inhibitor |
No |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.041378401 |
14.5 |
NaN |
|
PTGFR |
| regorafenib |
Kinase inhibitor |
No |
Up |
Proteasomal regulatory particle organization |
0.012004155 |
19.5 |
NaN |
|
PSMC4;PSMD14 |
| regorafenib |
Kinase inhibitor |
No |
Down |
Retinol metabolism |
0.029170805 |
10.5 |
NaN |
|
RDH10;STRA6 |
| regorafenib |
Kinase inhibitor |
No |
Down |
Serine and glycine metabolism |
0.001314959 |
3 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| regorafenib |
Kinase inhibitor |
No |
Down |
Serotonin inactivation |
0.041378401 |
14.5 |
NaN |
|
MAOA |
| regorafenib |
Kinase inhibitor |
No |
Up |
Sister chromatid attachment to mitotic spindle |
0.049308339 |
30 |
NaN |
|
NUF2 |
| regorafenib |
Kinase inhibitor |
No |
Up |
Sister chromatid segregation |
0.000291184 |
8 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| regorafenib |
Kinase inhibitor |
No |
Down |
Tropoelastin synthesis |
0.020906845 |
9 |
NaN |
|
ELN |
| regorafenib |
Kinase inhibitor |
No |
Down |
Vasoactive intestinal peptide receptor signaling |
0.041378401 |
14.5 |
NaN |
|
VIPR1 |
| regorafenib |
Kinase inhibitor |
No |
Up |
WNT-Beta-catenin signaling pathway |
0.001032546 |
9 |
NaN |
|
APCDD1;CTHRC1;DKK2;FRZB;SFRP4;SFRP5;WNT2 |
| regorafenib |
Kinase inhibitor |
No |
Down |
Z-disc organization |
0.000278145 |
1 |
NaN |
|
CSRP3;DES;MYOZ1;PDLIM3 |
| prednisolone |
Glucocorticoid |
Yes |
Up |
Albumin mediated blood protein transport |
0.018966126 |
5 |
NaN |
|
ALB |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Base excision repair |
0.007309952 |
22 |
NaN |
|
FEN1;NEIL3;PCNA;POLQ |
| prednisolone |
Glucocorticoid |
Yes |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.028045575 |
7 |
NaN |
|
KCNJ12;KCNJ2 |
| prednisolone |
Glucocorticoid |
Yes |
Down |
CCN intercellular signaling protein family receptor signaling |
0.00741681 |
23.5 |
NaN |
|
CTGF;CYR61 |
| prednisolone |
Glucocorticoid |
Yes |
Up |
Cellular iron uptake and export |
0.024338824 |
6 |
NaN |
|
RASD1;SLC39A14 |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Centrosome maturation |
0.003985148 |
19 |
NaN |
|
AURKA;PLK1;TPX2 |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Centrosome organization |
0.011839456 |
29 |
NaN |
|
ASPM;NEK2;PLK4;POC1A;TACC3;WDR62 |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Centrosome separation |
1.43E-09 |
3 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| prednisolone |
Glucocorticoid |
Yes |
Up |
Class switch recombination |
0.049549457 |
11 |
NaN |
|
BCL6;IRF8 |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Collagen fibril organization by fibril-associated bridges |
0.010919862 |
27 |
NaN |
|
COL14A1;COL9A1 |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Contractile ring constriction |
0.00741681 |
23.5 |
NaN |
|
ANLN;ECT2 |
| prednisolone |
Glucocorticoid |
Yes |
Down |
DNA replication elongation |
1.68E-08 |
4 |
NaN |
|
MCM2;MCM4;MCM5;MCM7;PCNA |
| prednisolone |
Glucocorticoid |
Yes |
Down |
DNA replication initiation |
4.75E-16 |
1 |
NaN |
|
CDC45;CDC6;GINS1;GINS2;GINS4;MCM10;MCM2;MCM3;MCM4;MCM5;MCM6;MCM7;ORC6;TICRR |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Equatorial RhoA activation |
0.004533971 |
20.5 |
NaN |
|
ECT2;KIF23 |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Eukaryotic kinetochore dynamics |
7.41E-13 |
2 |
NaN |
|
BUB1;CENPE;CENPF;CENPH;CENPI;CENPU;KIF15;MAD2L1;NDC80;NUF2;SKA3;SPC24;TTK;ZWINT |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Fanconi anemia interstrand cross-link repair pathway |
5.32E-06 |
8 |
NaN |
|
BRCA2;BRIP1;FANCA;FANCD2;FANCG;FANCI;UBE2T |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Fibrillar collagen core structure organization |
3.78E-06 |
7 |
NaN |
|
COL1A1;COL1A2;COL2A1;COL3A1;COL5A2 |
| prednisolone |
Glucocorticoid |
Yes |
Down |
G2 M transition checkpoint |
0.000251674 |
12 |
NaN |
|
CCNB1;CDC25C;CDK1;CHEK2 |
| prednisolone |
Glucocorticoid |
Yes |
Up |
Glycogen synthesis and glycogenolysis |
0.036079961 |
9 |
NaN |
|
AGL;PPP1R3B |
| prednisolone |
Glucocorticoid |
Yes |
Up |
HIF-1 receptor signaling pathway |
0.000519411 |
1 |
NaN |
|
EGLN1;EGLN3;HIF1A |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Homologous recombination DSB repair |
0.000267364 |
13 |
NaN |
|
BRCA2;EXO1;PIF1;RAD51AP1;RECQL4;RMI2;XRCC2 |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Intracellular bridge assembly |
0.002309819 |
17.5 |
NaN |
|
INCENP;KIF23 |
| prednisolone |
Glucocorticoid |
Yes |
Up |
Lipid droplet biogenesis |
0.000731661 |
2 |
NaN |
|
FITM2;PLIN2;PLIN5 |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Metaphase to anaphase checkpoint |
2.72E-07 |
5 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;MXD3;PTTG1;TTK |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Microtubule destabilization |
0.010919862 |
27 |
NaN |
|
KIF2C;STMN1 |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Mitotic chromosome condensation |
1.99E-05 |
9 |
NaN |
|
INCENP;NCAPG2;SMC2;SMC4 |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.000209712 |
11 |
NaN |
|
AURKB;CCNA2;INCENP |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Mitotic spindle assembly |
6.76E-07 |
6 |
NaN |
|
CKAP2;DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| prednisolone |
Glucocorticoid |
Yes |
Up |
Natriuretic peptide receptor signaling |
0.005107525 |
3 |
NaN |
|
NPPA;NPPB |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Notch receptor signaling |
0.017499293 |
30 |
NaN |
|
DLK1;JAG1;NOTCH3 |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Nuclear envelope maintenance |
0.010919862 |
27 |
NaN |
|
LMNB1;TMPO |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Nuclear intermediate filaments |
0.000410704 |
14.5 |
NaN |
|
LMNB1;LMNB2;TMPO |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Osteonectin receptor signaling |
0.004533971 |
20.5 |
NaN |
|
SPARC;SPOCK1 |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Ribonucleotide reduction |
0.002309819 |
17.5 |
NaN |
|
RRM1;RRM2 |
| prednisolone |
Glucocorticoid |
Yes |
Up |
Serotonin inactivation |
0.037574179 |
10 |
NaN |
|
MAOA |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Sister chromatid attachment to mitotic spindle |
0.000784522 |
16 |
NaN |
|
NUF2;TACC3 |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Sister chromatid segregation |
0.000410704 |
14.5 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Telomere replication and maintenance |
0.00933578 |
25 |
NaN |
|
EXO1;PIF1;RECQL4 |
| prednisolone |
Glucocorticoid |
Yes |
Down |
Thrombospondin receptor signaling |
8.57E-05 |
10 |
NaN |
|
CD47;THBS1;THBS2 |
| prednisolone |
Glucocorticoid |
Yes |
Up |
Water transmembrane transport |
0.009298267 |
4 |
NaN |
|
AQP1;AQP10 |
| prednisolone |
Glucocorticoid |
Yes |
Up |
WNT-Beta-catenin signaling pathway |
0.033030217 |
8 |
NaN |
|
AXIN2;DKK3;SFRP5;WNT9A |
| ponatinib |
Kinase inhibitor |
Yes |
Down |
Adrenergic receptor signaling |
0.026192093 |
14 |
8 |
Down by cardiotoxic TKIs |
RASD1;RGS16;RGS4 |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
Albumin mediated blood protein transport |
0.021436133 |
18 |
NaN |
|
ALB |
| ponatinib |
Kinase inhibitor |
Yes |
Down |
Biglycan synthesis |
0.024964714 |
12.5 |
18 |
Down by cardiotoxic TKIs |
BGN |
| ponatinib |
Kinase inhibitor |
Yes |
Down |
Cardiomyocyte pacemaker current generation |
0.000785504 |
4 |
NaN |
|
CACNA1D;CACNA1G;HCN4 |
| ponatinib |
Kinase inhibitor |
Yes |
Down |
CCN intercellular signaling protein family receptor signaling |
0.005908595 |
6 |
NaN |
|
CTGF;CYR61 |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
Centrosome maturation |
0.001854703 |
10.5 |
NaN |
|
AURKA;PLK1;TPX2 |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
Centrosome separation |
2.17E-10 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| ponatinib |
Kinase inhibitor |
Yes |
Down |
Chloride transmembrane transport |
0.003656435 |
5 |
17 |
Down by cardiotoxic TKIs |
ANO1;SLC12A6;SLC12A7 |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
Contractile ring constriction |
0.004385018 |
14 |
NaN |
|
ANLN;ECT2 |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
Decorin synthesis |
0.021436133 |
18 |
NaN |
|
DCN |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
Equatorial RhoA activation |
0.00266871 |
12.5 |
NaN |
|
ECT2;KIF23 |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
Eukaryotic kinetochore dynamics |
1.11E-06 |
4 |
NaN |
|
BUB1;CENPE;CENPF;KNSTRN;MAD2L1;NDC80;NUF2;TTK |
| ponatinib |
Kinase inhibitor |
Yes |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.019911463 |
9 |
NaN |
|
MMP14;MMP3 |
| ponatinib |
Kinase inhibitor |
Yes |
Down |
Fibrillar collagen core structure organization |
0.024483872 |
10.5 |
NaN |
|
COL1A1;COL1A2 |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
G2 M transition checkpoint |
0.001854703 |
10.5 |
NaN |
|
CCNB1;CDC25C;CDK1 |
| ponatinib |
Kinase inhibitor |
Yes |
Down |
Gap junction organization |
0.046379866 |
15 |
24 |
Down by cardiotoxic TKIs |
GJA5;GJB2 |
| ponatinib |
Kinase inhibitor |
Yes |
Down |
Growth differentiation factor receptor signaling |
0.015743705 |
8 |
NaN |
|
GDF11;GDF6 |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
Hyaluronan-mediated motility receptor signaling |
0.021436133 |
18 |
NaN |
|
HMMR |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
Inhibition of apoptosis |
0.026216245 |
21 |
NaN |
|
BIRC5;IFI6 |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
Intracellular bridge assembly |
0.001353509 |
8 |
NaN |
|
INCENP;KIF23 |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
Metaphase to anaphase checkpoint |
4.46E-07 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;PTTG1;TTK |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
Methionine cycle |
0.042414608 |
22.5 |
NaN |
|
BHMT |
| ponatinib |
Kinase inhibitor |
Yes |
Down |
Microfibril scaffold organization |
0.049308339 |
16 |
NaN |
|
FBN1 |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
Mitotic chromosome condensation |
0.008950881 |
15 |
NaN |
|
INCENP;SMC4 |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
9.42E-05 |
5 |
NaN |
|
AURKB;CCNA2;INCENP |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
Mitotic spindle assembly |
1.38E-07 |
2 |
NaN |
|
CKAP2;DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
Mitotic spindle disassembly |
0.021436133 |
18 |
NaN |
|
CDK1 |
| ponatinib |
Kinase inhibitor |
Yes |
Down |
Muscarinic receptor signaling |
0.0087173 |
7 |
NaN |
|
CHRM4;RGS4 |
| ponatinib |
Kinase inhibitor |
Yes |
Down |
Myofibril formation |
0.024483872 |
10.5 |
6 |
Down by cardiotoxic TKIs |
KLHL41;XIRP1 |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
Osteonectin receptor signaling |
0.00266871 |
12.5 |
NaN |
|
SMOC2;SPOCK1 |
| ponatinib |
Kinase inhibitor |
Yes |
Down |
Platelet-derived growth factor receptor signaling |
0.000109262 |
2 |
14 |
Down by cardiotoxic TKIs |
FOSL1;PDGFB;PDGFRA;PDGFRB |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
Protein polyubiquitination |
0.04507252 |
24 |
NaN |
|
ISG15;UCHL1 |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
Serine and glycine metabolism |
0.001413291 |
9 |
19 |
Up by cardiotoxic TKIs |
PHGDH;PSAT1;SHMT2 |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
Sister chromatid attachment to mitotic spindle |
0.000457657 |
7 |
NaN |
|
NUF2;TACC3 |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
Sister chromatid segregation |
0.000185509 |
6 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| ponatinib |
Kinase inhibitor |
Yes |
Down |
Thin myofilament organization |
1.25E-05 |
1 |
21 |
Down by cardiotoxic TKIs |
ACTA1;LMOD3;TNNI3;TPM2 |
| ponatinib |
Kinase inhibitor |
Yes |
Down |
Tropoelastin synthesis |
0.024964714 |
12.5 |
NaN |
|
ELN |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
Versican receptor signaling |
0.042414608 |
22.5 |
NaN |
|
VCAN |
| ponatinib |
Kinase inhibitor |
Yes |
Up |
Versican synthesis |
0.021436133 |
18 |
NaN |
|
VCAN |
| ponatinib |
Kinase inhibitor |
Yes |
Down |
Z-disc organization |
0.000545929 |
3 |
NaN |
|
CSRP3;MYPN;PDLIM3;TCAP |
| pioglitazone |
Antidiabetic |
No |
Down |
Aggrecan synthesis |
0.023553282 |
13.5 |
NaN |
|
ACAN |
| pioglitazone |
Antidiabetic |
No |
Up |
Albumin mediated blood protein transport |
0.020906845 |
13 |
NaN |
|
ALB |
| pioglitazone |
Antidiabetic |
No |
Up |
Axonal intermediate filament dynamics |
0.00852857 |
7.5 |
NaN |
|
NEFH;NES |
| pioglitazone |
Antidiabetic |
No |
Down |
Basement membrane assembly and organization |
0.02195395 |
10 |
NaN |
|
COL8A2;HSPG2 |
| pioglitazone |
Antidiabetic |
No |
Up |
Biglycan synthesis |
0.020906845 |
13 |
NaN |
|
BGN |
| pioglitazone |
Antidiabetic |
No |
Down |
CCN intercellular signaling protein family receptor signaling |
0.005273302 |
5.5 |
NaN |
|
CTGF;CYR61 |
| pioglitazone |
Antidiabetic |
No |
Down |
Cellular cholesterol uptake and efflux |
0.036331775 |
18.5 |
NaN |
|
ARL4C;SCARA3 |
| pioglitazone |
Antidiabetic |
No |
Up |
Cholesterol-sensitive control of SREBP activation |
0.006176635 |
5.5 |
NaN |
|
INSIG1;SREBF1 |
| pioglitazone |
Antidiabetic |
No |
Down |
Classical complement pathway |
9.96E-06 |
1 |
NaN |
|
C1QA;C1QB;C1QC;C1R |
| pioglitazone |
Antidiabetic |
No |
Down |
Collagen fibril organization by fibril-associated bridges |
0.007787369 |
7.5 |
NaN |
|
COL12A1;COL14A1 |
| pioglitazone |
Antidiabetic |
No |
Down |
Decorin synthesis |
0.023553282 |
13.5 |
NaN |
|
DCN |
| pioglitazone |
Antidiabetic |
No |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.018142498 |
9 |
NaN |
|
ADAM19;ADAMTS1;ADAMTS8 |
| pioglitazone |
Antidiabetic |
No |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.014222736 |
9 |
NaN |
|
MMP1;MMP2 |
| pioglitazone |
Antidiabetic |
No |
Up |
Fibrillar collagen core structure organization |
0.017535602 |
10.5 |
NaN |
|
COL1A1;COL5A1 |
| pioglitazone |
Antidiabetic |
No |
Down |
Fibrillar collagen core structure organization |
5.65E-05 |
3 |
NaN |
|
COL11A1;COL1A2;COL2A1;COL3A1 |
| pioglitazone |
Antidiabetic |
No |
Down |
Glutamate and glutamine metabolism |
0.0031016 |
4 |
NaN |
|
SLC1A5;SLC38A2;SLC7A5 |
| pioglitazone |
Antidiabetic |
No |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.046553835 |
22 |
NaN |
|
JUND |
| pioglitazone |
Antidiabetic |
No |
Down |
Hepatocyte growth factor receptor signaling |
0.046553835 |
22 |
NaN |
|
HGF |
| pioglitazone |
Antidiabetic |
No |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.00128782 |
1 |
NaN |
|
A2M;PLAT |
| pioglitazone |
Antidiabetic |
No |
Down |
Macrophage migration inhibitory factor signaling |
0.005273302 |
5.5 |
NaN |
|
ACKR3;JUND |
| pioglitazone |
Antidiabetic |
No |
Up |
Microfibril scaffold organization |
0.041378401 |
16.5 |
NaN |
|
FBN1 |
| pioglitazone |
Antidiabetic |
No |
Up |
Myofibril formation |
0.017535602 |
10.5 |
NaN |
|
DES;KLHL41 |
| pioglitazone |
Antidiabetic |
No |
Down |
Natriuretic peptide receptor signaling |
0.007787369 |
7.5 |
NaN |
|
NPPB;NPR3 |
| pioglitazone |
Antidiabetic |
No |
Down |
Osteonectin receptor signaling |
5.08E-05 |
2 |
NaN |
|
SMOC2;SPARC;SPOCK1 |
| pioglitazone |
Antidiabetic |
No |
Up |
Osteopontin receptor signaling |
0.020906845 |
13 |
NaN |
|
SPP1 |
| pioglitazone |
Antidiabetic |
No |
Down |
Perlecan synthesis |
0.023553282 |
13.5 |
NaN |
|
HSPG2 |
| pioglitazone |
Antidiabetic |
No |
Up |
Platelet-derived growth factor receptor signaling |
0.02114019 |
15 |
NaN |
|
PDGFRA;PDGFRB |
| pioglitazone |
Antidiabetic |
No |
Down |
Progesterone receptor signaling |
0.023553282 |
13.5 |
NaN |
|
PGR |
| pioglitazone |
Antidiabetic |
No |
Up |
Prostaglandin E2 receptor signaling |
0.006176635 |
5.5 |
NaN |
|
PTGER3;RAPGEF4 |
| pioglitazone |
Antidiabetic |
No |
Down |
Removal of caspase inhibition |
0.046553835 |
22 |
NaN |
|
XAF1 |
| pioglitazone |
Antidiabetic |
No |
Down |
Retinoic acid receptor signaling |
0.036331775 |
18.5 |
NaN |
|
NCOR2;NR4A1 |
| pioglitazone |
Antidiabetic |
No |
Up |
Retinol metabolism |
0.002209804 |
2 |
NaN |
|
ALDH1A1;RBP1;STRA6 |
| pioglitazone |
Antidiabetic |
No |
Down |
Serine and glycine metabolism |
0.026420838 |
17 |
NaN |
|
SHMT2;SLC1A5 |
| pioglitazone |
Antidiabetic |
No |
Down |
Serotonin inactivation |
0.046553835 |
22 |
NaN |
|
MAOA |
| pioglitazone |
Antidiabetic |
No |
Up |
Sulfonation |
0.004175176 |
4 |
NaN |
|
SULT1A1;SULT1E1 |
| pioglitazone |
Antidiabetic |
No |
Up |
Thin myofilament organization |
0.00852857 |
7.5 |
NaN |
|
ACTA1;TNNI3 |
| pioglitazone |
Antidiabetic |
No |
Up |
Thrombospondin receptor signaling |
0.002540098 |
3 |
NaN |
|
THBS1;THBS2 |
| pioglitazone |
Antidiabetic |
No |
Down |
Tropoelastin synthesis |
0.023553282 |
13.5 |
NaN |
|
ELN |
| pioglitazone |
Antidiabetic |
No |
Up |
Vasoactive intestinal peptide receptor signaling |
0.041378401 |
16.5 |
NaN |
|
VIPR1 |
| pioglitazone |
Antidiabetic |
No |
Down |
Versican receptor signaling |
0.046553835 |
22 |
NaN |
|
VCAN |
| pioglitazone |
Antidiabetic |
No |
Down |
Versican synthesis |
0.023553282 |
13.5 |
NaN |
|
VCAN |
| pioglitazone |
Antidiabetic |
No |
Up |
Z-disc organization |
0.043080025 |
18 |
NaN |
|
DES;TCAP |
| phenylephrine |
Sympathomimetic |
No |
Up |
Actin filament bundling and crosslinking |
0.003732001 |
3 |
NaN |
|
FLNA;FLNB;TAGLN;USH1C |
| phenylephrine |
Sympathomimetic |
No |
Up |
Actin polymerization |
0.020461081 |
8 |
NaN |
|
ACTA1;CYFIP2;FMNL2;HSPB1 |
| phenylephrine |
Sympathomimetic |
No |
Down |
Adenylyl cyclase signaling pathway |
0.046780829 |
17 |
NaN |
|
ADCY3;PDE3A |
| phenylephrine |
Sympathomimetic |
No |
Up |
Adrenergic receptor signaling |
0.02643188 |
13 |
NaN |
|
PPP1R9B;RASD1;RGS4 |
| phenylephrine |
Sympathomimetic |
No |
Down |
Albumin mediated blood protein transport |
0.019407198 |
10.5 |
NaN |
|
ALB |
| phenylephrine |
Sympathomimetic |
No |
Up |
Amyloid plaque organization |
0.029631379 |
14.5 |
NaN |
|
COL25A1;HSPB6 |
| phenylephrine |
Sympathomimetic |
No |
Down |
Antigen presentation via MHC class I molecules |
0.015226725 |
7 |
NaN |
|
HLA-B;HLA-C |
| phenylephrine |
Sympathomimetic |
No |
Up |
Biglycan synthesis |
0.025052929 |
11 |
NaN |
|
BGN |
| phenylephrine |
Sympathomimetic |
No |
Up |
Calcium transmembrane transport |
0.023812663 |
9 |
NaN |
|
ATP2B4;SLC8A1;TRPC4 |
| phenylephrine |
Sympathomimetic |
No |
Up |
Cardiomyocyte depolarization during action potential |
0.025052929 |
11 |
NaN |
|
SCN5A |
| phenylephrine |
Sympathomimetic |
No |
Down |
Centrosome separation |
0.000782324 |
2.5 |
NaN |
|
CDK1;ESPL1;KIF11 |
| phenylephrine |
Sympathomimetic |
No |
Up |
Chaperone-mediated autophagy |
0.049480363 |
18.5 |
NaN |
|
HSPA8 |
| phenylephrine |
Sympathomimetic |
No |
Down |
Collagen fibril organization by fibril-associated bridges |
0.005342076 |
6 |
NaN |
|
COL9A1;COL9A3 |
| phenylephrine |
Sympathomimetic |
No |
Down |
Decorin synthesis |
0.019407198 |
10.5 |
NaN |
|
DCN |
| phenylephrine |
Sympathomimetic |
No |
Down |
Fibrillar collagen core structure organization |
0.000782324 |
2.5 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| phenylephrine |
Sympathomimetic |
No |
Up |
Glutamate and glutamine metabolism |
0.04066719 |
16 |
NaN |
|
SLC1A3;SLC7A5 |
| phenylephrine |
Sympathomimetic |
No |
Down |
Inhibition of apoptosis |
0.021771043 |
13 |
NaN |
|
BIRC5;XAF1 |
| phenylephrine |
Sympathomimetic |
No |
Up |
JAK-STAT signaling pathway |
0.046676079 |
17 |
NaN |
|
SOCS2;STAT4 |
| phenylephrine |
Sympathomimetic |
No |
Up |
Microfibril scaffold organization |
0.049480363 |
18.5 |
NaN |
|
FBN1 |
| phenylephrine |
Sympathomimetic |
No |
Down |
Mitotic spindle disassembly |
0.019407198 |
10.5 |
NaN |
|
CDK1 |
| phenylephrine |
Sympathomimetic |
No |
Up |
Natriuretic peptide receptor signaling |
0.008777038 |
5 |
NaN |
|
NPPA;NPPB |
| phenylephrine |
Sympathomimetic |
No |
Up |
Nodal growth differentiation factor receptor signaling |
0.004613854 |
4 |
NaN |
|
LEFTY2;NCLN;TGIF1 |
| phenylephrine |
Sympathomimetic |
No |
Up |
Notch receptor signaling |
0.012935202 |
6 |
NaN |
|
JAG2;NOTCH1;NOTCH3 |
| phenylephrine |
Sympathomimetic |
No |
Down |
Osteopontin receptor signaling |
0.019407198 |
10.5 |
NaN |
|
SPP1 |
| phenylephrine |
Sympathomimetic |
No |
Up |
Platelet-derived growth factor receptor signaling |
0.029631379 |
14.5 |
NaN |
|
PDGFB;PDGFRB |
| phenylephrine |
Sympathomimetic |
No |
Down |
Platelet-derived growth factor receptor signaling |
0.018374809 |
8 |
NaN |
|
PDGFD;PDGFRA |
| phenylephrine |
Sympathomimetic |
No |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.038439436 |
15.5 |
NaN |
|
PTGFR |
| phenylephrine |
Sympathomimetic |
No |
Down |
Removal of caspase inhibition |
0.038439436 |
15.5 |
NaN |
|
XAF1 |
| phenylephrine |
Sympathomimetic |
No |
Down |
Retinol metabolism |
0.001785928 |
4 |
NaN |
|
ALDH1A1;DHRS3;TTR |
| phenylephrine |
Sympathomimetic |
No |
Down |
Serotonin inactivation |
0.00037496 |
1 |
NaN |
|
MAOA;MAOB |
| phenylephrine |
Sympathomimetic |
No |
Down |
Syndecan receptor signaling |
0.003607424 |
5 |
NaN |
|
SDC1;SDC3 |
| phenylephrine |
Sympathomimetic |
No |
Up |
Thin myofilament organization |
0.000505368 |
1 |
NaN |
|
ACTA1;LMOD3;TPM2 |
| phenylephrine |
Sympathomimetic |
No |
Up |
Thrombospondin receptor signaling |
0.003629621 |
2 |
NaN |
|
THBS2;THBS4 |
| phenylephrine |
Sympathomimetic |
No |
Up |
Tropoelastin synthesis |
0.025052929 |
11 |
NaN |
|
ELN |
| phenylephrine |
Sympathomimetic |
No |
Up |
Water transmembrane transport |
0.015849734 |
7 |
NaN |
|
AQP1;AQP3 |
| phenylephrine |
Sympathomimetic |
No |
Down |
WNT-Beta-catenin signaling pathway |
0.035494567 |
14 |
NaN |
|
FRZB;FZD7;PAX6;SFRP2 |
| pazopanib |
Kinase inhibitor |
Yes |
Down |
Alternative complement pathway |
0.005081819 |
2.5 |
NaN |
|
C3;CFH |
| pazopanib |
Kinase inhibitor |
Yes |
Down |
CCN intercellular signaling protein family receptor signaling |
0.005081819 |
2.5 |
NaN |
|
CTGF;CYR61 |
| pazopanib |
Kinase inhibitor |
Yes |
Down |
CD44-Mediated leukocyte rolling |
0.045692235 |
12 |
NaN |
|
CD44 |
| pazopanib |
Kinase inhibitor |
Yes |
Up |
Cholesterol synthesis |
0.006522404 |
7 |
22 |
Up by cardiotoxic TKIs |
DHCR24;DHCR7;EBP |
| pazopanib |
Kinase inhibitor |
Yes |
Up |
Cholesterol-sensitive control of SREBP activation |
0.005389583 |
5.5 |
15 |
Up by cardiotoxic TKIs |
INSIG1;SREBF1 |
| pazopanib |
Kinase inhibitor |
Yes |
Up |
Citric acid cycle |
0.0018093 |
3 |
1 |
Up by cardiotoxic TKIs |
ACO2;CS;OGDH |
| pazopanib |
Kinase inhibitor |
Yes |
Up |
Decorin synthesis |
0.019495413 |
11.5 |
NaN |
|
DCN |
| pazopanib |
Kinase inhibitor |
Yes |
Up |
Desaturation of fatty acids |
0.007448831 |
9 |
11 |
Up by cardiotoxic TKIs |
FADS2;SCD |
| pazopanib |
Kinase inhibitor |
Yes |
Up |
ER unfolded protein response pathway |
0.000380789 |
2 |
NaN |
|
ATF4;DDIT3;HERPUD1 |
| pazopanib |
Kinase inhibitor |
Yes |
Down |
Gap junction organization |
0.003678073 |
1 |
24 |
Down by cardiotoxic TKIs |
GJA5;GJC1;PANX1 |
| pazopanib |
Kinase inhibitor |
Yes |
Up |
Glutamate and glutamine metabolism |
0.025620183 |
13 |
NaN |
|
GLUL;SLC1A5 |
| pazopanib |
Kinase inhibitor |
Yes |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.045692235 |
12 |
NaN |
|
JAK2 |
| pazopanib |
Kinase inhibitor |
Yes |
Down |
HIF-1 receptor signaling pathway |
0.017209911 |
5 |
20 |
Down by cardiotoxic TKIs |
CITED2;EGLN3 |
| pazopanib |
Kinase inhibitor |
Yes |
Up |
Lipogenesis |
0.038612441 |
15 |
NaN |
|
FASN |
| pazopanib |
Kinase inhibitor |
Yes |
Up |
Lysosomal glycoprotein degradation |
0.005389583 |
5.5 |
2 |
Up by cardiotoxic TKIs |
CTSA;IFI30 |
| pazopanib |
Kinase inhibitor |
Yes |
Up |
Mammalian target of rapamycin signaling pathway |
0.004061432 |
4 |
NaN |
|
DDIT4;EIF4EBP1;FLCN |
| pazopanib |
Kinase inhibitor |
Yes |
Down |
Microfibril scaffold organization |
0.045692235 |
12 |
NaN |
|
FBN1 |
| pazopanib |
Kinase inhibitor |
Yes |
Up |
Mitochondrial ADP import and ATP export |
0.019495413 |
11.5 |
NaN |
|
SLC25A5 |
| pazopanib |
Kinase inhibitor |
Yes |
Down |
Osteopontin receptor signaling |
0.023112209 |
7 |
NaN |
|
SPP1 |
| pazopanib |
Kinase inhibitor |
Yes |
Up |
Peroxisome proliferator-activated receptor alpha signaling |
0.038612441 |
15 |
NaN |
|
PPARA |
| pazopanib |
Kinase inhibitor |
Yes |
Down |
Progesterone receptor signaling |
0.023112209 |
7 |
NaN |
|
PGR |
| pazopanib |
Kinase inhibitor |
Yes |
Down |
Retinol metabolism |
0.035094106 |
9 |
NaN |
|
ALDH1A3;RDH10 |
| pazopanib |
Kinase inhibitor |
Yes |
Up |
Serine and glycine metabolism |
1.13E-06 |
1 |
19 |
Up by cardiotoxic TKIs |
AMT;PHGDH;PSAT1;SHMT2;SLC1A5 |
| pazopanib |
Kinase inhibitor |
Yes |
Up |
Serotonin inactivation |
0.038612441 |
15 |
NaN |
|
MAOB |
| pazopanib |
Kinase inhibitor |
Yes |
Down |
Sodium transmembrane transport |
0.036972701 |
10 |
NaN |
|
ATP1A2;SLC38A2;SLC5A1 |
| pazopanib |
Kinase inhibitor |
Yes |
Up |
Transamination pathways |
0.007448831 |
9 |
25 |
Up by cardiotoxic TKIs |
GOT1;GOT2 |
| pazopanib |
Kinase inhibitor |
Yes |
Down |
Tropoelastin synthesis |
0.023112209 |
7 |
NaN |
|
ELN |
| pazopanib |
Kinase inhibitor |
Yes |
Up |
Vascular endothelial growth factor receptor signaling |
0.007448831 |
9 |
12 |
Up by cardiotoxic TKIs |
VEGFA;VEGFB |
| pazopanib |
Kinase inhibitor |
Yes |
Down |
WNT-Beta-catenin signaling pathway |
0.015982704 |
4 |
NaN |
|
APCDD1;CDK14;FZD1;FZD8;SFRP5 |
| olmesartan |
Antihypertensive |
No |
Down |
Biglycan synthesis |
0.022759351 |
13.5 |
NaN |
|
BGN |
| olmesartan |
Antihypertensive |
No |
Up |
Cellular cholesterol uptake and efflux |
0.002183285 |
2 |
NaN |
|
ABCA7;ABCG1;ARL4C |
| olmesartan |
Antihypertensive |
No |
Down |
Centrosome separation |
0.001242048 |
2 |
NaN |
|
CCNB1;CDK1;KIF11 |
| olmesartan |
Antihypertensive |
No |
Down |
Collagen fiber crosslinking |
0.00493106 |
5.5 |
NaN |
|
LOX;LOXL1 |
| olmesartan |
Antihypertensive |
No |
Up |
Collagen fibril organization by fibril-associated bridges |
0.006125965 |
3 |
NaN |
|
COL9A2;COL9A3 |
| olmesartan |
Antihypertensive |
No |
Up |
Decorin synthesis |
0.020818631 |
6.5 |
NaN |
|
DCN |
| olmesartan |
Antihypertensive |
No |
Down |
Elastin cross-linking and assembly |
0.001524767 |
3 |
NaN |
|
LOX;LOXL1 |
| olmesartan |
Antihypertensive |
No |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.016567078 |
11 |
NaN |
|
ADAMTS14;ADAMTS17;ADAMTS8 |
| olmesartan |
Antihypertensive |
No |
Down |
Fibrillar collagen core structure organization |
4.94E-05 |
1 |
NaN |
|
COL11A1;COL1A1;COL2A1;COL5A2 |
| olmesartan |
Antihypertensive |
No |
Up |
Fibulin receptor signaling |
0.041205645 |
10.5 |
NaN |
|
FBLN1 |
| olmesartan |
Antihypertensive |
No |
Down |
G2 M transition checkpoint |
0.029300737 |
16 |
NaN |
|
CCNB1;CDK1 |
| olmesartan |
Antihypertensive |
No |
Down |
Glycolysis and Gluconeogenesis |
0.01473936 |
10 |
NaN |
|
ENO1;LDHA;PFKFB3 |
| olmesartan |
Antihypertensive |
No |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.045002676 |
19 |
NaN |
|
JUND |
| olmesartan |
Antihypertensive |
No |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001277029 |
1 |
NaN |
|
A2M;PLAT |
| olmesartan |
Antihypertensive |
No |
Up |
Ketone body metabolism |
0.020818631 |
6.5 |
NaN |
|
OXCT1 |
| olmesartan |
Antihypertensive |
No |
Up |
Lipogenesis |
0.041205645 |
10.5 |
NaN |
|
FASN |
| olmesartan |
Antihypertensive |
No |
Down |
Macrophage migration inhibitory factor signaling |
0.00493106 |
5.5 |
NaN |
|
CXCR4;JUND |
| olmesartan |
Antihypertensive |
No |
Down |
Mitotic spindle assembly |
0.034116484 |
17 |
NaN |
|
DLGAP5;TPX2 |
| olmesartan |
Antihypertensive |
No |
Down |
Mitotic spindle disassembly |
0.022759351 |
13.5 |
NaN |
|
CDK1 |
| olmesartan |
Antihypertensive |
No |
Down |
Natriuretic peptide receptor signaling |
0.007285832 |
7.5 |
NaN |
|
NPPA;NPPB |
| olmesartan |
Antihypertensive |
No |
Up |
Platelet-derived growth factor receptor signaling |
0.020972888 |
8 |
NaN |
|
PDGFRB;RGS5 |
| olmesartan |
Antihypertensive |
No |
Down |
Progesterone receptor signaling |
0.022759351 |
13.5 |
NaN |
|
PGR |
| olmesartan |
Antihypertensive |
No |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.045002676 |
19 |
NaN |
|
PTGFR |
| olmesartan |
Antihypertensive |
No |
Up |
Proteasomal regulatory particle organization |
0.008459104 |
4.5 |
NaN |
|
PSMC4;PSMD14 |
| olmesartan |
Antihypertensive |
No |
Down |
Retinol metabolism |
0.002814129 |
4 |
NaN |
|
ALDH1A1;STRA6;TTR |
| olmesartan |
Antihypertensive |
No |
Up |
Roundabout signaling |
0.008459104 |
4.5 |
NaN |
|
ROBO1;ROBO2 |
| olmesartan |
Antihypertensive |
No |
Up |
Semaphorin signaling |
0.033182637 |
9 |
NaN |
|
DPYSL4;PLXNA2;SEMA3F |
| olmesartan |
Antihypertensive |
No |
Down |
Serotonin inactivation |
0.045002676 |
19 |
NaN |
|
MAOA |
| olmesartan |
Antihypertensive |
No |
Down |
Sister chromatid segregation |
0.007285832 |
7.5 |
NaN |
|
PTTG1;TOP2A |
| olmesartan |
Antihypertensive |
No |
Down |
Thin myofilament organization |
0.010047711 |
9 |
NaN |
|
TNNI3;TPM1 |
| olmesartan |
Antihypertensive |
No |
Down |
Tropoelastin synthesis |
0.022759351 |
13.5 |
NaN |
|
ELN |
| olmesartan |
Antihypertensive |
No |
Up |
WNT-Beta-catenin signaling pathway |
0.044085052 |
12 |
NaN |
|
APCDD1;PAX6;SFRP2;SFRP5 |
| nilotinib |
Kinase inhibitor |
No |
Down |
Albumin mediated blood protein transport |
0.019407198 |
14 |
NaN |
|
ALB |
| nilotinib |
Kinase inhibitor |
No |
Up |
Aspartate and arginine metabolism |
0.028324186 |
28 |
NaN |
|
ARG2;SLC7A1 |
| nilotinib |
Kinase inhibitor |
No |
Down |
Cardiomyocyte pacemaker current generation |
0.009719559 |
9.5 |
NaN |
|
CACNA1G;TRPM4 |
| nilotinib |
Kinase inhibitor |
No |
Down |
CCN intercellular signaling protein family receptor signaling |
0.003607424 |
7 |
NaN |
|
CYR61;WISP1 |
| nilotinib |
Kinase inhibitor |
No |
Down |
CD44-Mediated leukocyte rolling |
0.038439436 |
17 |
NaN |
|
CD44 |
| nilotinib |
Kinase inhibitor |
No |
Up |
Centrosome duplication |
0.028878239 |
29 |
NaN |
|
CDKN1A;PLK2;PLK4 |
| nilotinib |
Kinase inhibitor |
No |
Up |
Centrosome maturation |
0.003575188 |
14.5 |
NaN |
|
AURKA;PLK1;TPX2 |
| nilotinib |
Kinase inhibitor |
No |
Up |
Centrosome organization |
0.002308941 |
13 |
NaN |
|
ASPM;ATF5;NEK2;PLK4;POC1A;TACC3;WDR62 |
| nilotinib |
Kinase inhibitor |
No |
Up |
Centrosome separation |
1.11E-11 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;NEK6;SPAG5 |
| nilotinib |
Kinase inhibitor |
No |
Up |
Cholesterol synthesis |
0.015797556 |
23 |
NaN |
|
DHCR24;DHCR7;MVK |
| nilotinib |
Kinase inhibitor |
No |
Up |
Cholesterol-sensitive control of SREBP activation |
0.010138932 |
19.5 |
NaN |
|
INSIG1;SREBF1 |
| nilotinib |
Kinase inhibitor |
No |
Up |
Contractile ring constriction |
0.000187089 |
6.5 |
NaN |
|
ANLN;ECT2;MYLK |
| nilotinib |
Kinase inhibitor |
No |
Down |
Decorin synthesis |
0.019407198 |
14 |
NaN |
|
DCN |
| nilotinib |
Kinase inhibitor |
No |
Up |
Desaturation of fatty acids |
0.013942946 |
22 |
NaN |
|
FADS2;SCD |
| nilotinib |
Kinase inhibitor |
No |
Down |
Epithelial intermediate filament dynamics |
0.009719559 |
9.5 |
NaN |
|
KRT19;KRT7 |
| nilotinib |
Kinase inhibitor |
No |
Up |
Equatorial RhoA activation |
0.004203747 |
16.5 |
NaN |
|
ECT2;KIF23 |
| nilotinib |
Kinase inhibitor |
No |
Up |
ER unfolded protein response pathway |
0.000986163 |
11 |
NaN |
|
ATF4;DDIT3;HERPUD1 |
| nilotinib |
Kinase inhibitor |
No |
Up |
Eukaryotic kinetochore dynamics |
1.74E-10 |
2 |
NaN |
|
BUB1;CENPE;CENPF;KIF15;KNSTRN;MAD2L1;NDC80;NUF2;SKA3;SPC24;TTK;ZWINT |
| nilotinib |
Kinase inhibitor |
No |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.001080992 |
4 |
NaN |
|
ADAM12;ADAM19;ADAMTS5;ADAMTS6 |
| nilotinib |
Kinase inhibitor |
No |
Down |
Extracellular matrix breakdown by cathepsins |
0.015226725 |
12 |
NaN |
|
CTSF;CTSV |
| nilotinib |
Kinase inhibitor |
No |
Down |
Fibrillar collagen core structure organization |
2.64E-05 |
2 |
NaN |
|
COL11A1;COL11A2;COL1A1;COL2A1 |
| nilotinib |
Kinase inhibitor |
No |
Up |
G2 M transition checkpoint |
0.003575188 |
14.5 |
NaN |
|
CCNB1;CDC25C;CDK1 |
| nilotinib |
Kinase inhibitor |
No |
Up |
GABA metabolism |
0.010138932 |
19.5 |
NaN |
|
ABAT;SLC6A1 |
| nilotinib |
Kinase inhibitor |
No |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.038439436 |
17 |
NaN |
|
JAK2 |
| nilotinib |
Kinase inhibitor |
No |
Up |
Growth differentiation factor receptor signaling |
0.018261874 |
24 |
NaN |
|
GDF15;GDF2 |
| nilotinib |
Kinase inhibitor |
No |
Up |
Hyaluronan-mediated motility receptor signaling |
0.026993649 |
26 |
NaN |
|
HMMR |
| nilotinib |
Kinase inhibitor |
No |
Up |
Inhibition of apoptosis |
0.04009759 |
30 |
NaN |
|
BIRC5;IFI6 |
| nilotinib |
Kinase inhibitor |
No |
Up |
Intracellular bridge assembly |
0.002140056 |
12 |
NaN |
|
INCENP;KIF23 |
| nilotinib |
Kinase inhibitor |
No |
Up |
Metaphase to anaphase checkpoint |
1.96E-07 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;MXD3;PTTG1;TTK |
| nilotinib |
Kinase inhibitor |
No |
Up |
Mitotic chromosome condensation |
0.000628897 |
9 |
NaN |
|
INCENP;NCAPG2;SMC4 |
| nilotinib |
Kinase inhibitor |
No |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
0.000187089 |
6.5 |
NaN |
|
AURKB;CCNA2;INCENP |
| nilotinib |
Kinase inhibitor |
No |
Up |
Mitotic spindle assembly |
5.39E-07 |
4 |
NaN |
|
CKAP2;DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| nilotinib |
Kinase inhibitor |
No |
Up |
Mitotic spindle disassembly |
0.026993649 |
26 |
NaN |
|
CDK1 |
| nilotinib |
Kinase inhibitor |
No |
Up |
Nuclear envelope maintenance |
0.010138932 |
19.5 |
NaN |
|
LMNB1;TMPO |
| nilotinib |
Kinase inhibitor |
No |
Up |
Nuclear intermediate filaments |
0.010138932 |
19.5 |
NaN |
|
LMNB1;TMPO |
| nilotinib |
Kinase inhibitor |
No |
Down |
Osteopontin receptor signaling |
0.019407198 |
14 |
NaN |
|
SPP1 |
| nilotinib |
Kinase inhibitor |
No |
Down |
Potassium transmembrane transport |
0.010803729 |
11 |
NaN |
|
ABCC9;ATP1A2;FXYD1 |
| nilotinib |
Kinase inhibitor |
No |
Down |
Retinol metabolism |
0.001785928 |
6 |
NaN |
|
ALDH1A1;ALDH1A3;STRA6 |
| nilotinib |
Kinase inhibitor |
No |
Up |
Serine and glycine metabolism |
5.61E-06 |
5 |
NaN |
|
PHGDH;PSAT1;PSPH;SHMT2;SLC1A5 |
| nilotinib |
Kinase inhibitor |
No |
Up |
Sister chromatid attachment to mitotic spindle |
0.00072634 |
10 |
NaN |
|
NUF2;TACC3 |
| nilotinib |
Kinase inhibitor |
No |
Up |
Sister chromatid segregation |
0.000366694 |
8 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| nilotinib |
Kinase inhibitor |
No |
Down |
Thick myofilament organization |
0.001110457 |
5 |
NaN |
|
MYBPC3;MYH7 |
| nilotinib |
Kinase inhibitor |
No |
Down |
Thin myofilament organization |
0.00023825 |
3 |
NaN |
|
ACTA1;TNNI3;TPM2 |
| nilotinib |
Kinase inhibitor |
No |
Up |
Thrombospondin receptor signaling |
0.004203747 |
16.5 |
NaN |
|
THBS1;THBS4 |
| nilotinib |
Kinase inhibitor |
No |
Up |
Tropoelastin synthesis |
0.026993649 |
26 |
NaN |
|
ELN |
| nilotinib |
Kinase inhibitor |
No |
Down |
Vascular endothelial growth factor receptor signaling |
0.007383606 |
8 |
NaN |
|
FLT1;KDR |
| nilotinib |
Kinase inhibitor |
No |
Down |
Vasoactive intestinal peptide receptor signaling |
0.038439436 |
17 |
NaN |
|
VIPR2 |
| nilotinib |
Kinase inhibitor |
No |
Down |
Z-disc organization |
9.65E-06 |
1 |
NaN |
|
ACTN2;CSRP3;LDB3;PDLIM3;TCAP |
| milrinone |
Vasodilatator |
Yes |
Down |
Aggrecan synthesis |
0.024258998 |
11 |
NaN |
|
ACAN |
| milrinone |
Vasodilatator |
Yes |
Up |
Albumin mediated blood protein transport |
0.019936486 |
15 |
NaN |
|
ALB |
| milrinone |
Vasodilatator |
Yes |
Up |
Alternative complement pathway |
0.003803269 |
6 |
NaN |
|
C3;CFH |
| milrinone |
Vasodilatator |
Yes |
Down |
Antigen presentation via MHC class I molecules |
0.00149326 |
4 |
NaN |
|
HLA-A;HLA-B;HLA-C |
| milrinone |
Vasodilatator |
Yes |
Up |
Biglycan synthesis |
0.019936486 |
15 |
NaN |
|
BGN |
| milrinone |
Vasodilatator |
Yes |
Down |
CD44-Mediated leukocyte rolling |
0.047931585 |
20 |
NaN |
|
CD44 |
| milrinone |
Vasodilatator |
Yes |
Down |
Cellular cholesterol uptake and efflux |
0.003371923 |
5 |
NaN |
|
ABCA1;ABCG1;SCARA3 |
| milrinone |
Vasodilatator |
Yes |
Up |
Chaperone-mediated autophagy |
0.039477231 |
20.5 |
NaN |
|
HSPA8 |
| milrinone |
Vasodilatator |
Yes |
Up |
Classical complement pathway |
0.007778956 |
10 |
NaN |
|
C4A;C4B |
| milrinone |
Vasodilatator |
Yes |
Down |
Decorin synthesis |
0.024258998 |
11 |
NaN |
|
DCN |
| milrinone |
Vasodilatator |
Yes |
Up |
Endogenous control of complement activity |
0.003803269 |
6 |
NaN |
|
CFH;CFI |
| milrinone |
Vasodilatator |
Yes |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.001194517 |
3 |
NaN |
|
ADAM12;ADAMTS14;ADAMTS2;ADAMTS5 |
| milrinone |
Vasodilatator |
Yes |
Down |
Fibrillar collagen core structure organization |
6.34E-05 |
1 |
NaN |
|
COL1A1;COL1A2;COL2A1;COL3A1 |
| milrinone |
Vasodilatator |
Yes |
Up |
Fibronectin synthesis and extracellular assembly |
0.003803269 |
6 |
NaN |
|
FN1;ITGB3 |
| milrinone |
Vasodilatator |
Yes |
Up |
Gap junction organization |
0.030757337 |
17 |
NaN |
|
GJA1;GJA5 |
| milrinone |
Vasodilatator |
Yes |
Down |
Glutamate and glutamine metabolism |
0.000203815 |
3 |
NaN |
|
SLC1A3;SLC1A5;SLC38A2;SLC7A5 |
| milrinone |
Vasodilatator |
Yes |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.039477231 |
20.5 |
NaN |
|
JAK2 |
| milrinone |
Vasodilatator |
Yes |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.047931585 |
20 |
NaN |
|
JUND |
| milrinone |
Vasodilatator |
Yes |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.012989342 |
12 |
NaN |
|
SOCS3;STAT3 |
| milrinone |
Vasodilatator |
Yes |
Down |
Hepatocyte growth factor receptor signaling |
0.047931585 |
20 |
NaN |
|
MET |
| milrinone |
Vasodilatator |
Yes |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001171577 |
2 |
NaN |
|
A2M;MME |
| milrinone |
Vasodilatator |
Yes |
Up |
Interleukin 6 receptor signaling |
0.039477231 |
20.5 |
NaN |
|
JAK3 |
| milrinone |
Vasodilatator |
Yes |
Up |
Interleukin 7 receptor signaling |
0.039477231 |
20.5 |
NaN |
|
JAK3 |
| milrinone |
Vasodilatator |
Yes |
Up |
JAK-STAT signaling pathway |
0.000131598 |
1 |
NaN |
|
SOCS2;SOCS3;STAT3;STAT4 |
| milrinone |
Vasodilatator |
Yes |
Up |
Leptin receptor signaling |
0.00231233 |
4 |
NaN |
|
SOCS3;STAT3 |
| milrinone |
Vasodilatator |
Yes |
Down |
Macrophage migration inhibitory factor signaling |
0.005586664 |
8 |
NaN |
|
CXCR4;JUND |
| milrinone |
Vasodilatator |
Yes |
Up |
Mammalian target of rapamycin signaling pathway |
0.044211458 |
25 |
NaN |
|
DDIT4;RICTOR |
| milrinone |
Vasodilatator |
Yes |
Down |
MAPK signaling pathway |
0.035387843 |
15 |
NaN |
|
DUSP1;MAP2K6;RPS6KA2 |
| milrinone |
Vasodilatator |
Yes |
Up |
Methionine cycle |
0.039477231 |
20.5 |
NaN |
|
BHMT |
| milrinone |
Vasodilatator |
Yes |
Up |
Microfibril scaffold organization |
0.039477231 |
20.5 |
NaN |
|
FBN1 |
| milrinone |
Vasodilatator |
Yes |
Up |
Natriuretic peptide receptor signaling |
0.0056301 |
8 |
NaN |
|
NPPA;NPPB |
| milrinone |
Vasodilatator |
Yes |
Down |
Osteonectin receptor signaling |
0.003406483 |
6 |
NaN |
|
SMOC2;SPOCK1 |
| milrinone |
Vasodilatator |
Yes |
Up |
Osteopontin receptor signaling |
0.019936486 |
15 |
NaN |
|
SPP1 |
| milrinone |
Vasodilatator |
Yes |
Down |
Platelet-derived growth factor receptor signaling |
0.027912485 |
14 |
NaN |
|
PDGFB;TNK2 |
| milrinone |
Vasodilatator |
Yes |
Down |
Progesterone receptor signaling |
0.024258998 |
11 |
NaN |
|
PGR |
| milrinone |
Vasodilatator |
Yes |
Down |
Removal of caspase inhibition |
0.047931585 |
20 |
NaN |
|
XAF1 |
| milrinone |
Vasodilatator |
Yes |
Up |
Restriction point |
0.016025171 |
13 |
NaN |
|
CDKN2A;PFKFB3 |
| milrinone |
Vasodilatator |
Yes |
Down |
Retinol metabolism |
0.038347708 |
16 |
NaN |
|
ALDH1A3;RLBP1 |
| milrinone |
Vasodilatator |
Yes |
Down |
Serine and glycine metabolism |
9.78E-05 |
2 |
NaN |
|
GLDC;PHGDH;SHMT2;SLC1A5 |
| milrinone |
Vasodilatator |
Yes |
Down |
Serotonin inactivation |
0.047931585 |
20 |
NaN |
|
MAOA |
| milrinone |
Vasodilatator |
Yes |
Up |
Thin myofilament organization |
0.007778956 |
10 |
NaN |
|
ACTA1;LMOD3 |
| milrinone |
Vasodilatator |
Yes |
Down |
Tropoelastin synthesis |
0.024258998 |
11 |
NaN |
|
ELN |
| milrinone |
Vasodilatator |
Yes |
Up |
Vascular endothelial growth factor receptor signaling |
0.007778956 |
10 |
NaN |
|
KDR;VEGFA |
| milrinone |
Vasodilatator |
Yes |
Down |
Vasoactive intestinal peptide receptor signaling |
0.047931585 |
20 |
NaN |
|
VIPR2 |
| milrinone |
Vasodilatator |
Yes |
Down |
Versican receptor signaling |
0.047931585 |
20 |
NaN |
|
VCAN |
| milrinone |
Vasodilatator |
Yes |
Down |
Versican synthesis |
0.024258998 |
11 |
NaN |
|
VCAN |
| milrinone |
Vasodilatator |
Yes |
Down |
WNT-Beta-catenin signaling pathway |
0.004454715 |
7 |
NaN |
|
APCDD1;FRZB;FZD1;SFRP1;SFRP2;SFRP5 |
| milrinone |
Vasodilatator |
Yes |
Up |
Z-disc organization |
0.039518883 |
24 |
NaN |
|
DES;TCAP |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
Axonal intermediate filament dynamics |
0.013510309 |
18 |
NaN |
|
NEFM;NES |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
Biglycan synthesis |
0.026552576 |
22 |
18 |
Down by cardiotoxic TKIs |
BGN |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
Centrosome separation |
0.001936235 |
5 |
NaN |
|
CDK1;KIF11;NEK6 |
| lapatinib |
Kinase inhibitor |
Yes |
Up |
Cholesterol synthesis |
2.52E-18 |
1 |
22 |
Up by cardiotoxic TKIs |
CYP51A1;DHCR24;DHCR7;FDFT1;FDPS;HMGCR;HMGCS1;LSS;MSMO1;MVD;MVK;NSDHL;SQLE |
| lapatinib |
Kinase inhibitor |
Yes |
Up |
Cholesterol-sensitive control of SREBP activation |
0.000136265 |
2 |
15 |
Up by cardiotoxic TKIs |
INSIG1;SREBF1;SREBF2 |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
Collagen fiber crosslinking |
0.006664064 |
12.5 |
NaN |
|
LOX;LOXL1 |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
Collagen fibril organization by fibril-associated bridges |
0.009821443 |
15 |
NaN |
|
COL9A1;COL9A2 |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
Contractile ring constriction |
0.000178158 |
2 |
NaN |
|
ANLN;MYH14;MYLK |
| lapatinib |
Kinase inhibitor |
Yes |
Up |
Decorin synthesis |
0.019318984 |
12 |
NaN |
|
DCN |
| lapatinib |
Kinase inhibitor |
Yes |
Up |
Desaturation of fatty acids |
0.000235064 |
3 |
11 |
Up by cardiotoxic TKIs |
FADS1;FADS2;SCD |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
DNA replication elongation |
0.006664064 |
12.5 |
NaN |
|
MCM5;PCNA |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
DNA replication initiation |
0.003966921 |
8 |
NaN |
|
CDC6;MCM10;MCM5;MCM6 |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
Elastin cross-linking and assembly |
0.002071198 |
6.5 |
NaN |
|
LOX;LOXL1 |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
Eukaryotic kinetochore dynamics |
5.40E-05 |
1 |
NaN |
|
BUB1;CENPE;CENPF;CENPU;SPC24;TTK;ZWINT |
| lapatinib |
Kinase inhibitor |
Yes |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.010671147 |
10 |
NaN |
|
ADAM33;ADAMTS2;ADAMTS5 |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.024834371 |
19 |
NaN |
|
ADAM19;ADAMTS12;ADAMTS8 |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
Fanconi anemia interstrand cross-link repair pathway |
0.004591664 |
11 |
NaN |
|
BRCA2;BRIP1;FANCD2;FANCI |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
Glutamate and glutamine metabolism |
0.004349738 |
10 |
NaN |
|
SLC1A5;SLC38A2;SLC7A5 |
| lapatinib |
Kinase inhibitor |
Yes |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.038266416 |
15 |
NaN |
|
JUND |
| lapatinib |
Kinase inhibitor |
Yes |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.012230733 |
11 |
16 |
Up by cardiotoxic TKIs |
SOCS3;STAT3 |
| lapatinib |
Kinase inhibitor |
Yes |
Up |
Heme degradation to bilirubin |
0.001100428 |
4.5 |
NaN |
|
BLVRB;HMOX1 |
| lapatinib |
Kinase inhibitor |
Yes |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001100428 |
4.5 |
NaN |
|
A2M;MME |
| lapatinib |
Kinase inhibitor |
Yes |
Up |
Interferon alpha receptor signaling |
0.009634616 |
9 |
NaN |
|
IRF9;STAT1 |
| lapatinib |
Kinase inhibitor |
Yes |
Up |
Interferon beta receptor signaling |
0.007318648 |
8 |
NaN |
|
IFIT2;IRF9 |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
Intracellular bridge assembly |
0.002071198 |
6.5 |
NaN |
|
KIF23;NEK7 |
| lapatinib |
Kinase inhibitor |
Yes |
Up |
Intrinsic apoptosis pathway |
0.029019694 |
13 |
NaN |
|
BCL2L11;BMF |
| lapatinib |
Kinase inhibitor |
Yes |
Up |
JAK-STAT signaling pathway |
0.00221172 |
7 |
NaN |
|
SOCS3;STAT1;STAT3 |
| lapatinib |
Kinase inhibitor |
Yes |
Up |
Leptin receptor signaling |
0.002172807 |
6 |
5 |
Up by cardiotoxic TKIs |
SOCS3;STAT3 |
| lapatinib |
Kinase inhibitor |
Yes |
Up |
Lipogenesis |
0.038266416 |
15 |
NaN |
|
FASN |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
Metaphase to anaphase checkpoint |
0.001887856 |
4 |
NaN |
|
BUB1;BUB1B;CENPE;PTTG1;TTK |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
Mitotic spindle assembly |
0.00028822 |
3 |
NaN |
|
DLGAP5;NUSAP1;TPX2;TTK |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
Mitotic spindle disassembly |
0.026552576 |
22 |
NaN |
|
CDK1 |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
Natriuretic peptide receptor signaling |
0.009821443 |
15 |
NaN |
|
NPPA;NPPB |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
Osteonectin receptor signaling |
0.004069701 |
9 |
NaN |
|
SPARC;SPOCK1 |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
Osteopontin receptor signaling |
0.026552576 |
22 |
NaN |
|
SPP1 |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
Retinol metabolism |
0.045193362 |
25 |
NaN |
|
ALDH1A1;ALDH1A3 |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
Sister chromatid segregation |
0.009821443 |
15 |
NaN |
|
PTTG1;TOP2A |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
Tight junction organization |
0.012068674 |
17 |
NaN |
|
CLDN1;CLDN6;CRB2;MYLK |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
Tropoelastin synthesis |
0.026552576 |
22 |
NaN |
|
ELN |
| lapatinib |
Kinase inhibitor |
Yes |
Up |
Vasoactive intestinal peptide receptor signaling |
0.038266416 |
15 |
NaN |
|
VIPR1 |
| lapatinib |
Kinase inhibitor |
Yes |
Down |
Versican synthesis |
0.026552576 |
22 |
NaN |
|
VCAN |
| isoprenaline |
Sympathomimetic |
No |
Down |
Acetylcholine-mediated control of postsynaptic potential |
0.006934528 |
5 |
NaN |
|
AGRN;DOK7 |
| isoprenaline |
Sympathomimetic |
No |
Up |
Adrenergic receptor signaling |
0.000413387 |
4 |
NaN |
|
GNB3;GRK5;PDE4D;RASD1;RGS16 |
| isoprenaline |
Sympathomimetic |
No |
Up |
Aggrecan synthesis |
0.025141143 |
14.5 |
NaN |
|
ACAN |
| isoprenaline |
Sympathomimetic |
No |
Down |
Albumin mediated blood protein transport |
0.018789697 |
8.5 |
NaN |
|
ALB |
| isoprenaline |
Sympathomimetic |
No |
Up |
Amyloid plaque organization |
0.029825004 |
17 |
NaN |
|
COL25A1;HSPB6 |
| isoprenaline |
Sympathomimetic |
No |
Up |
Androgen receptor signaling |
0.049652372 |
23 |
NaN |
|
AR |
| isoprenaline |
Sympathomimetic |
No |
Down |
Antigen presentation via MHC class I molecules |
0.000712003 |
1.5 |
NaN |
|
HLA-A;HLA-B;HLA-C |
| isoprenaline |
Sympathomimetic |
No |
Down |
Basement membrane assembly and organization |
0.000712003 |
1.5 |
NaN |
|
COL4A3;COL4A4;COL8A2 |
| isoprenaline |
Sympathomimetic |
No |
Down |
Biglycan synthesis |
0.018789697 |
8.5 |
NaN |
|
BGN |
| isoprenaline |
Sympathomimetic |
No |
Up |
CCN intercellular signaling protein family receptor signaling |
0.005990412 |
7 |
NaN |
|
CTGF;CYR61 |
| isoprenaline |
Sympathomimetic |
No |
Up |
CD44-Mediated leukocyte rolling |
0.049652372 |
23 |
NaN |
|
CD44 |
| isoprenaline |
Sympathomimetic |
No |
Up |
Cellular fatty acid uptake |
0.049652372 |
23 |
NaN |
|
CD36 |
| isoprenaline |
Sympathomimetic |
No |
Up |
Cellular iron uptake and export |
0.040928231 |
20 |
NaN |
|
RASD1;TFRC |
| isoprenaline |
Sympathomimetic |
No |
Up |
Cholesterol synthesis |
9.94E-19 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;EBP;FDFT1;FDPS;HMGCR;HMGCS1;LSS;MSMO1;MVD;MVK;NSDHL;SQLE |
| isoprenaline |
Sympathomimetic |
No |
Up |
Cholesterol-sensitive control of SREBP activation |
0.008836966 |
9 |
NaN |
|
INSIG1;SREBF1 |
| isoprenaline |
Sympathomimetic |
No |
Up |
Coagulation cascade |
0.035205397 |
19 |
NaN |
|
F2RL1;TFPI |
| isoprenaline |
Sympathomimetic |
No |
Up |
Collagen fibril organization by fibril-associated bridges |
0.000297304 |
3 |
NaN |
|
COL12A1;COL14A1;COL19A1 |
| isoprenaline |
Sympathomimetic |
No |
Up |
Desaturation of fatty acids |
0.000510607 |
5 |
NaN |
|
FADS1;FADS2;SCD |
| isoprenaline |
Sympathomimetic |
No |
Up |
Fatty acid elongation |
0.020177706 |
13 |
NaN |
|
ELOVL5;ELOVL6 |
| isoprenaline |
Sympathomimetic |
No |
Up |
Fibrillar collagen core structure organization |
2.20E-06 |
2 |
NaN |
|
COL11A1;COL11A2;COL1A2;COL2A1;COL3A1 |
| isoprenaline |
Sympathomimetic |
No |
Down |
Fibrillar collagen core structure organization |
0.014318179 |
6 |
NaN |
|
COL1A1;COL5A1 |
| isoprenaline |
Sympathomimetic |
No |
Up |
G-protein coupled receptor signaling pathway |
0.013058143 |
12 |
NaN |
|
GRK5;PDE4D;RGS16 |
| isoprenaline |
Sympathomimetic |
No |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.049652372 |
23 |
NaN |
|
JAK2 |
| isoprenaline |
Sympathomimetic |
No |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.037227967 |
12.5 |
NaN |
|
JUND |
| isoprenaline |
Sympathomimetic |
No |
Up |
Lipogenesis |
0.000629915 |
6 |
NaN |
|
ACLY;FASN |
| isoprenaline |
Sympathomimetic |
No |
Down |
Macrophage migration inhibitory factor signaling |
0.003385224 |
3 |
NaN |
|
CXCR4;JUND |
| isoprenaline |
Sympathomimetic |
No |
Up |
Microfibril scaffold organization |
0.049652372 |
23 |
NaN |
|
FBN1 |
| isoprenaline |
Sympathomimetic |
No |
Down |
Mitotic spindle assembly |
0.023917892 |
11 |
NaN |
|
DLGAP5;NUSAP1 |
| isoprenaline |
Sympathomimetic |
No |
Up |
Muscarinic receptor signaling |
0.008836966 |
9 |
NaN |
|
CHRM1;CHRM4 |
| isoprenaline |
Sympathomimetic |
No |
Up |
Natriuretic peptide receptor signaling |
0.008836966 |
9 |
NaN |
|
NPPA;NPPB |
| isoprenaline |
Sympathomimetic |
No |
Up |
Perlecan synthesis |
0.025141143 |
14.5 |
NaN |
|
HSPG2 |
| isoprenaline |
Sympathomimetic |
No |
Up |
Platelet-derived growth factor receptor signaling |
0.029825004 |
17 |
NaN |
|
PDGFRA;PDGFRB |
| isoprenaline |
Sympathomimetic |
No |
Down |
Semaphorin signaling |
0.00361285 |
4 |
NaN |
|
CRMP1;DPYSL4;NRP2;PLXNA2 |
| isoprenaline |
Sympathomimetic |
No |
Up |
Serine and glycine metabolism |
0.029825004 |
17 |
NaN |
|
PHGDH;SLC1A4 |
| isoprenaline |
Sympathomimetic |
No |
Up |
Thin myofilament organization |
0.012167509 |
11 |
NaN |
|
TNNI3;TPM2 |
| isoprenaline |
Sympathomimetic |
No |
Down |
Tropoelastin synthesis |
0.018789697 |
8.5 |
NaN |
|
ELN |
| isoprenaline |
Sympathomimetic |
No |
Down |
Versican receptor signaling |
0.037227967 |
12.5 |
NaN |
|
VCAN |
| isoprenaline |
Sympathomimetic |
No |
Down |
Versican synthesis |
0.018789697 |
8.5 |
NaN |
|
VCAN |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Actin filament bundling and crosslinking |
0.019414005 |
19 |
NaN |
|
FLNA;PLS3;SYNPO;TAGLN |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Aggrecan synthesis |
0.040402258 |
28 |
NaN |
|
ACAN |
| insulin-like growth factor 1 |
Hormone |
No |
Up |
Alternative complement pathway |
0.030931719 |
7.5 |
NaN |
|
C3 |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Alternative complement pathway |
0.015017541 |
17 |
NaN |
|
C1S;CFH |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Antigen presentation via MHC class I molecules |
0.000454745 |
5 |
NaN |
|
B2M;HLA-A;HLA-B;HLA-C |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Biglycan synthesis |
0.040402258 |
28 |
NaN |
|
BGN |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
CCN intercellular signaling protein family receptor signaling |
1.27E-05 |
2 |
NaN |
|
CTGF;CYR61;NOV;WISP1 |
| insulin-like growth factor 1 |
Hormone |
No |
Up |
Cholesterol-sensitive control of SREBP activation |
0.000570829 |
1 |
NaN |
|
INSIG1;SREBF1 |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Classical complement pathway |
8.35E-05 |
4 |
NaN |
|
C1QB;C1QC;C1R;C1S |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Collagen fiber crosslinking |
0.015017541 |
17 |
NaN |
|
LOX;PXDN |
| insulin-like growth factor 1 |
Hormone |
No |
Up |
Contractile ring constriction |
0.030931719 |
7.5 |
NaN |
|
MYH14 |
| insulin-like growth factor 1 |
Hormone |
No |
Up |
Contractile ring formation |
0.030931719 |
7.5 |
NaN |
|
MYH14 |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Decorin synthesis |
0.040402258 |
28 |
NaN |
|
DCN |
| insulin-like growth factor 1 |
Hormone |
No |
Up |
Desaturation of fatty acids |
0.043038559 |
11 |
NaN |
|
SCD |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Endogenous control of complement activity |
0.015017541 |
17 |
NaN |
|
CFH;CFI |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Epithelial intermediate filament dynamics |
0.038799267 |
24 |
NaN |
|
KRT7;KRT8 |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.002366842 |
8 |
NaN |
|
ADAM12;ADAMTS12;ADAMTS2;ADAMTS4;ADAMTS8 |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Extracellular matrix breakdown by heparanases and sulfatases |
0.009257136 |
11.5 |
NaN |
|
SULF1;SULF2 |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.004586711 |
9 |
NaN |
|
MMP1;MMP14;MMP2 |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Extracellular matrix breakdown by serine proteases |
0.029887387 |
21.5 |
NaN |
|
HTRA1;PRSS12 |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Fibrillar collagen core structure organization |
1.81E-08 |
1 |
NaN |
|
COL11A1;COL1A1;COL1A2;COL3A1;COL5A1;COL5A2;COL5A3 |
| insulin-like growth factor 1 |
Hormone |
No |
Up |
GABA metabolism |
0.037003897 |
10 |
NaN |
|
SLC6A1 |
| insulin-like growth factor 1 |
Hormone |
No |
Up |
Glycogen synthesis and glycogenolysis |
0.004385318 |
2 |
NaN |
|
PPP1R3A;PYGM |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Growth differentiation factor receptor signaling |
0.038799267 |
24 |
NaN |
|
GDF2;GDF6 |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Inhibin receptor signaling |
0.038799267 |
24 |
NaN |
|
INHBA;INHBE |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
6.55E-05 |
3 |
NaN |
|
A2M;MME;PLAT |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Inhibition of apoptosis |
0.010974619 |
13 |
NaN |
|
IFI6;PEA15;XAF1 |
| insulin-like growth factor 1 |
Hormone |
No |
Up |
Lipogenesis |
0.012487785 |
3.5 |
NaN |
|
FASN |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Microfibril scaffold organization |
0.001628922 |
7 |
NaN |
|
FBN1;MFAP2 |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Natriuretic peptide receptor signaling |
0.021928273 |
20 |
NaN |
|
NPPA;NPPB |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Osteonectin receptor signaling |
0.009257136 |
11.5 |
NaN |
|
SMOC2;SPARC |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Osteopontin receptor signaling |
0.040402258 |
28 |
NaN |
|
SPP1 |
| insulin-like growth factor 1 |
Hormone |
No |
Up |
Peroxisome proliferator-activated receptor gamma signaling |
0.024821795 |
5 |
NaN |
|
PPARGC1B |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Procollagen processing in the ER |
0.004755694 |
10 |
NaN |
|
P3H1;SERPINH1 |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Retinol metabolism |
0.013845369 |
14 |
NaN |
|
ALDH1A1;ALDH1A3;TTR |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Serine and glycine metabolism |
0.000691879 |
6 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| insulin-like growth factor 1 |
Hormone |
No |
Up |
Serotonin inactivation |
0.012487785 |
3.5 |
NaN |
|
MAOA |
| insulin-like growth factor 1 |
Hormone |
No |
Up |
Sulfonation |
0.030931719 |
7.5 |
NaN |
|
SULT1A1 |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Thin myofilament organization |
0.029887387 |
21.5 |
NaN |
|
ACTA1;TPM4 |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
Tropoelastin synthesis |
0.040402258 |
28 |
NaN |
|
ELN |
| insulin-like growth factor 1 |
Hormone |
No |
Down |
WNT-Beta-catenin signaling pathway |
0.014304543 |
15 |
NaN |
|
CTHRC1;DKK2;DKK3;FZD7;SFRP2;SFRP4;WNT2 |
| imatinib |
Kinase inhibitor |
No |
Down |
Biglycan synthesis |
0.026287932 |
17 |
NaN |
|
BGN |
| imatinib |
Kinase inhibitor |
No |
Up |
Centrosome maturation |
5.33E-05 |
4 |
NaN |
|
AURKA;CDC25B;PLK1;TPX2 |
| imatinib |
Kinase inhibitor |
No |
Up |
Centrosome organization |
0.038825593 |
22 |
NaN |
|
ASPM;NEK2;POC1A;TACC3 |
| imatinib |
Kinase inhibitor |
No |
Up |
Centrosome separation |
8.58E-11 |
2 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| imatinib |
Kinase inhibitor |
No |
Up |
Cholesterol synthesis |
1.56E-20 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;EBP;FDFT1;FDPS;HMGCR;HMGCS1;LSS;MSMO1;MVD;MVK;NSDHL;SQLE |
| imatinib |
Kinase inhibitor |
No |
Up |
Cholesterol-sensitive control of SREBP activation |
0.005015101 |
12 |
NaN |
|
INSIG1;SREBF1 |
| imatinib |
Kinase inhibitor |
No |
Up |
Citric acid cycle |
0.001627653 |
11 |
NaN |
|
OGDH;PDHA1;SDHA |
| imatinib |
Kinase inhibitor |
No |
Down |
Collagen fiber crosslinking |
0.006535173 |
9 |
NaN |
|
LOX;PXDN |
| imatinib |
Kinase inhibitor |
No |
Down |
Collagen fibril organization by fibril-associated bridges |
7.13E-08 |
2 |
NaN |
|
COL12A1;COL14A1;COL9A1;COL9A2;COL9A3 |
| imatinib |
Kinase inhibitor |
No |
Down |
Decorin synthesis |
0.026287932 |
17 |
NaN |
|
DCN |
| imatinib |
Kinase inhibitor |
No |
Up |
Desaturation of fatty acids |
0.006934528 |
13.5 |
NaN |
|
FADS2;SCD |
| imatinib |
Kinase inhibitor |
No |
Up |
Electron transport chain |
0.020488625 |
17 |
NaN |
|
COX7A1;SDHA |
| imatinib |
Kinase inhibitor |
No |
Down |
Epithelial intermediate filament dynamics |
0.017367241 |
11 |
NaN |
|
KRT19;KRT7 |
| imatinib |
Kinase inhibitor |
No |
Up |
Eukaryotic kinetochore dynamics |
0.000676926 |
8 |
NaN |
|
BUB1;CENPE;CENPF;KNSTRN;NDC80 |
| imatinib |
Kinase inhibitor |
No |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.00034208 |
4 |
NaN |
|
ADAM12;ADAMTS14;ADAMTS2;ADAMTS4;ADAMTS8 |
| imatinib |
Kinase inhibitor |
No |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.021945601 |
13.5 |
NaN |
|
MMP14;MMP2 |
| imatinib |
Kinase inhibitor |
No |
Down |
Fibrillar collagen core structure organization |
6.03E-08 |
1 |
NaN |
|
COL11A1;COL1A1;COL1A2;COL3A1;COL5A1;COL5A3 |
| imatinib |
Kinase inhibitor |
No |
Up |
G2 M transition checkpoint |
0.001269544 |
10 |
NaN |
|
CCNB1;CDC25B;CDK1 |
| imatinib |
Kinase inhibitor |
No |
Up |
Gap junction organization |
0.027563704 |
18.5 |
NaN |
|
GJA1;GJA5 |
| imatinib |
Kinase inhibitor |
No |
Down |
Glycolysis and Gluconeogenesis |
0.021582273 |
12 |
NaN |
|
HK2;LDHA;PGK1 |
| imatinib |
Kinase inhibitor |
No |
Down |
HIF-1 receptor signaling pathway |
0.021945601 |
13.5 |
NaN |
|
CITED2;EGLN3 |
| imatinib |
Kinase inhibitor |
No |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.002030414 |
6 |
NaN |
|
MME;PLAT |
| imatinib |
Kinase inhibitor |
No |
Up |
Intracellular bridge assembly |
0.001041194 |
9 |
NaN |
|
INCENP;KIF23 |
| imatinib |
Kinase inhibitor |
No |
Up |
JAK-STAT signaling pathway |
0.027563704 |
18.5 |
NaN |
|
SOCS2;STAT4 |
| imatinib |
Kinase inhibitor |
No |
Up |
Lipogenesis |
0.037227967 |
20.5 |
NaN |
|
FASN |
| imatinib |
Kinase inhibitor |
No |
Up |
Metaphase to anaphase checkpoint |
3.55E-05 |
3 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;PTTG1 |
| imatinib |
Kinase inhibitor |
No |
Up |
Mitochondrial ADP import and ATP export |
0.018789697 |
15.5 |
NaN |
|
SLC25A5 |
| imatinib |
Kinase inhibitor |
No |
Up |
Mitotic H3 phosphorylation and dephosphorylation |
6.36E-05 |
5 |
NaN |
|
AURKB;CCNA2;INCENP |
| imatinib |
Kinase inhibitor |
No |
Up |
Mitotic spindle assembly |
7.58E-05 |
6 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2 |
| imatinib |
Kinase inhibitor |
No |
Up |
Mitotic spindle disassembly |
0.018789697 |
15.5 |
NaN |
|
CDK1 |
| imatinib |
Kinase inhibitor |
No |
Down |
Natriuretic peptide receptor signaling |
0.009633191 |
10 |
NaN |
|
NPPB;NPR3 |
| imatinib |
Kinase inhibitor |
No |
Down |
Osteopontin receptor signaling |
0.026287932 |
17 |
NaN |
|
SPP1 |
| imatinib |
Kinase inhibitor |
No |
Down |
Platelet-derived growth factor receptor signaling |
0.002536833 |
7 |
NaN |
|
PDGFRA;PDGFRB;RGS5 |
| imatinib |
Kinase inhibitor |
No |
Down |
Progesterone receptor signaling |
0.026287932 |
17 |
NaN |
|
PGR |
| imatinib |
Kinase inhibitor |
No |
Down |
Retinol metabolism |
0.00027738 |
3 |
NaN |
|
ALDH1A1;ALDH1A3;RDH10;STRA6 |
| imatinib |
Kinase inhibitor |
No |
Up |
Sister chromatid attachment to mitotic spindle |
0.037227967 |
20.5 |
NaN |
|
TACC3 |
| imatinib |
Kinase inhibitor |
No |
Up |
Sister chromatid segregation |
0.000125472 |
7 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| imatinib |
Kinase inhibitor |
No |
Down |
Tenascin receptor signaling |
0.003990278 |
8 |
NaN |
|
TENM1;TNC |
| imatinib |
Kinase inhibitor |
No |
Up |
Transamination pathways |
0.006934528 |
13.5 |
NaN |
|
GOT1;GOT2 |
| imatinib |
Kinase inhibitor |
No |
Down |
Tropoelastin synthesis |
0.026287932 |
17 |
NaN |
|
ELN |
| imatinib |
Kinase inhibitor |
No |
Down |
WNT-Beta-catenin signaling pathway |
0.001392668 |
5 |
NaN |
|
CTHRC1;DKK1;DKK2;FRZB;FZD2;PAX6;SFRP2 |
| idarubicin |
Anthracycline |
Yes |
Up |
Bicarbonate transmembrane transport |
0.012073295 |
10.5 |
NaN |
|
SLC26A8;SLC26A9;SLC4A10 |
| idarubicin |
Anthracycline |
Yes |
Up |
Biglycan synthesis |
0.025758645 |
15.5 |
NaN |
|
BGN |
| idarubicin |
Anthracycline |
Yes |
Up |
Cell cycle arrest in response to DNA damage |
0.022948589 |
13 |
NaN |
|
BBC3;CDKN1A;MDM2 |
| idarubicin |
Anthracycline |
Yes |
Down |
Centrosome maturation |
0.022330855 |
16.5 |
NaN |
|
PLK1;TPX2 |
| idarubicin |
Anthracycline |
Yes |
Down |
Centrosome separation |
2.79E-05 |
2 |
NaN |
|
CCNB1;CDK1;KIF11;SPAG5 |
| idarubicin |
Anthracycline |
Yes |
Down |
Chaperone-mediated autophagy |
0.038958404 |
19.5 |
NaN |
|
HSPA8 |
| idarubicin |
Anthracycline |
Yes |
Up |
Chloride transmembrane transport |
0.042773869 |
19 |
NaN |
|
CFTR;SLC26A8 |
| idarubicin |
Anthracycline |
Yes |
Up |
Coagulation cascade |
0.003131352 |
7 |
NaN |
|
F11;F5;KLKB1 |
| idarubicin |
Anthracycline |
Yes |
Up |
Coagulation factor synthesis and vitamin K metabolism |
0.009261749 |
9 |
NaN |
|
F11;F5 |
| idarubicin |
Anthracycline |
Yes |
Down |
Contractile ring constriction |
0.003704726 |
8 |
NaN |
|
ANLN;MYH14 |
| idarubicin |
Anthracycline |
Yes |
Down |
Contractile ring formation |
0.003704726 |
8 |
NaN |
|
MYH14;RACGAP1 |
| idarubicin |
Anthracycline |
Yes |
Up |
Decorin synthesis |
0.025758645 |
15.5 |
NaN |
|
DCN |
| idarubicin |
Anthracycline |
Yes |
Up |
Desmosome organization |
0.012073295 |
10.5 |
NaN |
|
DSG1;DSG3;DSG4 |
| idarubicin |
Anthracycline |
Yes |
Down |
DNA replication elongation |
7.30E-05 |
3 |
NaN |
|
MCM2;MCM5;MCM7 |
| idarubicin |
Anthracycline |
Yes |
Down |
DNA replication initiation |
0.012553809 |
12 |
NaN |
|
MCM2;MCM5;MCM7 |
| idarubicin |
Anthracycline |
Yes |
Up |
Epithelial intermediate filament dynamics |
0.016709342 |
12 |
NaN |
|
KRT19;KRT8 |
| idarubicin |
Anthracycline |
Yes |
Down |
Eukaryotic kinetochore dynamics |
7.79E-06 |
1 |
NaN |
|
BUB1;CENPE;CENPF;CENPU;MTUS2;TTK;ZWINT |
| idarubicin |
Anthracycline |
Yes |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.011207265 |
11 |
NaN |
|
ADAM15;ADAMTS1;ADAMTS14 |
| idarubicin |
Anthracycline |
Yes |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.00126627 |
3 |
NaN |
|
MMP1;MMP14;MMP2 |
| idarubicin |
Anthracycline |
Yes |
Up |
Extrinsic apoptosis pathway |
0.000548269 |
2 |
NaN |
|
FAS;TNFRSF10A;TNFRSF10B |
| idarubicin |
Anthracycline |
Yes |
Up |
Fibrillar collagen core structure organization |
8.01E-05 |
1 |
NaN |
|
COL1A1;COL1A2;COL3A1;COL5A1 |
| idarubicin |
Anthracycline |
Yes |
Down |
G2 M transition checkpoint |
0.001449092 |
5 |
NaN |
|
CCNB1;CDK1;WEE1 |
| idarubicin |
Anthracycline |
Yes |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.038958404 |
19.5 |
NaN |
|
JAK2 |
| idarubicin |
Anthracycline |
Yes |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001950041 |
5 |
NaN |
|
A2M;PLAT |
| idarubicin |
Anthracycline |
Yes |
Down |
Intracellular bridge abscission |
0.01712795 |
13 |
NaN |
|
CEP55;EXOC6B;TEX14 |
| idarubicin |
Anthracycline |
Yes |
Up |
Intrinsic apoptosis pathway |
0.004987 |
8 |
NaN |
|
BAX;BBC3;BCL2L1 |
| idarubicin |
Anthracycline |
Yes |
Down |
Metaphase to anaphase checkpoint |
0.000492096 |
4 |
NaN |
|
BUB1;CCNB2;CDC20;CENPE;TTK |
| idarubicin |
Anthracycline |
Yes |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.003704726 |
8 |
NaN |
|
AURKB;CCNA2 |
| idarubicin |
Anthracycline |
Yes |
Down |
Mitotic spindle assembly |
0.001856622 |
6 |
NaN |
|
NUSAP1;TPX2;TTK |
| idarubicin |
Anthracycline |
Yes |
Down |
Mitotic spindle disassembly |
0.019671842 |
15 |
NaN |
|
CDK1 |
| idarubicin |
Anthracycline |
Yes |
Up |
Necroptosis induction |
0.025758645 |
15.5 |
NaN |
|
TNFRSF1A |
| idarubicin |
Anthracycline |
Yes |
Down |
Neuregulin receptor signaling |
0.018850561 |
14 |
NaN |
|
ERBB3;ERBB4 |
| idarubicin |
Anthracycline |
Yes |
Up |
Nucleotide excision repair |
0.002593632 |
6 |
NaN |
|
DDB2;PCNA;POLH;XPC |
| idarubicin |
Anthracycline |
Yes |
Up |
Platelet-derived growth factor receptor signaling |
0.031194976 |
18 |
NaN |
|
PDGFRB;RGS5 |
| idarubicin |
Anthracycline |
Yes |
Up |
RNA editing |
0.001774618 |
4 |
NaN |
|
A1CF;APOBEC2;APOBEC3C |
| idarubicin |
Anthracycline |
Yes |
Down |
Thin myofilament organization |
0.007580082 |
10 |
NaN |
|
ACTA1;TNNI3 |
| idarubicin |
Anthracycline |
Yes |
Up |
Tropoelastin synthesis |
0.025758645 |
15.5 |
NaN |
|
ELN |
| idarubicin |
Anthracycline |
Yes |
Down |
Vesicle tethering at plasma membrane |
0.022330855 |
16.5 |
NaN |
|
EXOC6B;RHOQ |
| idarubicin |
Anthracycline |
Yes |
Down |
Z-disc organization |
0.038568701 |
18 |
NaN |
|
ACTN2;PDLIM5 |
| gefitinib |
Kinase inhibitor |
No |
Up |
Alternative complement pathway |
5.59E-05 |
1 |
NaN |
|
C1S;C3;CFH |
| gefitinib |
Kinase inhibitor |
No |
Down |
Antigen presentation via MHC class I molecules |
0.030597968 |
29.5 |
NaN |
|
HLA-B;HLA-C |
| gefitinib |
Kinase inhibitor |
No |
Down |
Centrosome maturation |
0.004020563 |
13 |
NaN |
|
AURKA;PLK1;TPX2 |
| gefitinib |
Kinase inhibitor |
No |
Down |
Centrosome organization |
0.012010543 |
21 |
NaN |
|
ASPM;NEK2;PAX6;TACC3;TUBG1;WDR62 |
| gefitinib |
Kinase inhibitor |
No |
Down |
Centrosome separation |
1.46E-09 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| gefitinib |
Kinase inhibitor |
No |
Down |
Cholesterol synthesis |
0.002086621 |
10 |
NaN |
|
DHCR24;DHCR7;MVK;NSDHL |
| gefitinib |
Kinase inhibitor |
No |
Up |
Classical complement pathway |
0.006376527 |
4 |
NaN |
|
C1R;C1S |
| gefitinib |
Kinase inhibitor |
No |
Down |
Collagen fibril organization by fibril-associated bridges |
0.010986142 |
19.5 |
NaN |
|
COL9A1;COL9A2 |
| gefitinib |
Kinase inhibitor |
No |
Down |
Contractile ring constriction |
0.000211674 |
5.5 |
NaN |
|
ANLN;ECT2;MYLK |
| gefitinib |
Kinase inhibitor |
No |
Up |
Decorin synthesis |
0.017995766 |
7 |
NaN |
|
DCN |
| gefitinib |
Kinase inhibitor |
No |
Down |
Desaturation of fatty acids |
0.015096478 |
22 |
NaN |
|
FADS2;SCD |
| gefitinib |
Kinase inhibitor |
No |
Down |
Epithelial intermediate filament dynamics |
0.01975769 |
23.5 |
NaN |
|
KRT19;KRT7 |
| gefitinib |
Kinase inhibitor |
No |
Down |
Equatorial RhoA activation |
0.00456203 |
15.5 |
NaN |
|
ECT2;KIF23 |
| gefitinib |
Kinase inhibitor |
No |
Down |
Eukaryotic kinetochore dynamics |
8.43E-06 |
2 |
NaN |
|
BUB1;CENPE;CENPF;NDC80;NUF2;SPC24;TTK;ZWINT |
| gefitinib |
Kinase inhibitor |
No |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.008797024 |
6 |
NaN |
|
ADAM33;ADAMTS2;ADAMTS5 |
| gefitinib |
Kinase inhibitor |
No |
Down |
Fibrillar collagen core structure organization |
0.030597968 |
29.5 |
NaN |
|
COL11A1;COL2A1 |
| gefitinib |
Kinase inhibitor |
No |
Up |
Gap junction organization |
0.02543863 |
8 |
NaN |
|
GJA5;GJB2 |
| gefitinib |
Kinase inhibitor |
No |
Down |
Glycolysis and Gluconeogenesis |
0.003568606 |
12 |
NaN |
|
ENO1;LDHA;PGAM1;TPI1 |
| gefitinib |
Kinase inhibitor |
No |
Up |
Hedgehog receptor signaling |
0.045084589 |
10 |
NaN |
|
CDON;GAS1 |
| gefitinib |
Kinase inhibitor |
No |
Up |
Hepatocyte growth factor receptor signaling |
0.035669243 |
9 |
NaN |
|
HGF |
| gefitinib |
Kinase inhibitor |
No |
Down |
Intracellular bridge assembly |
0.002324253 |
11 |
NaN |
|
INCENP;KIF23 |
| gefitinib |
Kinase inhibitor |
No |
Down |
Lipogenesis |
0.000789471 |
8.5 |
NaN |
|
ACLY;FASN |
| gefitinib |
Kinase inhibitor |
No |
Down |
Metaphase to anaphase checkpoint |
3.66E-05 |
4 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;PTTG1;TTK |
| gefitinib |
Kinase inhibitor |
No |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.000211674 |
5.5 |
NaN |
|
AURKB;CCNA2;INCENP |
| gefitinib |
Kinase inhibitor |
No |
Down |
Mitotic spindle assembly |
1.83E-05 |
3 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| gefitinib |
Kinase inhibitor |
No |
Down |
Mitotic spindle disassembly |
0.028140438 |
26.5 |
NaN |
|
CDK1 |
| gefitinib |
Kinase inhibitor |
No |
Down |
Natriuretic peptide receptor signaling |
0.010986142 |
19.5 |
NaN |
|
NPPA;NPPB |
| gefitinib |
Kinase inhibitor |
No |
Down |
Osteopontin receptor signaling |
0.028140438 |
26.5 |
NaN |
|
SPP1 |
| gefitinib |
Kinase inhibitor |
No |
Down |
Pyrimidine synthesis and salvage |
0.01975769 |
23.5 |
NaN |
|
TK1;TYMS |
| gefitinib |
Kinase inhibitor |
No |
Down |
Retinol metabolism |
0.005118789 |
18 |
NaN |
|
ALDH1A1;ALDH1A3;RPE65 |
| gefitinib |
Kinase inhibitor |
No |
Up |
Semaphorin signaling |
0.003094259 |
3 |
NaN |
|
NRP2;RND1;SEMA6A;SEMA6D |
| gefitinib |
Kinase inhibitor |
No |
Up |
Serine and glycine metabolism |
0.000851742 |
2 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| gefitinib |
Kinase inhibitor |
No |
Down |
Sister chromatid attachment to mitotic spindle |
0.000789471 |
8.5 |
NaN |
|
NUF2;TACC3 |
| gefitinib |
Kinase inhibitor |
No |
Down |
Sister chromatid segregation |
0.000414519 |
7 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| gefitinib |
Kinase inhibitor |
No |
Down |
Tenascin receptor signaling |
0.00456203 |
15.5 |
NaN |
|
TENM1;TNC |
| gefitinib |
Kinase inhibitor |
No |
Down |
Thrombospondin receptor signaling |
0.00456203 |
15.5 |
NaN |
|
THBS1;THBS4 |
| gefitinib |
Kinase inhibitor |
No |
Down |
Transmembrane glucose transport |
0.00456203 |
15.5 |
NaN |
|
SLC2A1;SLC2A3 |
| gefitinib |
Kinase inhibitor |
No |
Down |
Tropoelastin synthesis |
0.028140438 |
26.5 |
NaN |
|
ELN |
| gefitinib |
Kinase inhibitor |
No |
Down |
Versican synthesis |
0.028140438 |
26.5 |
NaN |
|
VCAN |
| gefitinib |
Kinase inhibitor |
No |
Up |
Water transmembrane transport |
0.008401748 |
5 |
NaN |
|
AQP3;AQP7 |
| flecainide |
Antiarrhythmic |
Yes |
Down |
Aggrecan synthesis |
0.028757939 |
14 |
NaN |
|
ACAN |
| flecainide |
Antiarrhythmic |
Yes |
Up |
Alternative complement pathway |
0.002537364 |
5 |
NaN |
|
C3;CFH |
| flecainide |
Antiarrhythmic |
Yes |
Down |
Antigen presentation via MHC class I molecules |
0.031852436 |
18.5 |
NaN |
|
HLA-B;HLA-C |
| flecainide |
Antiarrhythmic |
Yes |
Down |
Aspartate and arginine metabolism |
0.031852436 |
18.5 |
NaN |
|
ARG2;SLC7A1 |
| flecainide |
Antiarrhythmic |
Yes |
Up |
Cellular iron storage |
0.047912477 |
21 |
NaN |
|
FTH1 |
| flecainide |
Antiarrhythmic |
Yes |
Up |
Centrosome maturation |
0.015540411 |
13 |
NaN |
|
PLK1;TPX2 |
| flecainide |
Antiarrhythmic |
Yes |
Up |
Centrosome separation |
0.010823703 |
11.5 |
NaN |
|
CDK1;KIF11 |
| flecainide |
Antiarrhythmic |
Yes |
Down |
Cholesterol synthesis |
0.000207154 |
3 |
NaN |
|
DHCR24;DHCR7;FDFT1;HMGCS1;MSMO1 |
| flecainide |
Antiarrhythmic |
Yes |
Up |
Collagen fibril organization by fibril-associated bridges |
0.003765459 |
7 |
NaN |
|
COL14A1;COL9A1 |
| flecainide |
Antiarrhythmic |
Yes |
Down |
Connection of muscle sarcomere to plasma membrane |
0.031852436 |
18.5 |
NaN |
|
ANK3;TLN2 |
| flecainide |
Antiarrhythmic |
Yes |
Up |
Decorin synthesis |
0.016231475 |
14.5 |
NaN |
|
DCN |
| flecainide |
Antiarrhythmic |
Yes |
Down |
ER unfolded protein response pathway |
0.020584442 |
10 |
NaN |
|
ATF4;HERPUD1 |
| flecainide |
Antiarrhythmic |
Yes |
Up |
Eukaryotic kinetochore dynamics |
1.33E-07 |
1 |
NaN |
|
BUB1;CENPE;CENPF;CENPU;MAD2L1;NDC80;NUF2;TTK |
| flecainide |
Antiarrhythmic |
Yes |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.03050589 |
16 |
NaN |
|
ADAMTS1;ADAMTS12;ADAMTS14 |
| flecainide |
Antiarrhythmic |
Yes |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.008751803 |
10 |
NaN |
|
MMP1;MMP2 |
| flecainide |
Antiarrhythmic |
Yes |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.025968562 |
12 |
NaN |
|
MMP12;MMP3 |
| flecainide |
Antiarrhythmic |
Yes |
Up |
Fibrillar collagen core structure organization |
0.010823703 |
11.5 |
NaN |
|
COL1A1;COL3A1 |
| flecainide |
Antiarrhythmic |
Yes |
Down |
Fibrillar collagen core structure organization |
0.031852436 |
18.5 |
NaN |
|
COL11A1;COL5A1 |
| flecainide |
Antiarrhythmic |
Yes |
Up |
Folate cycle |
0.047912477 |
21 |
NaN |
|
DHFR |
| flecainide |
Antiarrhythmic |
Yes |
Down |
Glycolysis and Gluconeogenesis |
3.60E-05 |
1 |
NaN |
|
ENO1;HK2;LDHA;PCK2;PFKFB3;PFKFB4 |
| flecainide |
Antiarrhythmic |
Yes |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.032200898 |
18 |
NaN |
|
JUND |
| flecainide |
Antiarrhythmic |
Yes |
Up |
Hepatocyte growth factor receptor signaling |
0.032200898 |
18 |
NaN |
|
HGF |
| flecainide |
Antiarrhythmic |
Yes |
Down |
Inhibin receptor signaling |
0.020584442 |
10 |
NaN |
|
INHBE;TGFBR3 |
| flecainide |
Antiarrhythmic |
Yes |
Down |
Interferon alpha receptor signaling |
0.020584442 |
10 |
NaN |
|
IRF9;STAT1 |
| flecainide |
Antiarrhythmic |
Yes |
Down |
JAK-STAT signaling pathway |
0.00677632 |
7 |
NaN |
|
SOCS3;STAT1;USP18 |
| flecainide |
Antiarrhythmic |
Yes |
Up |
Metaphase to anaphase checkpoint |
0.002129332 |
4 |
NaN |
|
BUB1;CENPE;MAD2L1;TTK |
| flecainide |
Antiarrhythmic |
Yes |
Up |
Mitotic spindle assembly |
1.24E-06 |
2 |
NaN |
|
CKAP2;DLGAP5;NUSAP1;TPX2;TTK |
| flecainide |
Antiarrhythmic |
Yes |
Up |
Mitotic spindle disassembly |
0.016231475 |
14.5 |
NaN |
|
CDK1 |
| flecainide |
Antiarrhythmic |
Yes |
Down |
Natriuretic peptide receptor signaling |
0.011455252 |
8 |
NaN |
|
NPPA;NPPB |
| flecainide |
Antiarrhythmic |
Yes |
Up |
Nuclear envelope maintenance |
0.003765459 |
7 |
NaN |
|
LMNB1;TMPO |
| flecainide |
Antiarrhythmic |
Yes |
Up |
Nuclear intermediate filaments |
0.003765459 |
7 |
NaN |
|
LMNB1;TMPO |
| flecainide |
Antiarrhythmic |
Yes |
Up |
Osteonectin receptor signaling |
0.00153885 |
3 |
NaN |
|
SMOC2;SPARC |
| flecainide |
Antiarrhythmic |
Yes |
Down |
Osteopontin receptor signaling |
0.028757939 |
14 |
NaN |
|
SPP1 |
| flecainide |
Antiarrhythmic |
Yes |
Up |
Pyrimidine synthesis and salvage |
0.006880038 |
9 |
NaN |
|
TK1;TYMS |
| flecainide |
Antiarrhythmic |
Yes |
Up |
Retinol metabolism |
0.018171887 |
16 |
NaN |
|
ALDH1A2;RDH10 |
| flecainide |
Antiarrhythmic |
Yes |
Down |
Retinol metabolism |
0.00543886 |
6 |
NaN |
|
ALDH1A1;STRA6;TTR |
| flecainide |
Antiarrhythmic |
Yes |
Up |
Ribonucleotide reduction |
0.047912477 |
21 |
NaN |
|
RRM2 |
| flecainide |
Antiarrhythmic |
Yes |
Down |
Serine and glycine metabolism |
0.000188817 |
2 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| flecainide |
Antiarrhythmic |
Yes |
Up |
Sister chromatid attachment to mitotic spindle |
0.032200898 |
18 |
NaN |
|
NUF2 |
| flecainide |
Antiarrhythmic |
Yes |
Down |
Tenascin receptor signaling |
0.004760776 |
4.5 |
NaN |
|
TENM1;TNC |
| flecainide |
Antiarrhythmic |
Yes |
Down |
Transmembrane glucose transport |
0.004760776 |
4.5 |
NaN |
|
SLC2A1;SLC2A3 |
| flecainide |
Antiarrhythmic |
Yes |
Down |
Tropoelastin synthesis |
0.028757939 |
14 |
NaN |
|
ELN |
| estradiol |
Female sex hormone |
No |
Down |
Adherens junction organization |
0.038033595 |
18 |
NaN |
|
CDH1;CDH3;CDH5 |
| estradiol |
Female sex hormone |
No |
Up |
Albumin mediated blood protein transport |
0.026199718 |
13 |
NaN |
|
ALB |
| estradiol |
Female sex hormone |
No |
Down |
Alternative complement pathway |
0.003169819 |
7 |
NaN |
|
C3;CFH |
| estradiol |
Female sex hormone |
No |
Up |
Axonal intermediate filament dynamics |
0.000576244 |
2 |
NaN |
|
NEFH;NEFL;NEFM |
| estradiol |
Female sex hormone |
No |
Down |
CCN intercellular signaling protein family receptor signaling |
0.003169819 |
7 |
NaN |
|
CTGF;CYR61 |
| estradiol |
Female sex hormone |
No |
Down |
Collagen fiber crosslinking |
0.003169819 |
7 |
NaN |
|
LOXL1;PXDN |
| estradiol |
Female sex hormone |
No |
Up |
Collagen fibril organization by fibril-associated bridges |
0.009570814 |
7.5 |
NaN |
|
COL9A2;COL9A3 |
| estradiol |
Female sex hormone |
No |
Up |
Contractile ring constriction |
0.006492473 |
6 |
NaN |
|
MYH14;MYLK |
| estradiol |
Female sex hormone |
No |
Down |
Decorin synthesis |
0.018172195 |
13.5 |
NaN |
|
DCN |
| estradiol |
Female sex hormone |
No |
Down |
Epithelial intermediate filament dynamics |
7.00E-06 |
1 |
NaN |
|
KRT19;KRT4;KRT7;TCHH |
| estradiol |
Female sex hormone |
No |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.023986054 |
10 |
NaN |
|
ADAM12;ADAM33;ADAMTS5 |
| estradiol |
Female sex hormone |
No |
Down |
Fibrillar collagen core structure organization |
2.04E-05 |
2 |
NaN |
|
COL1A2;COL2A1;COL3A1;COL5A2 |
| estradiol |
Female sex hormone |
No |
Up |
Fibroblast growth factor receptor signaling |
0.003285666 |
3 |
NaN |
|
FGF10;FGF18;FGFR3 |
| estradiol |
Female sex hormone |
No |
Up |
Growth differentiation factor receptor signaling |
0.01725681 |
9 |
NaN |
|
GDF2;GDF6 |
| estradiol |
Female sex hormone |
No |
Down |
Heme synthesis |
0.045884436 |
19 |
NaN |
|
ABCG2;ALAS2 |
| estradiol |
Female sex hormone |
No |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
1.78E-05 |
1 |
NaN |
|
A2M;MME;PLAT |
| estradiol |
Female sex hormone |
No |
Down |
Integrin-mediated leukocyte rolling |
0.006498634 |
11.5 |
NaN |
|
ICAM1;VCAM1 |
| estradiol |
Female sex hormone |
No |
Down |
Methionine cycle |
0.036015735 |
16.5 |
NaN |
|
BHMT |
| estradiol |
Female sex hormone |
No |
Down |
Microtubule crosslinking and bundling |
0.004697925 |
9.5 |
NaN |
|
MAP2;MTCL1 |
| estradiol |
Female sex hormone |
No |
Down |
Natriuretic peptide receptor signaling |
0.000113608 |
3 |
NaN |
|
NPPA;NPPB;NPR1 |
| estradiol |
Female sex hormone |
No |
Up |
Osteonectin receptor signaling |
0.003963971 |
4 |
NaN |
|
SMOC2;SPOCK1 |
| estradiol |
Female sex hormone |
No |
Up |
Osteopontin receptor signaling |
0.026199718 |
13 |
NaN |
|
SPP1 |
| estradiol |
Female sex hormone |
No |
Up |
Platelet-derived growth factor receptor signaling |
0.032189046 |
15 |
NaN |
|
PDGFRA;RGS5 |
| estradiol |
Female sex hormone |
No |
Up |
Progesterone receptor signaling |
0.026199718 |
13 |
NaN |
|
PGR |
| estradiol |
Female sex hormone |
No |
Up |
Prostaglandin E2 receptor signaling |
0.009570814 |
7.5 |
NaN |
|
PTGER3;RAPGEF4 |
| estradiol |
Female sex hormone |
No |
Up |
Retinol metabolism |
0.004189215 |
5 |
NaN |
|
ALDH1A1;RDH10;RPE65 |
| estradiol |
Female sex hormone |
No |
Down |
Retinol metabolism |
0.02246927 |
15 |
NaN |
|
ALDH1A2;DHRS3 |
| estradiol |
Female sex hormone |
No |
Down |
Selectin-mediated Leukocyte rolling |
0.004697925 |
9.5 |
NaN |
|
ICAM1;VCAM1 |
| estradiol |
Female sex hormone |
No |
Down |
Serine and glycine metabolism |
0.000876231 |
4 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| estradiol |
Female sex hormone |
No |
Down |
Sister chromatid attachment to mitotic spindle |
0.036015735 |
16.5 |
NaN |
|
TACC3 |
| estradiol |
Female sex hormone |
No |
Down |
Thin myofilament organization |
0.006498634 |
11.5 |
NaN |
|
ACTA1;TNNI3 |
| estradiol |
Female sex hormone |
No |
Down |
Tropoelastin synthesis |
0.018172195 |
13.5 |
NaN |
|
ELN |
| estradiol |
Female sex hormone |
No |
Up |
WNT-Beta-catenin signaling pathway |
0.025887605 |
11 |
NaN |
|
APCDD1;DKK2;FRZB;PAX6;WNT9A |
| estradiol |
Female sex hormone |
No |
Down |
Z-disc organization |
0.002781024 |
5 |
NaN |
|
DES;LDB3;PDLIM3 |
| erlotinib |
Kinase inhibitor |
No |
Up |
Androgen receptor signaling |
0.024374358 |
9 |
NaN |
|
AR |
| erlotinib |
Kinase inhibitor |
No |
Up |
Aspartate and arginine metabolism |
0.006298081 |
3 |
NaN |
|
ARG2;SLC7A1 |
| erlotinib |
Kinase inhibitor |
No |
Down |
CCN intercellular signaling protein family receptor signaling |
0.010319741 |
26.5 |
NaN |
|
CTGF;CYR61 |
| erlotinib |
Kinase inhibitor |
No |
Up |
CD44-Mediated leukocyte rolling |
0.024374358 |
9 |
NaN |
|
CD44 |
| erlotinib |
Kinase inhibitor |
No |
Up |
Cellular iron storage |
0.036339415 |
13.5 |
NaN |
|
FTL |
| erlotinib |
Kinase inhibitor |
No |
Down |
Centrosome maturation |
0.006418182 |
22.5 |
NaN |
|
AURKA;PLK1;TPX2 |
| erlotinib |
Kinase inhibitor |
No |
Down |
Centrosome organization |
0.001796506 |
14 |
NaN |
|
ASPM;NEK2;PLK3;PLK4;POC1A;STIL;TACC3;WDR62 |
| erlotinib |
Kinase inhibitor |
No |
Down |
Centrosome separation |
4.69E-09 |
3 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| erlotinib |
Kinase inhibitor |
No |
Up |
Class switch recombination |
0.022270657 |
7 |
NaN |
|
BCL6;IL7R |
| erlotinib |
Kinase inhibitor |
No |
Down |
Collagen fiber crosslinking |
0.010319741 |
26.5 |
NaN |
|
LOX;LOXL1 |
| erlotinib |
Kinase inhibitor |
No |
Down |
Contractile ring constriction |
0.000347172 |
8.5 |
NaN |
|
ANLN;ECT2;MYLK |
| erlotinib |
Kinase inhibitor |
No |
Up |
Discoidin domain receptor signaling |
0.036339415 |
13.5 |
NaN |
|
DDR2 |
| erlotinib |
Kinase inhibitor |
No |
Down |
DNA replication elongation |
3.96E-08 |
4 |
NaN |
|
MCM2;MCM4;MCM5;MCM7;PCNA |
| erlotinib |
Kinase inhibitor |
No |
Down |
DNA replication initiation |
1.80E-13 |
1 |
NaN |
|
CDC45;CDC6;GINS1;GINS2;GINS4;MCM10;MCM2;MCM3;MCM4;MCM5;MCM6;MCM7;ORC6 |
| erlotinib |
Kinase inhibitor |
No |
Down |
Elastin cross-linking and assembly |
0.003236551 |
17 |
NaN |
|
LOX;LOXL1 |
| erlotinib |
Kinase inhibitor |
No |
Down |
Epithelial intermediate filament dynamics |
0.001804023 |
15 |
NaN |
|
KRT19;KRT7;KRT8 |
| erlotinib |
Kinase inhibitor |
No |
Down |
Equatorial RhoA activation |
0.006330714 |
20 |
NaN |
|
ECT2;KIF23 |
| erlotinib |
Kinase inhibitor |
No |
Up |
ER unfolded protein response pathway |
1.46E-06 |
2 |
NaN |
|
ATF4;DDIT3;HERPUD1;PPP1R15A |
| erlotinib |
Kinase inhibitor |
No |
Down |
Eukaryotic kinetochore dynamics |
3.94E-13 |
2 |
NaN |
|
BUB1;CENPE;CENPF;CENPH;CENPI;CENPU;CENPW;KIF15;MAD2L1;NDC80;NUF2;SKA3;SPC24;TTK;ZWINT |
| erlotinib |
Kinase inhibitor |
No |
Down |
Fanconi anemia interstrand cross-link repair pathway |
0.000170094 |
7 |
NaN |
|
BRCA2;BRIP1;FANCA;FANCD2;FANCI;UBE2T |
| erlotinib |
Kinase inhibitor |
No |
Down |
G2 M transition checkpoint |
0.006418182 |
22.5 |
NaN |
|
CCNB1;CDC25C;CDK1 |
| erlotinib |
Kinase inhibitor |
No |
Up |
Glutamate and glutamine metabolism |
0.010657121 |
5 |
NaN |
|
SLC1A5;SLC7A5 |
| erlotinib |
Kinase inhibitor |
No |
Up |
Heme degradation to bilirubin |
0.036339415 |
13.5 |
NaN |
|
HMOX1 |
| erlotinib |
Kinase inhibitor |
No |
Down |
Homologous recombination DSB repair |
0.000743214 |
11 |
NaN |
|
BRCA2;EXO1;PIF1;RAD51AP1;RECQL4;RMI2;XRCC2 |
| erlotinib |
Kinase inhibitor |
No |
Up |
Hyaluronan receptor CD44 signaling |
0.036339415 |
13.5 |
NaN |
|
CD44 |
| erlotinib |
Kinase inhibitor |
No |
Down |
Intracellular bridge assembly |
0.003236551 |
17 |
NaN |
|
INCENP;KIF23 |
| erlotinib |
Kinase inhibitor |
No |
Up |
Mammalian target of rapamycin signaling pathway |
0.01799692 |
6 |
NaN |
|
DDIT4;EIF4EBP1 |
| erlotinib |
Kinase inhibitor |
No |
Down |
Metaphase to anaphase checkpoint |
1.14E-06 |
5 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;PLK3;PTTG1;TTK |
| erlotinib |
Kinase inhibitor |
No |
Down |
Mitotic chromosome condensation |
0.001155937 |
13 |
NaN |
|
INCENP;NCAPG2;SMC4 |
| erlotinib |
Kinase inhibitor |
No |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.000347172 |
8.5 |
NaN |
|
AURKB;CCNA2;INCENP |
| erlotinib |
Kinase inhibitor |
No |
Down |
Mitotic spindle assembly |
4.09E-05 |
6 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| erlotinib |
Kinase inhibitor |
No |
Up |
Neuregulin receptor signaling |
0.007636099 |
4 |
NaN |
|
ERBB3;ERBB4 |
| erlotinib |
Kinase inhibitor |
No |
Up |
Potassium transmembrane transport |
0.034546233 |
11 |
NaN |
|
ABCC9;ATP1A3 |
| erlotinib |
Kinase inhibitor |
No |
Down |
Retinol metabolism |
0.008140214 |
24 |
NaN |
|
ALDH1A1;ALDH1A3;RBP1 |
| erlotinib |
Kinase inhibitor |
No |
Down |
Ribonucleotide reduction |
0.003236551 |
17 |
NaN |
|
RRM1;RRM2 |
| erlotinib |
Kinase inhibitor |
No |
Up |
Serine and glycine metabolism |
1.12E-07 |
1 |
NaN |
|
PHGDH;PSAT1;PSPH;SHMT2;SLC1A5 |
| erlotinib |
Kinase inhibitor |
No |
Down |
Sister chromatid attachment to mitotic spindle |
0.001103184 |
12 |
NaN |
|
NUF2;TACC3 |
| erlotinib |
Kinase inhibitor |
No |
Down |
Sister chromatid cohesion |
0.010080538 |
25 |
NaN |
|
CDCA5;CHTF18;ESCO2;WDHD1 |
| erlotinib |
Kinase inhibitor |
No |
Down |
Sister chromatid segregation |
0.000677215 |
10 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| erlotinib |
Kinase inhibitor |
No |
Down |
Telomere replication and maintenance |
0.014805151 |
28 |
NaN |
|
EXO1;PIF1;RECQL4 |
| erlotinib |
Kinase inhibitor |
No |
Down |
Tenascin receptor signaling |
0.006330714 |
20 |
NaN |
|
TENM1;TNC |
| erlotinib |
Kinase inhibitor |
No |
Down |
Thrombospondin receptor signaling |
0.006330714 |
20 |
NaN |
|
THBS2;THBS4 |
| erlotinib |
Kinase inhibitor |
No |
Up |
Vasoactive intestinal peptide receptor signaling |
0.024374358 |
9 |
NaN |
|
VIPR1 |
| epirubicin |
Anthracycline |
Yes |
Up |
Actin filament severing and depolymerization |
0.001294662 |
9 |
NaN |
|
CFL1;CFL2;DSTN;GSN |
| epirubicin |
Anthracycline |
Yes |
Up |
Albumin mediated blood protein transport |
0.039520113 |
25.5 |
NaN |
|
ALB |
| epirubicin |
Anthracycline |
Yes |
Up |
Amination of alpha-keto acids and deamination of amino acids |
0.008867547 |
15 |
NaN |
|
GLUD1;LOXL2 |
| epirubicin |
Anthracycline |
Yes |
Up |
Amyloid plaque organization |
0.00063643 |
5 |
NaN |
|
APOE;APP;HSPB6;SNCA |
| epirubicin |
Anthracycline |
Yes |
Up |
Antigen presentation via MHC class I molecules |
0.000418001 |
4 |
NaN |
|
B2M;HLA-A;HLA-B;HLA-C |
| epirubicin |
Anthracycline |
Yes |
Up |
Basement membrane attachment to cell surface |
3.39E-05 |
3 |
NaN |
|
BCAM;BSG;CD151;NID1 |
| epirubicin |
Anthracycline |
Yes |
Up |
Beta-oxidation |
0.002999064 |
11 |
NaN |
|
ACADM;ACADVL;DECR1;HADH |
| epirubicin |
Anthracycline |
Yes |
Up |
Biglycan synthesis |
0.039520113 |
25.5 |
NaN |
|
BGN |
| epirubicin |
Anthracycline |
Yes |
Up |
Chaperone mediated protein folding in ER |
0.042412632 |
30 |
NaN |
|
ERP29;FKBP10;PDIA3 |
| epirubicin |
Anthracycline |
Yes |
Up |
Collagen fibril organization by fibril-associated bridges |
0.021030373 |
19.5 |
NaN |
|
COL9A1;COL9A3 |
| epirubicin |
Anthracycline |
Yes |
Up |
Contractile ring constriction |
0.014394098 |
17.5 |
NaN |
|
CDC42;MYLK |
| epirubicin |
Anthracycline |
Yes |
Up |
Cytosolic protein folding |
0.039520113 |
25.5 |
NaN |
|
HSP90AA1 |
| epirubicin |
Anthracycline |
Yes |
Up |
Decorin synthesis |
0.039520113 |
25.5 |
NaN |
|
DCN |
| epirubicin |
Anthracycline |
Yes |
Up |
Extracellular matrix breakdown by cathepsins |
2.02E-05 |
2 |
NaN |
|
CTSB;CTSF;CTSL;CTSV;CTSZ |
| epirubicin |
Anthracycline |
Yes |
Up |
Fibrillar collagen core structure organization |
1.56E-08 |
1 |
NaN |
|
COL11A2;COL1A1;COL1A2;COL2A1;COL3A1;COL5A1;COL5A2 |
| epirubicin |
Anthracycline |
Yes |
Up |
Fibulin receptor signaling |
0.001558491 |
10 |
NaN |
|
EFEMP2;FBLN1 |
| epirubicin |
Anthracycline |
Yes |
Down |
Glycogen synthesis and glycogenolysis |
0.003151912 |
2 |
NaN |
|
PPP1R3B;PPP1R3C |
| epirubicin |
Anthracycline |
Yes |
Up |
GPI-anchor synthesis and attachment to protein |
0.000924994 |
6.5 |
NaN |
|
GPAA1;PIGK;PIGS;PIGT |
| epirubicin |
Anthracycline |
Yes |
Up |
G-protein coupled receptor signaling pathway |
0.042412632 |
30 |
NaN |
|
GNAS;RGS16;RGS5 |
| epirubicin |
Anthracycline |
Yes |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.010558195 |
3 |
NaN |
|
JUND |
| epirubicin |
Anthracycline |
Yes |
Up |
Ketone body metabolism |
0.039520113 |
25.5 |
NaN |
|
OXCT1 |
| epirubicin |
Anthracycline |
Yes |
Up |
Lipid droplet mitochondria interaction |
0.004552817 |
12 |
NaN |
|
SCP2;SNAP23 |
| epirubicin |
Anthracycline |
Yes |
Up |
Lysosomal acidification |
0.008867547 |
15 |
NaN |
|
ATP6AP1;ATP6AP2 |
| epirubicin |
Anthracycline |
Yes |
Up |
Lysosomal glycosaminoglycan degradation |
0.000924994 |
6.5 |
NaN |
|
ARSB;GNS;IDS;SUMF1 |
| epirubicin |
Anthracycline |
Yes |
Up |
Lysosomal lipid degradation |
0.001121548 |
8 |
NaN |
|
GALC;HEXA;PSAP |
| epirubicin |
Anthracycline |
Yes |
Up |
Macroautophagy |
0.042412632 |
30 |
NaN |
|
BECN1;MAP1LC3A;MAP1LC3B |
| epirubicin |
Anthracycline |
Yes |
Down |
Macrophage migration inhibitory factor signaling |
0.026190267 |
4 |
NaN |
|
JUND |
| epirubicin |
Anthracycline |
Yes |
Down |
Myelin biogenesis and maturation |
0.031346792 |
5 |
NaN |
|
PMP22 |
| epirubicin |
Anthracycline |
Yes |
Down |
Myofibril formation |
0.001206358 |
1 |
NaN |
|
KLHL41;XIRP1 |
| epirubicin |
Anthracycline |
Yes |
Up |
Natriuretic peptide receptor signaling |
0.021030373 |
19.5 |
NaN |
|
NPPA;NPPB |
| epirubicin |
Anthracycline |
Yes |
Up |
Non-vesicular phospholipid transport |
0.028680422 |
22 |
NaN |
|
PITPNM1;SCP2 |
| epirubicin |
Anthracycline |
Yes |
Up |
Phase I biotransformation via alcohol dehydrogenases |
0.008867547 |
15 |
NaN |
|
ALDH2;ALDH9A1 |
| epirubicin |
Anthracycline |
Yes |
Up |
Protein N-linked glycosylation in ER |
0.007980244 |
13 |
NaN |
|
DDOST;RPN2;TUSC3 |
| epirubicin |
Anthracycline |
Yes |
Up |
Protein polyubiquitination |
0.023395932 |
21 |
NaN |
|
NEDD8;SKP1;UCHL1 |
| epirubicin |
Anthracycline |
Yes |
Down |
Retrograde vesicle traffic from Golgi to ER |
0.046655803 |
6 |
NaN |
|
COPB1 |
| epirubicin |
Anthracycline |
Yes |
Up |
Syndecan receptor signaling |
0.014394098 |
17.5 |
NaN |
|
SDC4;SDCBP |
| epirubicin |
Anthracycline |
Yes |
Up |
Tropoelastin synthesis |
0.039520113 |
25.5 |
NaN |
|
ELN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Up |
Actin filament bundling and crosslinking |
0.027648786 |
17 |
NaN |
|
PLS3;SYNPO2;TAGLN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Up |
Aggrecan synthesis |
0.025494001 |
15 |
NaN |
|
ACAN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Up |
Albumin mediated blood protein transport |
0.025494001 |
15 |
NaN |
|
ALB |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Down |
Alternative complement pathway |
0.003737436 |
7.5 |
NaN |
|
C3;CFH |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Up |
Amyloid plaque organization |
0.030604726 |
18 |
NaN |
|
APBB2;APOE |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Up |
Antigen presentation via MHC class I molecules |
0.025462828 |
13 |
NaN |
|
HLA-B;HLA-C |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Down |
Biglycan synthesis |
0.019760056 |
12 |
NaN |
|
BGN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Down |
Calcitonin receptor signaling |
0.039131362 |
18.5 |
NaN |
|
RAMP1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Down |
CD44-Mediated leukocyte rolling |
0.039131362 |
18.5 |
NaN |
|
CD44 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Down |
Cellular cholesterol uptake and efflux |
0.001880573 |
6 |
NaN |
|
ABCA1;ABCG1;SCARA3 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Down |
Cellular iron storage |
0.001151024 |
5 |
NaN |
|
FTH1;FTL |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Up |
Centrosome maturation |
0.036117476 |
19.5 |
NaN |
|
PLK1;TPX2 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Up |
Centrosome separation |
7.70E-05 |
3 |
NaN |
|
CCNB1;CDK1;KIF11;NEK2 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Down |
Chaperone-mediated autophagy |
0.039131362 |
18.5 |
NaN |
|
HSPA8 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Up |
Cholesterol synthesis |
5.28E-10 |
1 |
NaN |
|
CYP51A1;DHCR24;DHCR7;FDFT1;FDPS;HMGCR;HMGCS1;MSMO1;MVD |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Up |
Classical complement pathway |
1.36E-05 |
2 |
NaN |
|
C1QA;C1QB;C1QC;C1R |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Up |
Collagen fiber crosslinking |
0.006155642 |
9 |
NaN |
|
LOXL1;PXDN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Down |
Collagen fibril organization by fibril-associated bridges |
0.000145711 |
2 |
NaN |
|
COL12A1;COL14A1;COL9A2 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Down |
Decorin synthesis |
0.019760056 |
12 |
NaN |
|
DCN |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Down |
Endogenous control of complement activity |
0.003737436 |
7.5 |
NaN |
|
CFH;CFI |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Up |
Eukaryotic kinetochore dynamics |
0.000361948 |
6 |
NaN |
|
BUB1;CENPE;CENPF;DYNLT3;SPC24;ZWINT |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Down |
Extracellular matrix breakdown by cathepsins |
0.015757014 |
10 |
NaN |
|
CTSF;CTSH |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Up |
Fibrillar collagen core structure organization |
0.001722716 |
7 |
NaN |
|
COL11A2;COL2A1;COL5A1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Down |
Fibrillar collagen core structure organization |
2.84E-05 |
1 |
NaN |
|
COL1A1;COL1A2;COL3A1;COL5A2 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Up |
G2 M transition checkpoint |
0.036117476 |
19.5 |
NaN |
|
CCNB1;CDK1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Up |
Glycolysis and Gluconeogenesis |
0.00024 |
4 |
NaN |
|
ALDOA;ENO1;LDHA;PGK1;TPI1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Up |
Growth differentiation factor receptor signaling |
0.016384625 |
11.5 |
NaN |
|
GDF2;GDF6 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Down |
Hepatocyte growth factor receptor signaling |
0.039131362 |
18.5 |
NaN |
|
MET |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Up |
Inhibition of apoptosis |
0.003040976 |
8 |
NaN |
|
BIRC5;IFI6;XAF1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Up |
JAK-STAT signaling pathway |
0.048167963 |
22 |
NaN |
|
SOCS2;STAT1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Down |
Methionine cycle |
0.039131362 |
18.5 |
NaN |
|
BHMT |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Down |
Microfibril scaffold organization |
0.039131362 |
18.5 |
NaN |
|
FBN1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Up |
Mitotic spindle assembly |
0.041978966 |
21 |
NaN |
|
NUSAP1;TPX2 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Up |
Mitotic spindle disassembly |
0.025494001 |
15 |
NaN |
|
CDK1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Up |
Natriuretic peptide receptor signaling |
0.000309793 |
5 |
NaN |
|
NPPA;NPPB;NPR3 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Down |
Parathyroid hormone receptor signaling |
0.007646107 |
9 |
NaN |
|
PTHLH;SLC9A3R1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Down |
Platelet-derived growth factor receptor signaling |
0.001117129 |
3.5 |
NaN |
|
FOSL1;PDGFRA;PDGFRB |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Up |
Prostaglandin E2 receptor signaling |
0.009078567 |
10 |
NaN |
|
PTGER3;RAPGEF4 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Down |
Protein polyubiquitination |
0.038884414 |
15 |
NaN |
|
UBC;UCHL1 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Up |
Pyrimidine synthesis and salvage |
0.016384625 |
11.5 |
NaN |
|
TK1;TYMP |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Down |
Retinol metabolism |
0.026271217 |
14 |
NaN |
|
ALDH1A1;ALDH1A3 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Down |
Serine and glycine metabolism |
0.001117129 |
3.5 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| endothelin-1 |
Endogenous vasoconstrictor |
No |
Down |
Tropoelastin synthesis |
0.019760056 |
12 |
NaN |
|
ELN |
| doxorubicin |
Anthracycline |
Yes |
Down |
Apoptosome assembly |
0.024461509 |
11 |
NaN |
|
BAG3 |
| doxorubicin |
Anthracycline |
Yes |
Down |
Axonal intermediate filament dynamics |
0.034080706 |
15 |
NaN |
|
NEFM |
| doxorubicin |
Anthracycline |
Yes |
Up |
Cardiomyocyte pacemaker current generation |
0.03076651 |
11 |
NaN |
|
CACNA1G;KCNJ5 |
| doxorubicin |
Anthracycline |
Yes |
Down |
CD44-Mediated leukocyte rolling |
0.009856058 |
5.5 |
NaN |
|
CD44 |
| doxorubicin |
Anthracycline |
Yes |
Down |
Cellular iron storage |
0.014748246 |
8 |
NaN |
|
FTL |
| doxorubicin |
Anthracycline |
Yes |
Down |
Chaperone-mediated autophagy |
2.40E-05 |
1 |
NaN |
|
HSP90AA1;HSPA8 |
| doxorubicin |
Anthracycline |
Yes |
Up |
Contractile ring constriction |
0.011795627 |
4.5 |
NaN |
|
ANLN;MYLK |
| doxorubicin |
Anthracycline |
Yes |
Down |
Contractile ring constriction |
0.024461509 |
11 |
NaN |
|
MYH14 |
| doxorubicin |
Anthracycline |
Yes |
Down |
Contractile ring formation |
0.024461509 |
11 |
NaN |
|
MYH14 |
| doxorubicin |
Anthracycline |
Yes |
Down |
Cytosolic protein folding |
0.004940014 |
4 |
NaN |
|
HSP90AA1 |
| doxorubicin |
Anthracycline |
Yes |
Down |
ER unfolded protein response pathway |
0.038855309 |
16 |
NaN |
|
DDIT3 |
| doxorubicin |
Anthracycline |
Yes |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.043606731 |
17 |
NaN |
|
MMP1 |
| doxorubicin |
Anthracycline |
Yes |
Up |
Extracellular matrix breakdown by serine proteases |
0.023625158 |
9.5 |
NaN |
|
HTRA1;ST14 |
| doxorubicin |
Anthracycline |
Yes |
Up |
Extrinsic apoptosis pathway |
0.023625158 |
9.5 |
NaN |
|
TNFRSF10A;TNFRSF10B |
| doxorubicin |
Anthracycline |
Yes |
Up |
Gap junction organization |
0.012201709 |
6 |
NaN |
|
GJA5;GJB2;PRKCG |
| doxorubicin |
Anthracycline |
Yes |
Down |
Heme degradation to bilirubin |
0.014748246 |
8 |
NaN |
|
HMOX1 |
| doxorubicin |
Anthracycline |
Yes |
Down |
Hepatocyte growth factor receptor signaling |
0.009856058 |
5.5 |
NaN |
|
MET |
| doxorubicin |
Anthracycline |
Yes |
Down |
Hyaluronan receptor CD44 signaling |
0.014748246 |
8 |
NaN |
|
CD44 |
| doxorubicin |
Anthracycline |
Yes |
Up |
Lipid droplet fusion |
0.035638673 |
13 |
NaN |
|
CIDEC |
| doxorubicin |
Anthracycline |
Yes |
Down |
Microtubule crosslinking and bundling |
0.02928281 |
13.5 |
NaN |
|
MAP2 |
| doxorubicin |
Anthracycline |
Yes |
Down |
Mitochondrial transport |
0.048335081 |
18 |
NaN |
|
KIF1A |
| doxorubicin |
Anthracycline |
Yes |
Up |
Mitotic spindle disassembly |
0.035638673 |
13 |
NaN |
|
CDK1 |
| doxorubicin |
Anthracycline |
Yes |
Up |
Muscarinic receptor signaling |
0.017278804 |
7.5 |
NaN |
|
CHRM4;RGS5 |
| doxorubicin |
Anthracycline |
Yes |
Up |
Natriuretic peptide receptor signaling |
0.017278804 |
7.5 |
NaN |
|
NPPA;NPPC |
| doxorubicin |
Anthracycline |
Yes |
Down |
NFkB signaling pathway |
0.02928281 |
13.5 |
NaN |
|
SQSTM1 |
| doxorubicin |
Anthracycline |
Yes |
Up |
Nucleosome assembly |
0.000893891 |
2 |
NaN |
|
ASF1B;BAZ1A;HIST1H1D;HIST1H1E;HIST2H2BE |
| doxorubicin |
Anthracycline |
Yes |
Down |
Proteasomal regulatory particle organization |
0.000495433 |
2 |
NaN |
|
PSMC4;PSMD14 |
| doxorubicin |
Anthracycline |
Yes |
Down |
Protein polyubiquitination |
0.002751374 |
3 |
NaN |
|
UBC;UCHL1 |
| doxorubicin |
Anthracycline |
Yes |
Up |
Syndecan receptor signaling |
0.011795627 |
4.5 |
NaN |
|
SDC1;SDC4 |
| doxorubicin |
Anthracycline |
Yes |
Up |
Thick myofilament organization |
0.003711366 |
3 |
NaN |
|
MYBPC3;MYH7 |
| doxorubicin |
Anthracycline |
Yes |
Up |
Tropoelastin synthesis |
0.035638673 |
13 |
NaN |
|
ELN |
| doxorubicin |
Anthracycline |
Yes |
Up |
WNT-Beta-catenin signaling pathway |
0.000410988 |
1 |
NaN |
|
APCDD1;DKK2;DKK3;FZD1;FZD7;FZD8;LEF1;MSX2;SFRP5 |
| dobutamine |
Sympathomimetic |
No |
Up |
Actin filament bundling and crosslinking |
0.000247349 |
1 |
NaN |
|
EPS8;FLNA;FSCN2;TAGLN;USH1C |
| dobutamine |
Sympathomimetic |
No |
Down |
Aggrecan synthesis |
0.022141849 |
8.5 |
NaN |
|
ACAN |
| dobutamine |
Sympathomimetic |
No |
Down |
Albumin mediated blood protein transport |
0.022141849 |
8.5 |
NaN |
|
ALB |
| dobutamine |
Sympathomimetic |
No |
Down |
Bicarbonate transmembrane transport |
0.007994779 |
5 |
NaN |
|
CA2;CA9;SLC4A8 |
| dobutamine |
Sympathomimetic |
No |
Up |
Biglycan synthesis |
0.022494707 |
8.5 |
NaN |
|
BGN |
| dobutamine |
Sympathomimetic |
No |
Up |
Collagen fibril organization by fibril-associated bridges |
0.007122126 |
5 |
NaN |
|
COL12A1;COL9A1 |
| dobutamine |
Sympathomimetic |
No |
Down |
Extracellular matrix breakdown by cathepsins |
0.019543779 |
7 |
NaN |
|
CTSF;CTSZ |
| dobutamine |
Sympathomimetic |
No |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.000854681 |
2 |
NaN |
|
MMP12;MMP2;MMP3 |
| dobutamine |
Sympathomimetic |
No |
Up |
Extracellular matrix breakdown by serine proteases |
0.00982368 |
6 |
NaN |
|
HTRA1;KLK5 |
| dobutamine |
Sympathomimetic |
No |
Up |
Fibrillar collagen core structure organization |
0.001200742 |
3 |
NaN |
|
COL11A2;COL2A1;COL5A2 |
| dobutamine |
Sympathomimetic |
No |
Down |
Fibrillar collagen core structure organization |
4.44E-05 |
1 |
NaN |
|
COL1A1;COL1A2;COL3A1;COL5A3 |
| dobutamine |
Sympathomimetic |
No |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.043795347 |
12 |
NaN |
|
JUND |
| dobutamine |
Sympathomimetic |
No |
Down |
Hepatocyte growth factor receptor signaling |
0.000488351 |
3 |
NaN |
|
HGF;MET |
| dobutamine |
Sympathomimetic |
No |
Up |
JAK-STAT signaling pathway |
0.03838784 |
13 |
NaN |
|
SOCS2;STAT4 |
| dobutamine |
Sympathomimetic |
No |
Up |
Methionine cycle |
0.044485342 |
14.5 |
NaN |
|
BHMT |
| dobutamine |
Sympathomimetic |
No |
Down |
Microfibril scaffold organization |
0.043795347 |
12 |
NaN |
|
FBN1 |
| dobutamine |
Sympathomimetic |
No |
Down |
Mineralocorticoid receptor signaling |
0.043795347 |
12 |
NaN |
|
GPER1 |
| dobutamine |
Sympathomimetic |
No |
Up |
Osteopontin receptor signaling |
0.022494707 |
8.5 |
NaN |
|
SPP1 |
| dobutamine |
Sympathomimetic |
No |
Up |
Platelet-derived growth factor receptor signaling |
0.024248529 |
11 |
NaN |
|
FOSL1;PDGFRB |
| dobutamine |
Sympathomimetic |
No |
Up |
Polyol pathway |
0.002935166 |
4 |
NaN |
|
AKR1B1;AKR1B10 |
| dobutamine |
Sympathomimetic |
No |
Down |
Removal of caspase inhibition |
0.043795347 |
12 |
NaN |
|
XAF1 |
| dobutamine |
Sympathomimetic |
No |
Up |
Retinol metabolism |
0.033390636 |
12 |
NaN |
|
RPE65;STRA6 |
| dobutamine |
Sympathomimetic |
No |
Down |
Retinol metabolism |
0.000143348 |
2 |
NaN |
|
ALDH1A3;CYP26A1;DHRS3;RBP1 |
| dobutamine |
Sympathomimetic |
No |
Down |
Serotonin inactivation |
0.043795347 |
12 |
NaN |
|
MAOB |
| dobutamine |
Sympathomimetic |
No |
Down |
Thin myofilament organization |
0.009528592 |
6 |
NaN |
|
LMOD3;TPM4 |
| dobutamine |
Sympathomimetic |
No |
Down |
Thrombospondin receptor signaling |
0.002844982 |
4 |
NaN |
|
THBS2;THBS4 |
| dobutamine |
Sympathomimetic |
No |
Up |
Tropoelastin synthesis |
0.022494707 |
8.5 |
NaN |
|
ELN |
| dobutamine |
Sympathomimetic |
No |
Up |
Versican receptor signaling |
0.044485342 |
14.5 |
NaN |
|
VCAN |
| dobutamine |
Sympathomimetic |
No |
Up |
Versican synthesis |
0.022494707 |
8.5 |
NaN |
|
VCAN |
| diclofenac |
Nsaid |
No |
Up |
Aggrecan synthesis |
0.024170783 |
14 |
NaN |
|
ACAN |
| diclofenac |
Nsaid |
No |
Up |
Alternative complement pathway |
0.005547025 |
6 |
NaN |
|
C1S;C3 |
| diclofenac |
Nsaid |
No |
Down |
Amyloid plaque organization |
0.02047443 |
3.5 |
NaN |
|
APOE;HSPB6 |
| diclofenac |
Nsaid |
No |
Up |
Androgen receptor signaling |
0.047759421 |
17.5 |
NaN |
|
AR |
| diclofenac |
Nsaid |
No |
Down |
Antigen presentation via MHC class I molecules |
0.016979423 |
2 |
NaN |
|
HLA-B;HLA-C |
| diclofenac |
Nsaid |
No |
Down |
Biglycan synthesis |
0.020553987 |
6 |
NaN |
|
BGN |
| diclofenac |
Nsaid |
No |
Up |
Cardiomyocyte pacemaker current generation |
0.014803768 |
11 |
NaN |
|
CACNA1G;KCNK2 |
| diclofenac |
Nsaid |
No |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.004172266 |
4 |
NaN |
|
KCNA1;KCNA4;KCNIP2 |
| diclofenac |
Nsaid |
No |
Up |
CCN intercellular signaling protein family receptor signaling |
0.005547025 |
6 |
NaN |
|
CTGF;CYR61 |
| diclofenac |
Nsaid |
No |
Down |
Cholesterol-sensitive control of SREBP activation |
0.005975135 |
1 |
NaN |
|
INSIG1;SREBF1 |
| diclofenac |
Nsaid |
No |
Up |
Classical complement pathway |
0.011281532 |
9.5 |
NaN |
|
C1R;C1S |
| diclofenac |
Nsaid |
No |
Up |
Collagen fibril organization by fibril-associated bridges |
4.82E-06 |
1 |
NaN |
|
COL12A1;COL14A1;COL19A1;COL9A3 |
| diclofenac |
Nsaid |
No |
Down |
Decorin synthesis |
0.020553987 |
6 |
NaN |
|
DCN |
| diclofenac |
Nsaid |
No |
Up |
Fibrillar collagen core structure organization |
0.023046241 |
12 |
NaN |
|
COL2A1;COL5A3 |
| diclofenac |
Nsaid |
No |
Up |
Fibulin receptor signaling |
0.047759421 |
17.5 |
NaN |
|
FBLN1 |
| diclofenac |
Nsaid |
No |
Down |
Glutamate and glutamine metabolism |
0.028265172 |
8.5 |
NaN |
|
SLC1A5;SLC7A5 |
| diclofenac |
Nsaid |
No |
Up |
Hepatocyte growth factor receptor signaling |
0.047759421 |
17.5 |
NaN |
|
HGF |
| diclofenac |
Nsaid |
No |
Down |
Lipogenesis |
0.040687284 |
10.5 |
NaN |
|
FASN |
| diclofenac |
Nsaid |
No |
Down |
Methionine cycle |
0.040687284 |
10.5 |
NaN |
|
BHMT |
| diclofenac |
Nsaid |
No |
Up |
Microfibril scaffold organization |
0.047759421 |
17.5 |
NaN |
|
FBN1 |
| diclofenac |
Nsaid |
No |
Down |
Mitotic spindle assembly |
0.028265172 |
8.5 |
NaN |
|
NUSAP1;TPX2 |
| diclofenac |
Nsaid |
No |
Up |
Natriuretic peptide receptor signaling |
0.008188205 |
8 |
NaN |
|
NPPB;NPR3 |
| diclofenac |
Nsaid |
No |
Down |
Osteopontin receptor signaling |
0.020553987 |
6 |
NaN |
|
SPP1 |
| diclofenac |
Nsaid |
No |
Up |
Perlecan synthesis |
0.024170783 |
14 |
NaN |
|
HSPG2 |
| diclofenac |
Nsaid |
No |
Up |
Platelet-derived growth factor receptor signaling |
0.001995643 |
2 |
NaN |
|
PDGFRB;RGS5;TNK2 |
| diclofenac |
Nsaid |
No |
Down |
Platelet-derived growth factor receptor signaling |
0.02047443 |
3.5 |
NaN |
|
FOSL1;PDGFRA |
| diclofenac |
Nsaid |
No |
Up |
Progesterone receptor signaling |
0.024170783 |
14 |
NaN |
|
PGR |
| diclofenac |
Nsaid |
No |
Up |
Roundabout signaling |
0.011281532 |
9.5 |
NaN |
|
ROBO1;ROBO2 |
| diclofenac |
Nsaid |
No |
Up |
Sulfonation |
0.005547025 |
6 |
NaN |
|
SULT1A1;SULT1E1 |
| diclofenac |
Nsaid |
No |
Up |
Thrombospondin receptor signaling |
0.003382112 |
3 |
NaN |
|
CD47;THBS2 |
| diclofenac |
Nsaid |
No |
Down |
WNT-Beta-catenin signaling pathway |
0.04239236 |
13 |
NaN |
|
FRAT1;FRZB;PAX6;SFRP5 |
| diclofenac |
Nsaid |
No |
Down |
Z-disc organization |
0.041771182 |
12 |
NaN |
|
DES;TCAP |
| delavirdine |
Antiviral |
No |
Down |
Albumin mediated blood protein transport |
0.027081863 |
11.5 |
NaN |
|
ALB |
| delavirdine |
Antiviral |
No |
Up |
Alternative complement pathway |
0.003079589 |
4.5 |
NaN |
|
C1S;CFH |
| delavirdine |
Antiviral |
No |
Down |
Biglycan synthesis |
0.027081863 |
11.5 |
NaN |
|
BGN |
| delavirdine |
Antiviral |
No |
Down |
CCN intercellular signaling protein family receptor signaling |
0.006925405 |
3 |
NaN |
|
CTGF;CYR61 |
| delavirdine |
Antiviral |
No |
Up |
Cellular cholesterol uptake and efflux |
0.021860273 |
15.5 |
NaN |
|
ABCA1;SCARA3 |
| delavirdine |
Antiviral |
No |
Up |
Centrosome separation |
0.000618808 |
1 |
NaN |
|
CCNB1;NEK2;SPAG5 |
| delavirdine |
Antiviral |
No |
Up |
Chaperone-mediated autophagy |
0.035495973 |
20.5 |
NaN |
|
HSPA8 |
| delavirdine |
Antiviral |
No |
Up |
Cholesterol synthesis |
0.049079429 |
22 |
NaN |
|
DHCR24;FDFT1 |
| delavirdine |
Antiviral |
No |
Up |
Classical complement pathway |
0.006315881 |
8 |
NaN |
|
C1R;C1S |
| delavirdine |
Antiviral |
No |
Up |
Decorin synthesis |
0.017907551 |
13.5 |
NaN |
|
DCN |
| delavirdine |
Antiviral |
No |
Up |
Drug and toxin export via membrane transport proteins |
0.003786015 |
7 |
NaN |
|
ABCA1;ABCC3;ABCC5 |
| delavirdine |
Antiviral |
No |
Down |
Eicosanoid metabolism |
0.007026965 |
4 |
NaN |
|
PLA2G4A;PTGS1;PTGS2 |
| delavirdine |
Antiviral |
No |
Up |
Endogenous control of complement activity |
0.003079589 |
4.5 |
NaN |
|
CFH;CFI |
| delavirdine |
Antiviral |
No |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.023206981 |
7 |
NaN |
|
BSG;MMP9 |
| delavirdine |
Antiviral |
No |
Up |
Fibronectin synthesis and extracellular assembly |
0.003079589 |
4.5 |
NaN |
|
FN1;ITGB3 |
| delavirdine |
Antiviral |
No |
Down |
Filopodium organization |
0.026137435 |
9 |
NaN |
|
ENAH;GPM6A;TNK2 |
| delavirdine |
Antiviral |
No |
Down |
GABA metabolism |
0.010202989 |
5 |
NaN |
|
ABAT;SLC6A1 |
| delavirdine |
Antiviral |
No |
Down |
Glutamate and glutamine metabolism |
0.004597545 |
1.5 |
NaN |
|
SLC1A5;SLC38A2;SLC7A5 |
| delavirdine |
Antiviral |
No |
Down |
Glycolysis and Gluconeogenesis |
0.023326766 |
8 |
NaN |
|
HK2;PFKFB3;PFKFB4 |
| delavirdine |
Antiviral |
No |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.010574722 |
11 |
NaN |
|
SOCS3;STAT3 |
| delavirdine |
Antiviral |
No |
Up |
Growth differentiation factor receptor signaling |
0.008322328 |
9.5 |
NaN |
|
GDF2;GDF6 |
| delavirdine |
Antiviral |
No |
Down |
Hippo signaling |
0.032277294 |
14 |
NaN |
|
AMOTL1;CRB2;WWC1 |
| delavirdine |
Antiviral |
No |
Up |
Inhibin receptor signaling |
0.008322328 |
9.5 |
NaN |
|
INHBE;TGFBR3 |
| delavirdine |
Antiviral |
No |
Up |
JAK-STAT signaling pathway |
0.025206934 |
17 |
NaN |
|
SOCS3;STAT3 |
| delavirdine |
Antiviral |
No |
Up |
Leptin receptor signaling |
0.001869797 |
2 |
NaN |
|
SOCS3;STAT3 |
| delavirdine |
Antiviral |
No |
Up |
Macrophage migration inhibitory factor signaling |
0.003079589 |
4.5 |
NaN |
|
ACKR3;CXCR4 |
| delavirdine |
Antiviral |
No |
Up |
Microfibril scaffold organization |
0.035495973 |
20.5 |
NaN |
|
FBN1 |
| delavirdine |
Antiviral |
No |
Down |
Notch receptor signaling |
0.01593556 |
6 |
NaN |
|
DLK1;JAG1;LFNG |
| delavirdine |
Antiviral |
No |
Up |
Osteopontin receptor signaling |
0.017907551 |
13.5 |
NaN |
|
SPP1 |
| delavirdine |
Antiviral |
No |
Down |
Platelet-derived growth factor receptor signaling |
0.034215437 |
15.5 |
NaN |
|
PDGFRA;TNK2 |
| delavirdine |
Antiviral |
No |
Up |
Protein polyubiquitination |
0.032472681 |
19 |
NaN |
|
UBC;UCHL1 |
| delavirdine |
Antiviral |
No |
Up |
Retinol metabolism |
0.021860273 |
15.5 |
NaN |
|
ALDH1A1;STRA6 |
| delavirdine |
Antiviral |
No |
Down |
Retinol metabolism |
0.004597545 |
1.5 |
NaN |
|
ALDH1A2;DHRS3;RLBP1 |
| delavirdine |
Antiviral |
No |
Up |
Serine and glycine metabolism |
0.015780154 |
12 |
NaN |
|
PHGDH;SHMT2 |
| delavirdine |
Antiviral |
No |
Down |
Serine and glycine metabolism |
0.034215437 |
15.5 |
NaN |
|
PSAT1;SLC1A5 |
| delavirdine |
Antiviral |
No |
Down |
Tropoelastin synthesis |
0.027081863 |
11.5 |
NaN |
|
ELN |
| delavirdine |
Antiviral |
No |
Down |
Versican synthesis |
0.027081863 |
11.5 |
NaN |
|
VCAN |
| delavirdine |
Antiviral |
No |
Up |
WNT-Beta-catenin signaling pathway |
0.027539864 |
18 |
NaN |
|
FRZB;FZD8;SFRP2;WNT2 |
| decitabine |
Other chemotherapy drug |
No |
Down |
Aggrecan synthesis |
0.023376853 |
14.5 |
NaN |
|
ACAN |
| decitabine |
Other chemotherapy drug |
No |
Down |
Albumin mediated blood protein transport |
0.023376853 |
14.5 |
NaN |
|
ALB |
| decitabine |
Other chemotherapy drug |
No |
Down |
Alternative complement pathway |
0.005196305 |
4 |
NaN |
|
C1S;CFH |
| decitabine |
Other chemotherapy drug |
No |
Up |
Amyloid plaque organization |
0.001117129 |
2 |
NaN |
|
APOE;HSPB6;VSNL1 |
| decitabine |
Other chemotherapy drug |
No |
Up |
Antigen presentation via MHC class I molecules |
0.015757014 |
12 |
NaN |
|
HLA-A;HLA-B |
| decitabine |
Other chemotherapy drug |
No |
Up |
Aspartate and arginine metabolism |
0.015757014 |
12 |
NaN |
|
ARG2;DDAH1 |
| decitabine |
Other chemotherapy drug |
No |
Down |
Axonal intermediate filament dynamics |
0.010579453 |
7.5 |
NaN |
|
NEFH;NEFM |
| decitabine |
Other chemotherapy drug |
No |
Down |
Biglycan synthesis |
0.023376853 |
14.5 |
NaN |
|
BGN |
| decitabine |
Other chemotherapy drug |
No |
Down |
Cardiomyocyte depolarization during action potential |
0.023376853 |
14.5 |
NaN |
|
SCN5A |
| decitabine |
Other chemotherapy drug |
No |
Up |
Caveolin-mediated endocytosis |
0.001151024 |
3 |
NaN |
|
CAV1;CAV2 |
| decitabine |
Other chemotherapy drug |
No |
Down |
CD44-Mediated leukocyte rolling |
0.046209242 |
20 |
NaN |
|
CD44 |
| decitabine |
Other chemotherapy drug |
No |
Down |
Cellular cholesterol uptake and efflux |
0.035834633 |
19 |
NaN |
|
ABCA1;ABCG1 |
| decitabine |
Other chemotherapy drug |
No |
Down |
Cholesterol synthesis |
2.11E-07 |
1 |
NaN |
|
DHCR24;DHCR7;HMGCR;HMGCS1;MSMO1;MVD;MVK |
| decitabine |
Other chemotherapy drug |
No |
Down |
Collagen fibril organization by fibril-associated bridges |
0.007674569 |
5.5 |
NaN |
|
COL12A1;COL9A3 |
| decitabine |
Other chemotherapy drug |
No |
Down |
Decorin synthesis |
0.023376853 |
14.5 |
NaN |
|
DCN |
| decitabine |
Other chemotherapy drug |
No |
Up |
DNA replication initiation |
0.012705831 |
9 |
NaN |
|
CDC6;MCM5;MCM6 |
| decitabine |
Other chemotherapy drug |
No |
Down |
ER unfolded protein response pathway |
0.013889809 |
9 |
NaN |
|
ATF4;HERPUD1 |
| decitabine |
Other chemotherapy drug |
No |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.001155785 |
4 |
NaN |
|
ADAM19;ADAMTS1;ADAMTS2;ADAMTS7 |
| decitabine |
Other chemotherapy drug |
No |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.012770499 |
10 |
NaN |
|
MMP1;MMP14 |
| decitabine |
Other chemotherapy drug |
No |
Up |
Fibrillar collagen core structure organization |
0.000824437 |
1 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| decitabine |
Other chemotherapy drug |
No |
Down |
Fibrillar collagen core structure organization |
0.021646065 |
11 |
NaN |
|
COL11A1;COL2A1 |
| decitabine |
Other chemotherapy drug |
No |
Down |
GABA metabolism |
0.007674569 |
5.5 |
NaN |
|
ABAT;SLC6A1 |
| decitabine |
Other chemotherapy drug |
No |
Up |
Glycolysis and Gluconeogenesis |
0.01007022 |
8 |
NaN |
|
PCK2;PFKFB3;PFKFB4 |
| decitabine |
Other chemotherapy drug |
No |
Up |
Hepatocyte growth factor receptor signaling |
0.039131362 |
16.5 |
NaN |
|
HGF |
| decitabine |
Other chemotherapy drug |
No |
Up |
Inhibin receptor signaling |
0.010062749 |
7 |
NaN |
|
INHBB;INHBE |
| decitabine |
Other chemotherapy drug |
No |
Up |
JAK-STAT signaling pathway |
0.030256623 |
15 |
NaN |
|
SOCS2;STAT4 |
| decitabine |
Other chemotherapy drug |
No |
Up |
Microfibril scaffold organization |
0.039131362 |
16.5 |
NaN |
|
MFAP2 |
| decitabine |
Other chemotherapy drug |
No |
Down |
Mitochondrial fission |
0.030788722 |
18 |
NaN |
|
DNM1;MTFR2 |
| decitabine |
Other chemotherapy drug |
No |
Up |
Natriuretic peptide receptor signaling |
0.005533298 |
5 |
NaN |
|
NPPA;NPPB |
| decitabine |
Other chemotherapy drug |
No |
Up |
Neuregulin receptor signaling |
0.019010322 |
14 |
NaN |
|
ERBB3;SH3TC2 |
| decitabine |
Other chemotherapy drug |
No |
Down |
Osteonectin receptor signaling |
0.003166583 |
3 |
NaN |
|
SMOC2;SPOCK1 |
| decitabine |
Other chemotherapy drug |
No |
Down |
Progesterone receptor signaling |
0.023376853 |
14.5 |
NaN |
|
PGR |
| decitabine |
Other chemotherapy drug |
No |
Up |
Restriction point |
0.015757014 |
12 |
NaN |
|
CCND2;PFKFB3 |
| decitabine |
Other chemotherapy drug |
No |
Down |
Thin myofilament organization |
0.010579453 |
7.5 |
NaN |
|
ACTA1;TNNI3 |
| decitabine |
Other chemotherapy drug |
No |
Down |
Thrombospondin receptor signaling |
4.97E-05 |
2 |
NaN |
|
THBS1;THBS2;THBS4 |
| decitabine |
Other chemotherapy drug |
No |
Up |
Vascular endothelial growth factor receptor signaling |
0.007646107 |
6 |
NaN |
|
FLT1;KDR |
| decitabine |
Other chemotherapy drug |
No |
Down |
WNT-Beta-catenin signaling pathway |
0.016710881 |
10 |
NaN |
|
APCDD1;DACT1;DKK2;FRZB;WNT2 |
| daunorubicin |
Anthracycline |
Yes |
Down |
Apoptosome assembly |
0.048441967 |
13 |
NaN |
|
BAG3 |
| daunorubicin |
Anthracycline |
Yes |
Up |
Cardiomyocyte pacemaker current generation |
0.027854729 |
10 |
NaN |
|
CACNA1G;KCNJ5 |
| daunorubicin |
Anthracycline |
Yes |
Down |
CD44-Mediated leukocyte rolling |
0.019663305 |
5.5 |
NaN |
|
CD44 |
| daunorubicin |
Anthracycline |
Yes |
Down |
Cellular iron storage |
0.029350768 |
8 |
NaN |
|
FTL |
| daunorubicin |
Anthracycline |
Yes |
Down |
Chaperone-mediated autophagy |
9.68E-05 |
1 |
NaN |
|
HSP90AA1;HSPA8 |
| daunorubicin |
Anthracycline |
Yes |
Up |
Contractile ring constriction |
0.010639818 |
6 |
NaN |
|
ANLN;MYLK |
| daunorubicin |
Anthracycline |
Yes |
Down |
Contractile ring constriction |
0.048441967 |
13 |
NaN |
|
MYH14 |
| daunorubicin |
Anthracycline |
Yes |
Down |
Contractile ring formation |
0.048441967 |
13 |
NaN |
|
MYH14 |
| daunorubicin |
Anthracycline |
Yes |
Down |
Cytosolic protein folding |
0.009880028 |
3 |
NaN |
|
HSP90AA1 |
| daunorubicin |
Anthracycline |
Yes |
Down |
Erythropoietin receptor signaling |
0.038943348 |
10.5 |
NaN |
|
GAB2 |
| daunorubicin |
Anthracycline |
Yes |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.045801684 |
15 |
NaN |
|
ADAMTS5;ADAMTS7;ADAMTS8 |
| daunorubicin |
Anthracycline |
Yes |
Up |
Extracellular matrix breakdown by heparanases and sulfatases |
0.006529396 |
5 |
NaN |
|
SULF1;SULF2 |
| daunorubicin |
Anthracycline |
Yes |
Up |
Extracellular matrix breakdown by serine proteases |
0.021363034 |
8.5 |
NaN |
|
HTRA1;ST14 |
| daunorubicin |
Anthracycline |
Yes |
Up |
Extrinsic apoptosis pathway |
0.0012102 |
3 |
NaN |
|
FAS;TNFRSF10A;TNFRSF10B |
| daunorubicin |
Anthracycline |
Yes |
Up |
Fibrillar collagen core structure organization |
0.04281872 |
14 |
NaN |
|
COL5A1;COL5A2 |
| daunorubicin |
Anthracycline |
Yes |
Down |
Heme degradation to bilirubin |
0.029350768 |
8 |
NaN |
|
HMOX1 |
| daunorubicin |
Anthracycline |
Yes |
Down |
Hepatocyte growth factor receptor signaling |
0.019663305 |
5.5 |
NaN |
|
MET |
| daunorubicin |
Anthracycline |
Yes |
Down |
Hyaluronan receptor CD44 signaling |
0.029350768 |
8 |
NaN |
|
CD44 |
| daunorubicin |
Anthracycline |
Yes |
Up |
Interferon beta receptor signaling |
0.021363034 |
8.5 |
NaN |
|
IFIT2;IRF3 |
| daunorubicin |
Anthracycline |
Yes |
Up |
Mitotic spindle disassembly |
0.033786168 |
12.5 |
NaN |
|
CDK1 |
| daunorubicin |
Anthracycline |
Yes |
Up |
Muscarinic receptor signaling |
0.015605081 |
7 |
NaN |
|
CHRM4;RGS5 |
| daunorubicin |
Anthracycline |
Yes |
Up |
Notch receptor signaling |
0.028469401 |
11 |
NaN |
|
DLL4;LFNG;NOTCH1 |
| daunorubicin |
Anthracycline |
Yes |
Up |
Nucleosome assembly |
0.000702025 |
2 |
NaN |
|
ASF1B;BAZ1A;HIST1H1D;HIST1H1E;HIST2H2BE |
| daunorubicin |
Anthracycline |
Yes |
Down |
Proteasomal regulatory particle organization |
0.001967001 |
2 |
NaN |
|
PSMC4;PSMD14 |
| daunorubicin |
Anthracycline |
Yes |
Down |
Protein polyubiquitination |
0.010606382 |
4 |
NaN |
|
UBC;UCHL1 |
| daunorubicin |
Anthracycline |
Yes |
Down |
Syndecan ectodomain shedding |
0.038943348 |
10.5 |
NaN |
|
ADAMTS1 |
| daunorubicin |
Anthracycline |
Yes |
Up |
Thick myofilament organization |
0.003339324 |
4 |
NaN |
|
MYBPC3;MYH7 |
| daunorubicin |
Anthracycline |
Yes |
Up |
Tropoelastin synthesis |
0.033786168 |
12.5 |
NaN |
|
ELN |
| daunorubicin |
Anthracycline |
Yes |
Up |
WNT-Beta-catenin signaling pathway |
5.12E-05 |
1 |
NaN |
|
APCDD1;DKK2;DKK3;FRAT1;FZD10;FZD7;FZD8;SFRP2;SFRP5;WNT1 |
| dasatinib |
Kinase inhibitor |
No |
Down |
Albumin mediated blood protein transport |
0.025317572 |
15 |
NaN |
|
ALB |
| dasatinib |
Kinase inhibitor |
No |
Up |
Bicarbonate transmembrane transport |
0.04913699 |
14.5 |
NaN |
|
CA2;CA9 |
| dasatinib |
Kinase inhibitor |
No |
Down |
Biglycan synthesis |
0.025317572 |
15 |
NaN |
|
BGN |
| dasatinib |
Kinase inhibitor |
No |
Up |
Calcitonin receptor signaling |
0.037401081 |
12.5 |
NaN |
|
RAMP1 |
| dasatinib |
Kinase inhibitor |
No |
Up |
CCN intercellular signaling protein family receptor signaling |
0.003416552 |
2 |
NaN |
|
CTGF;NOV |
| dasatinib |
Kinase inhibitor |
No |
Down |
CCN intercellular signaling protein family receptor signaling |
0.006072761 |
5.5 |
NaN |
|
CYR61;WISP1 |
| dasatinib |
Kinase inhibitor |
No |
Up |
Centrosome separation |
0.014446446 |
5 |
NaN |
|
CCNB1;CDK1 |
| dasatinib |
Kinase inhibitor |
No |
Up |
Class switch recombination |
0.04913699 |
14.5 |
NaN |
|
BCL6;IRF4 |
| dasatinib |
Kinase inhibitor |
No |
Down |
Collagen fiber crosslinking |
0.006072761 |
5.5 |
NaN |
|
LOX;PXDN |
| dasatinib |
Kinase inhibitor |
No |
Up |
Collagen fibril organization by fibril-associated bridges |
0.005061213 |
3.5 |
NaN |
|
COL12A1;COL14A1 |
| dasatinib |
Kinase inhibitor |
No |
Up |
Decorin synthesis |
0.018877911 |
7.5 |
NaN |
|
DCN |
| dasatinib |
Kinase inhibitor |
No |
Down |
Epithelial intermediate filament dynamics |
0.016169721 |
11 |
NaN |
|
KRT19;KRT7 |
| dasatinib |
Kinase inhibitor |
No |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.020445489 |
12 |
NaN |
|
MMP14;MMP9 |
| dasatinib |
Kinase inhibitor |
No |
Down |
Extracellular matrix breakdown by serine proteases |
0.012331868 |
9 |
NaN |
|
PRSS12;PRSS8 |
| dasatinib |
Kinase inhibitor |
No |
Down |
Fibrillar collagen core structure organization |
7.49E-05 |
1 |
NaN |
|
COL11A1;COL11A2;COL2A1;COL5A1 |
| dasatinib |
Kinase inhibitor |
No |
Up |
G2 M transition checkpoint |
0.020669774 |
9 |
NaN |
|
CCNB1;CDK1 |
| dasatinib |
Kinase inhibitor |
No |
Down |
Gap junction organization |
0.047569054 |
19 |
NaN |
|
GJA1;GJA5 |
| dasatinib |
Kinase inhibitor |
No |
Down |
Glycolysis and Gluconeogenesis |
0.00243598 |
3 |
NaN |
|
ENO1;PCK2;PFKFB3;PFKFB4 |
| dasatinib |
Kinase inhibitor |
No |
Down |
Inhibition of apoptosis |
0.035660258 |
18 |
NaN |
|
IFI6;XAF1 |
| dasatinib |
Kinase inhibitor |
No |
Down |
Microfibril scaffold organization |
0.049996342 |
21 |
NaN |
|
FBN1 |
| dasatinib |
Kinase inhibitor |
No |
Up |
Mineralocorticoid receptor signaling |
0.037401081 |
12.5 |
NaN |
|
NR3C2 |
| dasatinib |
Kinase inhibitor |
No |
Up |
Mitotic spindle assembly |
0.024127969 |
10 |
NaN |
|
DLGAP5;NUSAP1 |
| dasatinib |
Kinase inhibitor |
No |
Up |
Mitotic spindle disassembly |
0.018877911 |
7.5 |
NaN |
|
CDK1 |
| dasatinib |
Kinase inhibitor |
No |
Up |
Natriuretic peptide receptor signaling |
0.005061213 |
3.5 |
NaN |
|
NPPA;NPPB |
| dasatinib |
Kinase inhibitor |
No |
Down |
Non-vesicular phospholipid transport |
0.012331868 |
9 |
NaN |
|
PITPNM1;PLTP |
| dasatinib |
Kinase inhibitor |
No |
Down |
Osteopontin receptor signaling |
0.025317572 |
15 |
NaN |
|
SPP1 |
| dasatinib |
Kinase inhibitor |
No |
Up |
Platelet-derived growth factor receptor signaling |
0.017439282 |
6 |
NaN |
|
PDGFRA;TNK2 |
| dasatinib |
Kinase inhibitor |
No |
Down |
Removal of caspase inhibition |
0.049996342 |
21 |
NaN |
|
XAF1 |
| dasatinib |
Kinase inhibitor |
No |
Down |
Restriction point |
0.001688656 |
2 |
NaN |
|
CCND2;CDKN1A;PFKFB3 |
| dasatinib |
Kinase inhibitor |
No |
Down |
Semaphorin signaling |
0.010263471 |
7 |
NaN |
|
DPYSL4;PLXND1;SEMA5A;SEMA6D |
| dasatinib |
Kinase inhibitor |
No |
Up |
Thin myofilament organization |
0.000219552 |
1 |
NaN |
|
ACTA1;LMOD3;TNNI3 |
| dasatinib |
Kinase inhibitor |
No |
Down |
Tropoelastin synthesis |
0.025317572 |
15 |
NaN |
|
ELN |
| dasatinib |
Kinase inhibitor |
No |
Down |
Vascular endothelial growth factor receptor signaling |
0.012331868 |
9 |
NaN |
|
FLT1;KDR |
| dasatinib |
Kinase inhibitor |
No |
Down |
Versican receptor signaling |
0.049996342 |
21 |
NaN |
|
VCAN |
| dasatinib |
Kinase inhibitor |
No |
Down |
Versican synthesis |
0.025317572 |
15 |
NaN |
|
VCAN |
| dasatinib |
Kinase inhibitor |
No |
Down |
WNT-Beta-catenin signaling pathway |
0.005475082 |
4 |
NaN |
|
FRZB;FZD2;SFRP1;SFRP5;WNT5A;WNT9A |
| dasatinib |
Kinase inhibitor |
No |
Up |
Z-disc organization |
0.035773535 |
11 |
NaN |
|
MYOZ1;TCAP |
| dabrafenib |
Kinase inhibitor |
Yes |
Up |
Aspartate and arginine metabolism |
0.002245939 |
4 |
NaN |
|
ARG2;SLC7A1;SLC7A2 |
| dabrafenib |
Kinase inhibitor |
Yes |
Up |
Chaperone mediated protein folding in ER |
0.002039177 |
3 |
NaN |
|
ERP29;HSP90B1;HSPA5;PDIA3 |
| dabrafenib |
Kinase inhibitor |
Yes |
Up |
Chondroitin sulfate and dermatan sulfate synthesis |
0.01491633 |
11.5 |
NaN |
|
CHST11;SOX9 |
| dabrafenib |
Kinase inhibitor |
Yes |
Down |
Decorin synthesis |
0.016584333 |
9 |
NaN |
|
DCN |
| dabrafenib |
Kinase inhibitor |
Yes |
Up |
Desaturation of fatty acids |
0.01491633 |
11.5 |
11 |
Up by cardiotoxic TKIs |
FADS3;SCD |
| dabrafenib |
Kinase inhibitor |
Yes |
Down |
DNA replication elongation |
0.002647307 |
2 |
NaN |
|
MCM4;PCNA |
| dabrafenib |
Kinase inhibitor |
Yes |
Down |
Epithelial intermediate filament dynamics |
0.007173082 |
4.5 |
NaN |
|
KRT19;KRT7 |
| dabrafenib |
Kinase inhibitor |
Yes |
Up |
ER unfolded protein response pathway |
8.66E-07 |
1 |
NaN |
|
ATF4;DDIT3;HERPUD1;HSP90B1;HSPA5 |
| dabrafenib |
Kinase inhibitor |
Yes |
Up |
Extracellular matrix breakdown by cathepsins |
0.030243397 |
14 |
NaN |
|
CTSB;CTSZ |
| dabrafenib |
Kinase inhibitor |
Yes |
Down |
Fibrillar collagen core structure organization |
0.011279449 |
7 |
NaN |
|
COL1A2;COL3A1 |
| dabrafenib |
Kinase inhibitor |
Yes |
Down |
Folate cycle |
0.048936686 |
16.5 |
NaN |
|
DHFR |
| dabrafenib |
Kinase inhibitor |
Yes |
Up |
GABA metabolism |
0.010853767 |
8 |
NaN |
|
ABAT;SLC6A1 |
| dabrafenib |
Kinase inhibitor |
Yes |
Up |
Glutamate and glutamine metabolism |
0.005029519 |
6 |
NaN |
|
SLC1A5;SLC38A2;SLC7A5 |
| dabrafenib |
Kinase inhibitor |
Yes |
Down |
Glycogen synthesis and glycogenolysis |
0.02818348 |
12.5 |
NaN |
|
PPP1R3A;PYGM |
| dabrafenib |
Kinase inhibitor |
Yes |
Down |
Hemoglobin and myoglobin synthesis |
0.048936686 |
16.5 |
NaN |
|
MB |
| dabrafenib |
Kinase inhibitor |
Yes |
Down |
Heparin-binding EGF-like growth factor receptor signaling |
0.048936686 |
16.5 |
NaN |
|
HBEGF |
| dabrafenib |
Kinase inhibitor |
Yes |
Down |
HIF-1 receptor signaling pathway |
0.009122437 |
6 |
20 |
Down by cardiotoxic TKIs |
CITED2;EGLN3 |
| dabrafenib |
Kinase inhibitor |
Yes |
Up |
Microtubule crosslinking and bundling |
0.010853767 |
8 |
NaN |
|
MAP1B;MAP2 |
| dabrafenib |
Kinase inhibitor |
Yes |
Up |
Natriuretic peptide receptor signaling |
0.010853767 |
8 |
NaN |
|
NPPA;NPPB |
| dabrafenib |
Kinase inhibitor |
Yes |
Down |
Osteopontin receptor signaling |
0.016584333 |
9 |
NaN |
|
SPP1 |
| dabrafenib |
Kinase inhibitor |
Yes |
Up |
Ras signaling pathway |
0.049620602 |
15 |
NaN |
|
KSR1;SHC1 |
| dabrafenib |
Kinase inhibitor |
Yes |
Down |
Retinol metabolism |
0.001135795 |
1 |
NaN |
|
ALDH1A1;ALDH1A2;ALDH1A3 |
| dabrafenib |
Kinase inhibitor |
Yes |
Up |
Semaphorin signaling |
0.014369829 |
10 |
NaN |
|
CRMP1;PLXNA2;PLXNB3;SEMA5A |
| dabrafenib |
Kinase inhibitor |
Yes |
Up |
Serine and glycine metabolism |
6.67E-06 |
2 |
19 |
Up by cardiotoxic TKIs |
PHGDH;PSAT1;PSPH;SHMT2;SLC1A5 |
| dabrafenib |
Kinase inhibitor |
Yes |
Down |
Serotonin and melatonin synthesis |
0.048936686 |
16.5 |
NaN |
|
SLC6A4 |
| dabrafenib |
Kinase inhibitor |
Yes |
Down |
Thin myofilament organization |
0.005438922 |
3 |
21 |
Down by cardiotoxic TKIs |
ACTA1;LMOD3 |
| dabrafenib |
Kinase inhibitor |
Yes |
Up |
Thrombospondin receptor signaling |
0.004505994 |
5 |
NaN |
|
THBS1;THBS4 |
| dabrafenib |
Kinase inhibitor |
Yes |
Down |
Tight junction organization |
0.018422427 |
11 |
NaN |
|
CLDN11;CLDN6;MPP5 |
| dabrafenib |
Kinase inhibitor |
Yes |
Down |
Tropoelastin synthesis |
0.016584333 |
9 |
NaN |
|
ELN |
| dabrafenib |
Kinase inhibitor |
Yes |
Down |
Vasoactive intestinal peptide receptor signaling |
0.032895065 |
14 |
NaN |
|
VIPR2 |
| dabrafenib |
Kinase inhibitor |
Yes |
Up |
Versican synthesis |
0.027964008 |
13 |
NaN |
|
VCAN |
| dabrafenib |
Kinase inhibitor |
Yes |
Down |
Water transmembrane transport |
0.007173082 |
4.5 |
9 |
Down by cardiotoxic TKIs |
AQP3;AQP7 |
| dabrafenib |
Kinase inhibitor |
Yes |
Down |
Z-disc organization |
0.02818348 |
12.5 |
NaN |
|
CSRP3;TCAP |
| cyclosporine |
Immunosuppressant |
Yes |
Down |
Albumin mediated blood protein transport |
0.02293578 |
13.5 |
NaN |
|
ALB |
| cyclosporine |
Immunosuppressant |
Yes |
Down |
Biglycan synthesis |
0.02293578 |
13.5 |
NaN |
|
BGN |
| cyclosporine |
Immunosuppressant |
Yes |
Up |
CCN intercellular signaling protein family receptor signaling |
0.004599768 |
2.5 |
NaN |
|
CTGF;CYR61 |
| cyclosporine |
Immunosuppressant |
Yes |
Down |
CD44-Mediated leukocyte rolling |
0.045347487 |
21.5 |
NaN |
|
CD44 |
| cyclosporine |
Immunosuppressant |
Yes |
Down |
Cellular iron uptake and export |
0.034603897 |
18 |
NaN |
|
RASD1;TFRC |
| cyclosporine |
Immunosuppressant |
Yes |
Down |
Decorin synthesis |
0.02293578 |
13.5 |
NaN |
|
DCN |
| cyclosporine |
Immunosuppressant |
Yes |
Down |
Discoidin domain receptor signaling |
0.00154836 |
2 |
NaN |
|
DDR2;RUNX2 |
| cyclosporine |
Immunosuppressant |
Yes |
Down |
Endogenous control of complement activity |
0.00500617 |
6 |
NaN |
|
CFH;CFI |
| cyclosporine |
Immunosuppressant |
Yes |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.01691013 |
8 |
NaN |
|
ADAMTS14;ADAMTS2;ADAMTS8 |
| cyclosporine |
Immunosuppressant |
Yes |
Down |
Extracellular matrix breakdown by heparanases and sulfatases |
0.003049812 |
4.5 |
NaN |
|
SULF1;SULF2 |
| cyclosporine |
Immunosuppressant |
Yes |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.01696168 |
9 |
NaN |
|
MMP1;MMP12 |
| cyclosporine |
Immunosuppressant |
Yes |
Down |
Fibrillar collagen core structure organization |
0.02088458 |
10 |
NaN |
|
COL1A2;COL2A1 |
| cyclosporine |
Immunosuppressant |
Yes |
Up |
Fibroblast growth factor receptor signaling |
0.027432825 |
9 |
NaN |
|
FGF1;FGF18 |
| cyclosporine |
Immunosuppressant |
Yes |
Up |
Fibronectin synthesis and extracellular assembly |
0.004599768 |
2.5 |
NaN |
|
FN1;ITGB3 |
| cyclosporine |
Immunosuppressant |
Yes |
Up |
Fibulin receptor signaling |
0.043450255 |
13 |
NaN |
|
FBLN1 |
| cyclosporine |
Immunosuppressant |
Yes |
Down |
Glutamate and glutamine metabolism |
0.000164225 |
1 |
NaN |
|
GLUL;SLC1A1;SLC1A5;SLC7A5 |
| cyclosporine |
Immunosuppressant |
Yes |
Up |
Growth differentiation factor receptor signaling |
0.012330009 |
5 |
NaN |
|
GDF15;GDF2 |
| cyclosporine |
Immunosuppressant |
Yes |
Down |
Hepatocyte growth factor receptor signaling |
0.045347487 |
21.5 |
NaN |
|
HGF |
| cyclosporine |
Immunosuppressant |
Yes |
Up |
JAK-STAT signaling pathway |
0.036753502 |
10 |
NaN |
|
SOCS3;STAT4 |
| cyclosporine |
Immunosuppressant |
Yes |
Down |
Mitotic spindle disassembly |
0.02293578 |
13.5 |
NaN |
|
CDK1 |
| cyclosporine |
Immunosuppressant |
Yes |
Down |
Natriuretic peptide receptor signaling |
0.007395936 |
7 |
NaN |
|
NPPA;NPPB |
| cyclosporine |
Immunosuppressant |
Yes |
Up |
Notch receptor signaling |
0.009053903 |
4 |
NaN |
|
DLK1;JAG1;NOTCH3 |
| cyclosporine |
Immunosuppressant |
Yes |
Down |
Osteonectin receptor signaling |
0.003049812 |
4.5 |
NaN |
|
SMOC2;SPARC |
| cyclosporine |
Immunosuppressant |
Yes |
Down |
Osteopontin receptor signaling |
0.02293578 |
13.5 |
NaN |
|
SPP1 |
| cyclosporine |
Immunosuppressant |
Yes |
Up |
Platelet-derived growth factor receptor signaling |
0.023192176 |
8 |
NaN |
|
PDGFB;TNK2 |
| cyclosporine |
Immunosuppressant |
Yes |
Up |
Progesterone receptor signaling |
0.02196542 |
7 |
NaN |
|
PGR |
| cyclosporine |
Immunosuppressant |
Yes |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.045347487 |
21.5 |
NaN |
|
PTGFR |
| cyclosporine |
Immunosuppressant |
Yes |
Down |
Retinol metabolism |
0.002876507 |
3 |
NaN |
|
ALDH1A1;ALDH1A2;STRA6 |
| cyclosporine |
Immunosuppressant |
Yes |
Down |
rRNA transcription |
0.045209403 |
19 |
NaN |
|
BNC1;BNC2 |
| cyclosporine |
Immunosuppressant |
Yes |
Up |
Semaphorin signaling |
0.037991607 |
11 |
NaN |
|
PLXNA2;PLXNA4;SEMA6B |
| cyclosporine |
Immunosuppressant |
Yes |
Down |
Serine and glycine metabolism |
0.025144066 |
17 |
NaN |
|
SHMT2;SLC1A5 |
| cyclosporine |
Immunosuppressant |
Yes |
Up |
Serotonin inactivation |
0.043450255 |
13 |
NaN |
|
MAOB |
| cyclosporine |
Immunosuppressant |
Yes |
Down |
Serotonin inactivation |
0.045347487 |
21.5 |
NaN |
|
MAOA |
| cyclosporine |
Immunosuppressant |
Yes |
Up |
Thrombospondin receptor signaling |
0.002800402 |
1 |
NaN |
|
THBS1;THBS4 |
| cyclosporine |
Immunosuppressant |
Yes |
Down |
Tropoelastin synthesis |
0.02293578 |
13.5 |
NaN |
|
ELN |
| cyclosporine |
Immunosuppressant |
Yes |
Up |
Vasoactive intestinal peptide receptor signaling |
0.043450255 |
13 |
NaN |
|
VIPR1 |
| cyclosporine |
Immunosuppressant |
Yes |
Up |
WNT-Beta-catenin signaling pathway |
0.013073502 |
6 |
NaN |
|
APCDD1;DACT1;SFRP4;SFRP5;WNT1 |
| crizotinib |
Kinase inhibitor |
No |
Down |
Adherens junction organization |
0.031245885 |
17 |
NaN |
|
ALCAM;CDH3;CTNND2;TIAM1 |
| crizotinib |
Kinase inhibitor |
No |
Down |
Aggrecan synthesis |
0.029287227 |
15 |
NaN |
|
ACAN |
| crizotinib |
Kinase inhibitor |
No |
Up |
Albumin mediated blood protein transport |
0.013849682 |
7 |
NaN |
|
ALB |
| crizotinib |
Kinase inhibitor |
No |
Down |
Basement membrane assembly and organization |
0.002563095 |
4 |
NaN |
|
COL4A1;COL4A4;COL8A2 |
| crizotinib |
Kinase inhibitor |
No |
Up |
Biglycan synthesis |
0.013849682 |
7 |
NaN |
|
BGN |
| crizotinib |
Kinase inhibitor |
No |
Down |
Cardiomyocyte pacemaker current generation |
0.021304837 |
12.5 |
NaN |
|
CACNA1G;HCN4 |
| crizotinib |
Kinase inhibitor |
No |
Up |
CD44-Mediated leukocyte rolling |
0.027508756 |
11 |
NaN |
|
CD44 |
| crizotinib |
Kinase inhibitor |
No |
Down |
Cellular cholesterol uptake and efflux |
0.005722729 |
6 |
NaN |
|
ABCA1;ABCA7;ABCG1 |
| crizotinib |
Kinase inhibitor |
No |
Up |
Cellular iron storage |
0.040979828 |
17.5 |
NaN |
|
FTH1 |
| crizotinib |
Kinase inhibitor |
No |
Up |
Coagulation cascade |
0.011484345 |
5 |
NaN |
|
F3;TFPI |
| crizotinib |
Kinase inhibitor |
No |
Down |
Collagen fiber crosslinking |
0.008065076 |
7.5 |
NaN |
|
LOX;LOXL1 |
| crizotinib |
Kinase inhibitor |
No |
Down |
Collagen fibril organization by fibril-associated bridges |
0.011864496 |
9 |
NaN |
|
COL12A1;COL9A1 |
| crizotinib |
Kinase inhibitor |
No |
Down |
Contractile ring constriction |
0.008065076 |
7.5 |
NaN |
|
ANLN;MYH14 |
| crizotinib |
Kinase inhibitor |
No |
Up |
Decorin synthesis |
0.013849682 |
7 |
NaN |
|
DCN |
| crizotinib |
Kinase inhibitor |
No |
Up |
Discoidin domain receptor signaling |
0.040979828 |
17.5 |
NaN |
|
DDR2 |
| crizotinib |
Kinase inhibitor |
No |
Down |
Elastin cross-linking and assembly |
0.002515899 |
3 |
NaN |
|
LOX;LOXL1 |
| crizotinib |
Kinase inhibitor |
No |
Up |
Endogenous control of complement activity |
0.001854483 |
3 |
NaN |
|
CFH;CFI |
| crizotinib |
Kinase inhibitor |
No |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.043108095 |
22 |
NaN |
|
ADAMTS2;ADAMTS5 |
| crizotinib |
Kinase inhibitor |
No |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.000561546 |
2 |
NaN |
|
ADAMTS1;ADAMTS12;ADAMTS14;ADAMTS6;ADAMTS7 |
| crizotinib |
Kinase inhibitor |
No |
Up |
Extracellular matrix breakdown by heparanases and sulfatases |
0.001122905 |
2 |
NaN |
|
SULF1;SULF2 |
| crizotinib |
Kinase inhibitor |
No |
Down |
Extracellular matrix breakdown by serine proteases |
0.016291005 |
10 |
NaN |
|
PRSS12;PRSS8 |
| crizotinib |
Kinase inhibitor |
No |
Up |
Fatty acid transfer between membranes |
0.040979828 |
17.5 |
NaN |
|
FABP3 |
| crizotinib |
Kinase inhibitor |
No |
Down |
Fibrillar collagen core structure organization |
0.000131941 |
1 |
NaN |
|
COL11A1;COL1A1;COL2A1;COL5A1 |
| crizotinib |
Kinase inhibitor |
No |
Up |
Fibrillin synthesis |
0.040979828 |
17.5 |
NaN |
|
FBN1 |
| crizotinib |
Kinase inhibitor |
No |
Down |
G-protein coupled receptor signaling pathway |
0.019611275 |
11 |
NaN |
|
PDE4D;RGS5;RGS6 |
| crizotinib |
Kinase inhibitor |
No |
Down |
Growth differentiation factor receptor signaling |
0.021304837 |
12.5 |
NaN |
|
GDF15;GDF6 |
| crizotinib |
Kinase inhibitor |
No |
Up |
Heparin-binding EGF-like growth factor receptor signaling |
0.040979828 |
17.5 |
NaN |
|
HBEGF |
| crizotinib |
Kinase inhibitor |
No |
Up |
Hepatocyte growth factor receptor signaling |
0.027508756 |
11 |
NaN |
|
HGF |
| crizotinib |
Kinase inhibitor |
No |
Up |
Hyaluronan receptor CD44 signaling |
0.040979828 |
17.5 |
NaN |
|
CD44 |
| crizotinib |
Kinase inhibitor |
No |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.040979828 |
17.5 |
NaN |
|
A2M |
| crizotinib |
Kinase inhibitor |
No |
Up |
Methionine cycle |
0.027508756 |
11 |
NaN |
|
BHMT |
| crizotinib |
Kinase inhibitor |
No |
Up |
Microfibril scaffold organization |
0.027508756 |
11 |
NaN |
|
FBN1 |
| crizotinib |
Kinase inhibitor |
No |
Up |
Natriuretic peptide receptor signaling |
0.002756446 |
4 |
NaN |
|
NPPA;NPPB |
| crizotinib |
Kinase inhibitor |
No |
Down |
Platelet-derived growth factor receptor signaling |
0.003448295 |
5 |
NaN |
|
PDGFB;RGS5;TNK2 |
| crizotinib |
Kinase inhibitor |
No |
Up |
Removal of caspase inhibition |
0.027508756 |
11 |
NaN |
|
XAF1 |
| crizotinib |
Kinase inhibitor |
No |
Up |
Retinol metabolism |
0.000673123 |
1 |
NaN |
|
ALDH1A1;ALDH1A2;DHRS3 |
| crizotinib |
Kinase inhibitor |
No |
Up |
Thick myofilament organization |
0.040979828 |
17.5 |
NaN |
|
MYH7 |
| crizotinib |
Kinase inhibitor |
No |
Down |
Tropoelastin synthesis |
0.029287227 |
15 |
NaN |
|
ELN |
| crizotinib |
Kinase inhibitor |
No |
Down |
Versican synthesis |
0.029287227 |
15 |
NaN |
|
VCAN |
| crizotinib |
Kinase inhibitor |
No |
Down |
WNT-Beta-catenin signaling pathway |
0.039082025 |
18 |
NaN |
|
AMER1;FRZB;PAX6;SFRP2;WNT9A |
| cetuximab |
Monoclonal antibody |
No |
Up |
Albumin mediated blood protein transport |
0.025935074 |
12.5 |
NaN |
|
ALB |
| cetuximab |
Monoclonal antibody |
No |
Up |
Alternative complement pathway |
0.006365168 |
4.5 |
NaN |
|
C3;CFH |
| cetuximab |
Monoclonal antibody |
No |
Up |
Axonal intermediate filament dynamics |
0.012914996 |
7.5 |
NaN |
|
NEFH;NES |
| cetuximab |
Monoclonal antibody |
No |
Down |
Centrosome maturation |
0.02346865 |
14.5 |
NaN |
|
PLK1;TPX2 |
| cetuximab |
Monoclonal antibody |
No |
Down |
Centrosome separation |
7.47E-07 |
1 |
NaN |
|
CCNB1;CDK1;KIF11;NEK2;SPAG5 |
| cetuximab |
Monoclonal antibody |
No |
Down |
Cholesterol synthesis |
1.95E-06 |
2 |
NaN |
|
DHCR24;DHCR7;HMGCR;HMGCS1;MSMO1;MVD |
| cetuximab |
Monoclonal antibody |
No |
Down |
Contractile ring constriction |
0.003903051 |
8 |
NaN |
|
ANLN;ECT2 |
| cetuximab |
Monoclonal antibody |
No |
Up |
Decorin synthesis |
0.025935074 |
12.5 |
NaN |
|
DCN |
| cetuximab |
Monoclonal antibody |
No |
Down |
Eukaryotic kinetochore dynamics |
0.000938379 |
5 |
NaN |
|
BUB1;CENPE;CENPF;NDC80;TTK |
| cetuximab |
Monoclonal antibody |
No |
Up |
Fibrillar collagen core structure organization |
8.23E-05 |
1 |
NaN |
|
COL1A1;COL1A2;COL3A1;COL5A1 |
| cetuximab |
Monoclonal antibody |
No |
Down |
G2 M transition checkpoint |
0.02346865 |
14.5 |
NaN |
|
CCNB1;CDK1 |
| cetuximab |
Monoclonal antibody |
No |
Down |
GABA metabolism |
0.005776787 |
9 |
NaN |
|
ABAT;SLC6A1 |
| cetuximab |
Monoclonal antibody |
No |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.000670399 |
2 |
NaN |
|
JAK2;JUND |
| cetuximab |
Monoclonal antibody |
No |
Down |
Hepatocyte growth factor receptor signaling |
0.039995919 |
18.5 |
NaN |
|
HGF |
| cetuximab |
Monoclonal antibody |
No |
Up |
HIF-1 receptor signaling pathway |
0.021394782 |
10 |
NaN |
|
CITED2;EGLN3 |
| cetuximab |
Monoclonal antibody |
No |
Down |
Hyaluronan-mediated motility receptor signaling |
0.020201129 |
11.5 |
NaN |
|
HMMR |
| cetuximab |
Monoclonal antibody |
No |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
8.14E-06 |
3 |
NaN |
|
A2M;MME;PLAT |
| cetuximab |
Monoclonal antibody |
No |
Down |
Inhibition of apoptosis |
0.001564153 |
7 |
NaN |
|
BIRC5;IFI6;XAF1 |
| cetuximab |
Monoclonal antibody |
No |
Up |
Macrophage migration inhibitory factor signaling |
0.006365168 |
4.5 |
NaN |
|
ACKR3;JUND |
| cetuximab |
Monoclonal antibody |
No |
Down |
Metaphase to anaphase checkpoint |
0.030735645 |
16 |
NaN |
|
BUB1;CENPE;TTK |
| cetuximab |
Monoclonal antibody |
No |
Down |
Mitotic spindle assembly |
0.000100501 |
4 |
NaN |
|
DLGAP5;NUSAP1;TPX2;TTK |
| cetuximab |
Monoclonal antibody |
No |
Down |
Mitotic spindle disassembly |
0.020201129 |
11.5 |
NaN |
|
CDK1 |
| cetuximab |
Monoclonal antibody |
No |
Up |
Myofibril formation |
0.001809764 |
3 |
NaN |
|
DES;KLHL41;XIRP1 |
| cetuximab |
Monoclonal antibody |
No |
Up |
Neuregulin receptor signaling |
0.031591061 |
15 |
NaN |
|
ERBB2;ERBB3 |
| cetuximab |
Monoclonal antibody |
No |
Down |
Osteopontin receptor signaling |
0.020201129 |
11.5 |
NaN |
|
SPP1 |
| cetuximab |
Monoclonal antibody |
No |
Up |
Progesterone receptor signaling |
0.025935074 |
12.5 |
NaN |
|
PGR |
| cetuximab |
Monoclonal antibody |
No |
Down |
Prostaglandin PGF2 alpha receptor signaling |
0.039995919 |
18.5 |
NaN |
|
PTGFR |
| cetuximab |
Monoclonal antibody |
No |
Down |
Removal of caspase inhibition |
0.039995919 |
18.5 |
NaN |
|
XAF1 |
| cetuximab |
Monoclonal antibody |
No |
Down |
Serine and glycine metabolism |
0.001190789 |
6 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| cetuximab |
Monoclonal antibody |
No |
Up |
Thin myofilament organization |
0.012914996 |
7.5 |
NaN |
|
ACTA1;LMOD3 |
| cetuximab |
Monoclonal antibody |
No |
Up |
Tropoelastin synthesis |
0.025935074 |
12.5 |
NaN |
|
ELN |
| cetuximab |
Monoclonal antibody |
No |
Down |
Versican receptor signaling |
0.039995919 |
18.5 |
NaN |
|
VCAN |
| cetuximab |
Monoclonal antibody |
No |
Down |
Versican synthesis |
0.020201129 |
11.5 |
NaN |
|
VCAN |
| cetuximab |
Monoclonal antibody |
No |
Up |
Water transmembrane transport |
0.01692739 |
9 |
NaN |
|
AQP3;AQP7 |
| cetuximab |
Monoclonal antibody |
No |
Up |
Z-disc organization |
0.007526147 |
6 |
NaN |
|
CSRP3;DES;PDLIM3 |
| ceritinib |
Kinase inhibitor |
No |
Up |
Actin filament bundling and crosslinking |
0.000886033 |
5 |
NaN |
|
FLNA;FLNB;FSCN2;PLS3;SYNPO |
| ceritinib |
Kinase inhibitor |
No |
Up |
Aggrecan synthesis |
0.029728299 |
22 |
NaN |
|
ACAN |
| ceritinib |
Kinase inhibitor |
No |
Up |
Amyloid plaque organization |
0.040591897 |
27 |
NaN |
|
APBB2;APOE |
| ceritinib |
Kinase inhibitor |
No |
Up |
Antigen presentation via MHC class I molecules |
0.033865605 |
26 |
NaN |
|
HLA-B;HLA-C |
| ceritinib |
Kinase inhibitor |
No |
Down |
Base excision repair |
0.001281927 |
15 |
NaN |
|
FEN1;NEIL3;PCNA;POLQ |
| ceritinib |
Kinase inhibitor |
No |
Up |
Biglycan synthesis |
0.029728299 |
22 |
NaN |
|
BGN |
| ceritinib |
Kinase inhibitor |
No |
Up |
CCN intercellular signaling protein family receptor signaling |
0.008302765 |
12.5 |
NaN |
|
CYR61;WISP1 |
| ceritinib |
Kinase inhibitor |
No |
Down |
Centrosome maturation |
0.000998085 |
13.5 |
NaN |
|
AURKA;PLK1;TPX2 |
| ceritinib |
Kinase inhibitor |
No |
Down |
Centrosome organization |
0.00634391 |
19 |
NaN |
|
ASPM;NEK2;POC1A;TACC3;WDR62 |
| ceritinib |
Kinase inhibitor |
No |
Down |
Centrosome separation |
4.77E-11 |
2 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| ceritinib |
Kinase inhibitor |
No |
Up |
Cholesterol-sensitive control of SREBP activation |
0.012210551 |
14 |
NaN |
|
INSIG1;SREBF1 |
| ceritinib |
Kinase inhibitor |
No |
Up |
Classical complement pathway |
0.000833823 |
3 |
NaN |
|
C1QB;C1QC;C1R |
| ceritinib |
Kinase inhibitor |
No |
Up |
Coagulation cascade |
0.047771954 |
28.5 |
NaN |
|
F2RL1;TFPI |
| ceritinib |
Kinase inhibitor |
No |
Up |
Collagen fiber crosslinking |
0.008302765 |
12.5 |
NaN |
|
LOX;PXDN |
| ceritinib |
Kinase inhibitor |
No |
Down |
Contractile ring constriction |
0.002873937 |
17.5 |
NaN |
|
ANLN;ECT2 |
| ceritinib |
Kinase inhibitor |
No |
Up |
Decorin synthesis |
0.029728299 |
22 |
NaN |
|
DCN |
| ceritinib |
Kinase inhibitor |
No |
Down |
DNA cleavage |
0.014762628 |
22 |
NaN |
|
FEN1;HMGB2 |
| ceritinib |
Kinase inhibitor |
No |
Down |
DNA replication elongation |
0.002873937 |
17.5 |
NaN |
|
MCM4;PCNA |
| ceritinib |
Kinase inhibitor |
No |
Down |
DNA replication initiation |
3.33E-06 |
6 |
NaN |
|
CDC45;CDC6;GINS1;GINS2;MCM10;MCM4 |
| ceritinib |
Kinase inhibitor |
No |
Up |
Epidermal growth factor receptor signaling |
0.029688885 |
19 |
NaN |
|
ERRFI1;SH3PXD2B;TNK2 |
| ceritinib |
Kinase inhibitor |
No |
Down |
Equatorial RhoA activation |
0.001744211 |
16 |
NaN |
|
ECT2;KIF23 |
| ceritinib |
Kinase inhibitor |
No |
Down |
Eukaryotic kinetochore dynamics |
3.07E-14 |
1 |
NaN |
|
BUB1;CENPE;CENPF;CENPH;CENPU;KIF15;MAD2L1;NDC80;NUF2;SKA3;SPC24;TTK;ZWINT |
| ceritinib |
Kinase inhibitor |
No |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.005090993 |
10 |
NaN |
|
ADAM12;ADAM33;ADAMTS10;ADAMTS2 |
| ceritinib |
Kinase inhibitor |
No |
Up |
Extracellular matrix breakdown by heparanases and sulfatases |
0.005081293 |
8 |
NaN |
|
SULF1;SULF2 |
| ceritinib |
Kinase inhibitor |
No |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.027627429 |
18 |
NaN |
|
MMP14;MMP2 |
| ceritinib |
Kinase inhibitor |
No |
Down |
Fanconi anemia interstrand cross-link repair pathway |
7.19E-05 |
8 |
NaN |
|
BRCA2;BRIP1;FANCD2;FANCI;UBE2T |
| ceritinib |
Kinase inhibitor |
No |
Up |
Fibrillar collagen core structure organization |
2.14E-09 |
1 |
NaN |
|
COL11A1;COL1A1;COL1A2;COL3A1;COL5A1;COL5A2;COL5A3 |
| ceritinib |
Kinase inhibitor |
No |
Up |
Filopodium organization |
0.033202869 |
25 |
NaN |
|
DAAM2;FMNL2;TNK2 |
| ceritinib |
Kinase inhibitor |
No |
Down |
G2 M transition checkpoint |
0.000998085 |
13.5 |
NaN |
|
CCNB1;CDC25C;CDK1 |
| ceritinib |
Kinase inhibitor |
No |
Down |
Glycolysis and Gluconeogenesis |
0.006986429 |
20 |
NaN |
|
LDHA;PGK1;TPI1 |
| ceritinib |
Kinase inhibitor |
No |
Down |
Homologous recombination DSB repair |
0.044900726 |
25 |
NaN |
|
BRCA2;EXO1;RAD51AP1 |
| ceritinib |
Kinase inhibitor |
No |
Down |
Hyaluronan-mediated motility receptor signaling |
0.017290049 |
23.5 |
NaN |
|
HMMR |
| ceritinib |
Kinase inhibitor |
No |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
2.60E-05 |
2 |
NaN |
|
A2M;MME;PLAT |
| ceritinib |
Kinase inhibitor |
No |
Up |
Inhibition of apoptosis |
0.047771954 |
28.5 |
NaN |
|
IFI6;XAF1 |
| ceritinib |
Kinase inhibitor |
No |
Up |
Interferon alpha receptor signaling |
0.02191339 |
17 |
NaN |
|
IRF9;STAT1 |
| ceritinib |
Kinase inhibitor |
No |
Down |
Intracellular bridge assembly |
0.000882158 |
11.5 |
NaN |
|
INCENP;KIF23 |
| ceritinib |
Kinase inhibitor |
No |
Down |
Metaphase to anaphase checkpoint |
8.55E-08 |
4 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;MAD2L1;PTTG1;TTK |
| ceritinib |
Kinase inhibitor |
No |
Up |
Microfibril scaffold organization |
0.000881227 |
4 |
NaN |
|
FBN1;MFAP2 |
| ceritinib |
Kinase inhibitor |
No |
Down |
Mitotic chromosome condensation |
2.91E-06 |
5 |
NaN |
|
INCENP;NCAPG2;SMC2;SMC4 |
| ceritinib |
Kinase inhibitor |
No |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
4.96E-05 |
7 |
NaN |
|
AURKB;CCNA2;INCENP |
| ceritinib |
Kinase inhibitor |
No |
Down |
Mitotic spindle assembly |
3.84E-08 |
3 |
NaN |
|
CKAP2;DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| ceritinib |
Kinase inhibitor |
No |
Down |
Mitotic spindle disassembly |
0.017290049 |
23.5 |
NaN |
|
CDK1 |
| ceritinib |
Kinase inhibitor |
No |
Up |
NOD-like receptor signaling |
0.005966066 |
11 |
NaN |
|
NLRC5;NLRP1;NOD1 |
| ceritinib |
Kinase inhibitor |
No |
Up |
Non-vesicular phospholipid transport |
0.016761242 |
15.5 |
NaN |
|
PITPNM1;PLTP |
| ceritinib |
Kinase inhibitor |
No |
Up |
Osteonectin receptor signaling |
0.005081293 |
8 |
NaN |
|
SMOC2;SPARC |
| ceritinib |
Kinase inhibitor |
No |
Up |
Osteopontin receptor signaling |
0.029728299 |
22 |
NaN |
|
SPP1 |
| ceritinib |
Kinase inhibitor |
No |
Up |
Platelet-derived growth factor receptor signaling |
0.00359729 |
6 |
NaN |
|
PDGFRA;PDGFRB;TNK2 |
| ceritinib |
Kinase inhibitor |
No |
Down |
Pyrimidine synthesis and salvage |
0.007776169 |
21 |
NaN |
|
TK1;TYMS |
| ceritinib |
Kinase inhibitor |
No |
Down |
Ribonucleotide reduction |
0.000882158 |
11.5 |
NaN |
|
RRM1;RRM2 |
| ceritinib |
Kinase inhibitor |
No |
Down |
Sister chromatid attachment to mitotic spindle |
0.000297447 |
10 |
NaN |
|
NUF2;TACC3 |
| ceritinib |
Kinase inhibitor |
No |
Down |
Sister chromatid segregation |
9.80E-05 |
9 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| ceritinib |
Kinase inhibitor |
No |
Up |
Thin myofilament organization |
0.016761242 |
15.5 |
NaN |
|
ACTA1;TPM4 |
| ceritinib |
Kinase inhibitor |
No |
Up |
Thrombospondin receptor signaling |
0.005081293 |
8 |
NaN |
|
THBS1;THBS2 |
| ceritinib |
Kinase inhibitor |
No |
Up |
Tropoelastin synthesis |
0.029728299 |
22 |
NaN |
|
ELN |
| carfilzomib |
Antiproteasome |
Yes |
Down |
Basement membrane assembly and organization |
0.041001024 |
16 |
NaN |
|
COL4A5;HSPG2 |
| carfilzomib |
Antiproteasome |
Yes |
Down |
Biglycan synthesis |
0.032992237 |
12.5 |
NaN |
|
BGN |
| carfilzomib |
Antiproteasome |
Yes |
Up |
CD44-Mediated leukocyte rolling |
0.020711186 |
5.5 |
NaN |
|
CD44 |
| carfilzomib |
Antiproteasome |
Yes |
Up |
Cellular iron storage |
0.030906711 |
10 |
NaN |
|
FTL |
| carfilzomib |
Antiproteasome |
Yes |
Up |
Chaperone-mediated autophagy |
0.020711186 |
5.5 |
NaN |
|
HSPA8 |
| carfilzomib |
Antiproteasome |
Yes |
Down |
Decorin synthesis |
0.032992237 |
12.5 |
NaN |
|
DCN |
| carfilzomib |
Antiproteasome |
Yes |
Up |
Epidermal growth factor receptor signaling |
0.023570453 |
8 |
NaN |
|
ERRFI1;SPINK1 |
| carfilzomib |
Antiproteasome |
Yes |
Down |
Epithelial intermediate filament dynamics |
0.026644498 |
9 |
NaN |
|
KRT8;TCHH |
| carfilzomib |
Antiproteasome |
Yes |
Up |
ER unfolded protein response pathway |
0.002887618 |
1 |
NaN |
|
DDIT3;PPP1R15A |
| carfilzomib |
Antiproteasome |
Yes |
Up |
Erythropoietin receptor signaling |
0.040996979 |
12 |
NaN |
|
GAB2 |
| carfilzomib |
Antiproteasome |
Yes |
Down |
Extracellular matrix breakdown by heparanases and sulfatases |
0.00623247 |
5 |
NaN |
|
SULF1;SULF2 |
| carfilzomib |
Antiproteasome |
Yes |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.00368744 |
2 |
NaN |
|
MMP1;MMP3 |
| carfilzomib |
Antiproteasome |
Yes |
Down |
Extracellular matrix breakdown by serine proteases |
0.020424115 |
7.5 |
NaN |
|
HTRA1;ST14 |
| carfilzomib |
Antiproteasome |
Yes |
Down |
Extrinsic apoptosis pathway |
0.001129403 |
3 |
NaN |
|
FAS;TNFRSF10A;TNFRSF10B |
| carfilzomib |
Antiproteasome |
Yes |
Down |
Fibrillar collagen core structure organization |
8.37E-06 |
1 |
NaN |
|
COL1A1;COL1A2;COL3A1;COL5A1;COL5A2 |
| carfilzomib |
Antiproteasome |
Yes |
Up |
Heme degradation to bilirubin |
0.030906711 |
10 |
NaN |
|
HMOX1 |
| carfilzomib |
Antiproteasome |
Yes |
Up |
Hepatocyte growth factor receptor signaling |
0.020711186 |
5.5 |
NaN |
|
MET |
| carfilzomib |
Antiproteasome |
Yes |
Up |
Hyaluronan receptor CD44 signaling |
0.030906711 |
10 |
NaN |
|
CD44 |
| carfilzomib |
Antiproteasome |
Yes |
Up |
Mineralocorticoid receptor signaling |
0.020711186 |
5.5 |
NaN |
|
GPER1 |
| carfilzomib |
Antiproteasome |
Yes |
Down |
Muscarinic receptor signaling |
0.01491134 |
6 |
NaN |
|
CHRM4;RGS5 |
| carfilzomib |
Antiproteasome |
Yes |
Down |
Notch receptor signaling |
0.026772904 |
10 |
NaN |
|
DLK1;DLL4;LFNG |
| carfilzomib |
Antiproteasome |
Yes |
Up |
Nuclear mRNA export |
0.013193945 |
3 |
NaN |
|
NXF1;THOC6 |
| carfilzomib |
Antiproteasome |
Yes |
Down |
Nucleosome assembly |
0.000630086 |
2 |
NaN |
|
ASF1B;HIST1H1C;HIST1H1D;HIST1H1E;HIST2H2BE |
| carfilzomib |
Antiproteasome |
Yes |
Down |
Nucleotide excision repair |
0.038691864 |
15 |
NaN |
|
DDB2;PCNA;XPC |
| carfilzomib |
Antiproteasome |
Yes |
Down |
Perlecan synthesis |
0.032992237 |
12.5 |
NaN |
|
HSPG2 |
| carfilzomib |
Antiproteasome |
Yes |
Down |
Ribonucleotide reduction |
0.003185752 |
4 |
NaN |
|
RRM2;RRM2B |
| carfilzomib |
Antiproteasome |
Yes |
Down |
Thin myofilament organization |
0.020424115 |
7.5 |
NaN |
|
NEBL;TPM1 |
| carfilzomib |
Antiproteasome |
Yes |
Down |
Tropoelastin synthesis |
0.032992237 |
12.5 |
NaN |
|
ELN |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Aggrecan synthesis |
0.022053634 |
15 |
NaN |
|
ACAN |
| cabozantinib |
Kinase inhibitor |
No |
Up |
Albumin mediated blood protein transport |
0.022318278 |
11 |
NaN |
|
ALB |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Alternative complement pathway |
0.004636036 |
8.5 |
NaN |
|
C3;CFH |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Basement membrane assembly and organization |
0.019397192 |
12 |
NaN |
|
COL4A1;HSPG2 |
| cabozantinib |
Kinase inhibitor |
No |
Up |
Betaglycan signaling |
0.004745654 |
4 |
NaN |
|
SMAD6;TGFBR3 |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Biglycan synthesis |
0.022053634 |
15 |
NaN |
|
BGN |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Cardiomyocyte depolarization during action potential |
0.022053634 |
15 |
NaN |
|
SCN5A |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Cardiomyocyte pacemaker current generation |
0.012425035 |
11 |
NaN |
|
CACNA1G;HCN4 |
| cabozantinib |
Kinase inhibitor |
No |
Down |
CCN intercellular signaling protein family receptor signaling |
0.004636036 |
8.5 |
NaN |
|
CTGF;CYR61 |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Cellular iron uptake and export |
0.032195057 |
19 |
NaN |
|
RASD1;TFRC |
| cabozantinib |
Kinase inhibitor |
No |
Up |
Centrosome separation |
0.019838394 |
8 |
NaN |
|
CCNB1;CDK1 |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Chaperone-mediated autophagy |
0.043622809 |
26 |
NaN |
|
HSPA8 |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Chloride transmembrane transport |
0.032195057 |
19 |
NaN |
|
ANO1;SLC12A7 |
| cabozantinib |
Kinase inhibitor |
No |
Up |
Cholesterol synthesis |
3.47E-06 |
1 |
NaN |
|
CYP51A1;HMGCR;HMGCS1;MSMO1;MVK;SQLE |
| cabozantinib |
Kinase inhibitor |
No |
Up |
Chondroitin sulfate and dermatan sulfate synthesis |
0.009675618 |
7 |
NaN |
|
CHST11;SOX9 |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Collagen fiber crosslinking |
0.00010257 |
4 |
NaN |
|
LOX;LOXL1;PXDN |
| cabozantinib |
Kinase inhibitor |
No |
Up |
Collagen fibril organization by fibril-associated bridges |
0.007013957 |
5.5 |
NaN |
|
COL14A1;COL9A2 |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Decorin synthesis |
0.022053634 |
15 |
NaN |
|
DCN |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Eicosanoid metabolism |
0.042110321 |
22 |
NaN |
|
CYP2J2;PTGS1 |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Elastin cross-linking and assembly |
0.001432179 |
6 |
NaN |
|
LOX;LOXL1 |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.001733291 |
7 |
NaN |
|
ADAM12;ADAMTS14;ADAMTS2;ADAMTS9 |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.000806813 |
5 |
NaN |
|
MMP1;MMP14;MMP2 |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Fibrillar collagen core structure organization |
2.11E-08 |
1 |
NaN |
|
COL1A1;COL1A2;COL2A1;COL3A1;COL5A1;COL5A3 |
| cabozantinib |
Kinase inhibitor |
No |
Up |
G2 M transition checkpoint |
0.028256676 |
15 |
NaN |
|
CCNB1;CDK1 |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Gap junction organization |
0.037023918 |
21 |
NaN |
|
GJA1;GJA5 |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Glycolysis and Gluconeogenesis |
7.98E-06 |
2 |
NaN |
|
ALDOA;ENO1;LDHA;PFKL;PGK1;TPI1 |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Hepatocyte growth factor receptor signaling |
0.043622809 |
26 |
NaN |
|
HGF |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
1.06E-05 |
3 |
NaN |
|
A2M;MME;PLAT |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Methionine cycle |
0.043622809 |
26 |
NaN |
|
BHMT |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Microfibril scaffold organization |
0.043622809 |
26 |
NaN |
|
FBN1 |
| cabozantinib |
Kinase inhibitor |
No |
Up |
Microtubule crosslinking and bundling |
0.007013957 |
5.5 |
NaN |
|
MAP2;MTCL1 |
| cabozantinib |
Kinase inhibitor |
No |
Up |
Mitotic spindle disassembly |
0.022318278 |
11 |
NaN |
|
CDK1 |
| cabozantinib |
Kinase inhibitor |
No |
Up |
Osteonectin receptor signaling |
0.002889904 |
2.5 |
NaN |
|
SMOC1;SPOCK1 |
| cabozantinib |
Kinase inhibitor |
No |
Up |
Osteopontin receptor signaling |
0.022318278 |
11 |
NaN |
|
SPP1 |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Perlecan synthesis |
0.022053634 |
15 |
NaN |
|
HSPG2 |
| cabozantinib |
Kinase inhibitor |
No |
Up |
Platelet-derived growth factor receptor signaling |
0.023894185 |
14 |
NaN |
|
PDGFD;TNK2 |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Removal of caspase inhibition |
0.043622809 |
26 |
NaN |
|
XAF1 |
| cabozantinib |
Kinase inhibitor |
No |
Up |
Retinol metabolism |
0.032910271 |
16 |
NaN |
|
ALDH1A1;RDH10 |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Retinol metabolism |
0.032195057 |
19 |
NaN |
|
ALDH1A2;DHRS3 |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Serotonin inactivation |
0.043622809 |
26 |
NaN |
|
MAOA |
| cabozantinib |
Kinase inhibitor |
No |
Up |
Thrombospondin receptor signaling |
0.002889904 |
2.5 |
NaN |
|
CD47;THBS4 |
| cabozantinib |
Kinase inhibitor |
No |
Up |
Tropoelastin synthesis |
0.022318278 |
11 |
NaN |
|
ELN |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Vascular endothelial growth factor receptor signaling |
0.009455468 |
10 |
NaN |
|
FLT1;VEGFA |
| cabozantinib |
Kinase inhibitor |
No |
Down |
Vasoactive intestinal peptide receptor signaling |
0.043622809 |
26 |
NaN |
|
VIPR2 |
| cabozantinib |
Kinase inhibitor |
No |
Up |
Versican receptor signaling |
0.044140376 |
17 |
NaN |
|
VCAN |
| cabozantinib |
Kinase inhibitor |
No |
Up |
Versican synthesis |
0.022318278 |
11 |
NaN |
|
VCAN |
| bosutinib |
Kinase inhibitor |
No |
Up |
Actin filament bundling and crosslinking |
0.016825429 |
7 |
NaN |
|
SYNPO;TAGLN;USH1C |
| bosutinib |
Kinase inhibitor |
No |
Up |
Aggrecan synthesis |
0.021083275 |
10 |
NaN |
|
ACAN |
| bosutinib |
Kinase inhibitor |
No |
Up |
Albumin mediated blood protein transport |
0.021083275 |
10 |
NaN |
|
ALB |
| bosutinib |
Kinase inhibitor |
No |
Down |
Alternative complement pathway |
0.004636036 |
6 |
NaN |
|
C3;CFH |
| bosutinib |
Kinase inhibitor |
No |
Down |
CD44-Mediated leukocyte rolling |
0.043622809 |
17.5 |
NaN |
|
CD44 |
| bosutinib |
Kinase inhibitor |
No |
Down |
Cholesterol synthesis |
0.009153583 |
9 |
NaN |
|
DHCR7;MVD;SQLE |
| bosutinib |
Kinase inhibitor |
No |
Up |
Collagen fibril organization by fibril-associated bridges |
0.006278564 |
5 |
NaN |
|
COL9A2;COL9A3 |
| bosutinib |
Kinase inhibitor |
No |
Down |
Collagen fibril organization by fibril-associated bridges |
0.006853158 |
7.5 |
NaN |
|
COL12A1;COL9A1 |
| bosutinib |
Kinase inhibitor |
No |
Down |
Decorin synthesis |
0.022053634 |
11 |
NaN |
|
DCN |
| bosutinib |
Kinase inhibitor |
No |
Up |
Epithelial intermediate filament dynamics |
0.011397983 |
6 |
NaN |
|
KRT7;KRT8 |
| bosutinib |
Kinase inhibitor |
No |
Up |
Fibrillar collagen core structure organization |
0.000995243 |
3 |
NaN |
|
COL11A1;COL11A2;COL2A1 |
| bosutinib |
Kinase inhibitor |
No |
Down |
Fibrillar collagen core structure organization |
0.001133868 |
3 |
NaN |
|
COL1A1;COL1A2;COL3A1 |
| bosutinib |
Kinase inhibitor |
No |
Down |
GABA metabolism |
0.006853158 |
7.5 |
NaN |
|
ABAT;SLC6A1 |
| bosutinib |
Kinase inhibitor |
No |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.043622809 |
17.5 |
NaN |
|
JAK2 |
| bosutinib |
Kinase inhibitor |
No |
Up |
Hepatocyte growth factor receptor signaling |
0.041723865 |
13.5 |
NaN |
|
MET |
| bosutinib |
Kinase inhibitor |
No |
Down |
Hepatocyte growth factor receptor signaling |
0.043622809 |
17.5 |
NaN |
|
HGF |
| bosutinib |
Kinase inhibitor |
No |
Down |
Inhibin receptor signaling |
0.000546766 |
2 |
NaN |
|
INHA;INHBB;TGFBR3 |
| bosutinib |
Kinase inhibitor |
No |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001432179 |
4 |
NaN |
|
MME;PLAT |
| bosutinib |
Kinase inhibitor |
No |
Down |
JAK-STAT signaling pathway |
0.037023918 |
13 |
NaN |
|
SOCS2;SOCS3 |
| bosutinib |
Kinase inhibitor |
No |
Up |
Lipid droplet fusion |
0.021083275 |
10 |
NaN |
|
CIDEC |
| bosutinib |
Kinase inhibitor |
No |
Down |
Lipogenesis |
0.043622809 |
17.5 |
NaN |
|
FASN |
| bosutinib |
Kinase inhibitor |
No |
Up |
Microfibril scaffold organization |
0.041723865 |
13.5 |
NaN |
|
FBN1 |
| bosutinib |
Kinase inhibitor |
No |
Up |
Natriuretic peptide receptor signaling |
2.80E-06 |
1 |
NaN |
|
NPPA;NPPB;NPPC;NPR3 |
| bosutinib |
Kinase inhibitor |
No |
Up |
Osteopontin receptor signaling |
0.021083275 |
10 |
NaN |
|
SPP1 |
| bosutinib |
Kinase inhibitor |
No |
Up |
Potassium transmembrane transport |
0.00146888 |
4 |
NaN |
|
ATP1A2;ATP1A3;KCNE4;SLC12A1 |
| bosutinib |
Kinase inhibitor |
No |
Down |
Retinol metabolism |
0.032195057 |
12 |
NaN |
|
CYP26A1;RDH10 |
| bosutinib |
Kinase inhibitor |
No |
Down |
Roundabout signaling |
0.009455468 |
10 |
NaN |
|
ROBO1;ROBO2 |
| bosutinib |
Kinase inhibitor |
No |
Down |
Semaphorin signaling |
0.038375695 |
14 |
NaN |
|
DPYSL4;SEMA5A;SEMA6D |
| bosutinib |
Kinase inhibitor |
No |
Down |
Serotonin inactivation |
0.043622809 |
17.5 |
NaN |
|
MAOA |
| bosutinib |
Kinase inhibitor |
No |
Up |
Thin myofilament organization |
6.42E-06 |
2 |
NaN |
|
ACTA1;TNNI3;TPM2;TPM4 |
| bosutinib |
Kinase inhibitor |
No |
Down |
Thrombospondin receptor signaling |
0.00282265 |
5 |
NaN |
|
THBS1;THBS4 |
| bosutinib |
Kinase inhibitor |
No |
Up |
Tropoelastin synthesis |
0.021083275 |
10 |
NaN |
|
ELN |
| bosutinib |
Kinase inhibitor |
No |
Down |
Vasoactive intestinal peptide receptor signaling |
0.043622809 |
17.5 |
NaN |
|
VIPR1 |
| bosutinib |
Kinase inhibitor |
No |
Down |
WNT-Beta-catenin signaling pathway |
7.62E-05 |
1 |
NaN |
|
APCDD1;DACT1;FZD10;FZD2;FZD7;LRP4;SFRP2;WNT9A |
| bosutinib |
Kinase inhibitor |
No |
Up |
Z-disc organization |
0.043740316 |
15 |
NaN |
|
DES;PDLIM3 |
| bortezomib |
Antiproteasome |
Yes |
Up |
Amyloid plaque organization |
0.017593716 |
8 |
NaN |
|
HSPB6;SOD1 |
| bortezomib |
Antiproteasome |
Yes |
Down |
Axonal intermediate filament dynamics |
0.011123733 |
2.5 |
NaN |
|
NEFH;NEFL |
| bortezomib |
Antiproteasome |
Yes |
Down |
Cardiomyocyte pacemaker current generation |
0.014598411 |
5.5 |
NaN |
|
CACNA1G;KCNJ5 |
| bortezomib |
Antiproteasome |
Yes |
Up |
Chaperone-mediated autophagy |
0.000358072 |
2 |
NaN |
|
HSP90AA1;HSPA8 |
| bortezomib |
Antiproteasome |
Yes |
Up |
Cholesterol synthesis |
0.00048019 |
3 |
NaN |
|
CYP51A1;HMGCR;HMGCS1;SQLE |
| bortezomib |
Antiproteasome |
Yes |
Up |
Clathrin-mediated endocytosis |
0.03976104 |
16 |
NaN |
|
AAK1;CLTC;DNM1 |
| bortezomib |
Antiproteasome |
Yes |
Up |
Cytosolic protein folding |
0.018966126 |
9 |
NaN |
|
HSP90AA1 |
| bortezomib |
Antiproteasome |
Yes |
Up |
Endoplasmic reticulum quality control system |
0.042319081 |
17 |
NaN |
|
BCAP31;FBXO2;NPLOC4 |
| bortezomib |
Antiproteasome |
Yes |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.010150423 |
6 |
NaN |
|
ADAM15;ADAMTS1;ADAMTS14 |
| bortezomib |
Antiproteasome |
Yes |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.019053024 |
8 |
NaN |
|
ADAMTS15;ADAMTS7;ADAMTS8 |
| bortezomib |
Antiproteasome |
Yes |
Down |
Extrinsic apoptosis pathway |
0.011123733 |
2.5 |
NaN |
|
FAS;TNFRSF10A |
| bortezomib |
Antiproteasome |
Yes |
Up |
Fibroblast growth factor receptor signaling |
0.02085161 |
10 |
NaN |
|
FGF1;FGF18 |
| bortezomib |
Antiproteasome |
Yes |
Up |
Hepatocyte growth factor receptor signaling |
0.037574179 |
14 |
NaN |
|
MET |
| bortezomib |
Antiproteasome |
Yes |
Down |
Intrinsic apoptosis pathway |
0.043169865 |
10 |
NaN |
|
BMF;PMAIP1 |
| bortezomib |
Antiproteasome |
Yes |
Up |
Lipogenesis |
0.037574179 |
14 |
NaN |
|
FASN |
| bortezomib |
Antiproteasome |
Yes |
Up |
Multivesicular body dynamics |
0.017100594 |
7 |
NaN |
|
HGS;NEDD4L;VPS37A |
| bortezomib |
Antiproteasome |
Yes |
Down |
Muscarinic receptor signaling |
0.008072724 |
1 |
NaN |
|
CHRM4;RGS5 |
| bortezomib |
Antiproteasome |
Yes |
Up |
NFkB signaling pathway |
0.005107525 |
4 |
NaN |
|
NFKB2;SQSTM1 |
| bortezomib |
Antiproteasome |
Yes |
Down |
Notch receptor signaling |
0.011512573 |
4 |
NaN |
|
DLL4;LFNG;NOTCH1 |
| bortezomib |
Antiproteasome |
Yes |
Down |
Nucleosome assembly |
0.015014532 |
7 |
NaN |
|
ASF1B;HIST1H1D;HIST1H1E |
| bortezomib |
Antiproteasome |
Yes |
Up |
Proteasomal core organization |
0.037574179 |
14 |
NaN |
|
PSMA7 |
| bortezomib |
Antiproteasome |
Yes |
Up |
Proteasomal regulatory particle organization |
0.000222599 |
1 |
NaN |
|
PSMC4;PSMD14;PSMD8 |
| bortezomib |
Antiproteasome |
Yes |
Up |
Protein polyubiquitination |
0.036079961 |
11.5 |
NaN |
|
UBC;UCHL1 |
| bortezomib |
Antiproteasome |
Yes |
Down |
Pyrimidine synthesis and salvage |
0.014598411 |
5.5 |
NaN |
|
TK1;TYMS |
| bortezomib |
Antiproteasome |
Yes |
Up |
Thin myofilament organization |
0.007061495 |
5 |
NaN |
|
ACTA1;TNNI3 |
| bortezomib |
Antiproteasome |
Yes |
Down |
Tropoelastin synthesis |
0.023994354 |
9 |
NaN |
|
ELN |
| bortezomib |
Antiproteasome |
Yes |
Up |
Z-disc organization |
0.036079961 |
11.5 |
NaN |
|
BAG3;MYPN |
| bevacizumab |
Monoclonal antibody |
Yes |
Down |
Adrenergic receptor signaling |
0.020170501 |
8 |
8 |
Down by cardiotoxic TKIs |
RASD1;RGS16;RGS4 |
| bevacizumab |
Monoclonal antibody |
Yes |
Down |
Aggrecan synthesis |
0.022582922 |
11.5 |
NaN |
|
ACAN |
| bevacizumab |
Monoclonal antibody |
Yes |
Down |
Albumin mediated blood protein transport |
0.022582922 |
11.5 |
NaN |
|
ALB |
| bevacizumab |
Monoclonal antibody |
Yes |
Up |
Biglycan synthesis |
0.023200423 |
12.5 |
NaN |
|
BGN |
| bevacizumab |
Monoclonal antibody |
Yes |
Up |
Cardiomyocyte pacemaker current generation |
0.013690263 |
8.5 |
NaN |
|
HCN4;KCNK2 |
| bevacizumab |
Monoclonal antibody |
Yes |
Up |
CCN intercellular signaling protein family receptor signaling |
0.005119846 |
6.5 |
NaN |
|
CYR61;WISP1 |
| bevacizumab |
Monoclonal antibody |
Yes |
Down |
CD44-Mediated leukocyte rolling |
0.044657802 |
15.5 |
NaN |
|
CD44 |
| bevacizumab |
Monoclonal antibody |
Yes |
Up |
Cellular cholesterol uptake and efflux |
0.035340255 |
15.5 |
NaN |
|
ABCA1;ABCA12 |
| bevacizumab |
Monoclonal antibody |
Yes |
Down |
Collagen fibril organization by fibril-associated bridges |
0.007176501 |
3 |
NaN |
|
COL12A1;COL9A2 |
| bevacizumab |
Monoclonal antibody |
Yes |
Up |
Contractile ring constriction |
0.005119846 |
6.5 |
NaN |
|
MYH14;MYLK |
| bevacizumab |
Monoclonal antibody |
Yes |
Up |
Eicosanoid metabolism |
0.046155652 |
23 |
NaN |
|
CYP2J2;PTGES |
| bevacizumab |
Monoclonal antibody |
Yes |
Down |
ER unfolded protein response pathway |
0.013002108 |
6 |
NaN |
|
ATF4;HERPUD1 |
| bevacizumab |
Monoclonal antibody |
Yes |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.017432245 |
11 |
NaN |
|
ADAM33;ADAMTS5;ADAMTS7 |
| bevacizumab |
Monoclonal antibody |
Yes |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.017334623 |
10 |
NaN |
|
MMP14;MMP2 |
| bevacizumab |
Monoclonal antibody |
Yes |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.016470005 |
7 |
NaN |
|
MMP12;MMP3 |
| bevacizumab |
Monoclonal antibody |
Yes |
Up |
Fibrillar collagen core structure organization |
5.33E-05 |
1 |
NaN |
|
COL1A1;COL1A2;COL2A1;COL3A1 |
| bevacizumab |
Monoclonal antibody |
Yes |
Down |
Fibrillar collagen core structure organization |
0.020283903 |
9 |
NaN |
|
COL11A2;COL5A1 |
| bevacizumab |
Monoclonal antibody |
Yes |
Down |
Gap junction organization |
0.038662978 |
14 |
24 |
Down by cardiotoxic TKIs |
GJA5;GJB2 |
| bevacizumab |
Monoclonal antibody |
Yes |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.045864587 |
19.5 |
NaN |
|
JAK2 |
| bevacizumab |
Monoclonal antibody |
Yes |
Up |
Inhibin receptor signaling |
0.013690263 |
8.5 |
NaN |
|
INHBA;INHBE |
| bevacizumab |
Monoclonal antibody |
Yes |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.001584083 |
3 |
NaN |
|
MME;PLAT |
| bevacizumab |
Monoclonal antibody |
Yes |
Up |
Inositol metabolism and transport |
0.045864587 |
19.5 |
NaN |
|
INPP5D |
| bevacizumab |
Monoclonal antibody |
Yes |
Up |
Lipid droplet fusion |
0.023200423 |
12.5 |
NaN |
|
CIDEC |
| bevacizumab |
Monoclonal antibody |
Yes |
Up |
Lipogenesis |
0.045864587 |
19.5 |
NaN |
|
FASN |
| bevacizumab |
Monoclonal antibody |
Yes |
Up |
Methionine cycle |
0.045864587 |
19.5 |
NaN |
|
BHMT |
| bevacizumab |
Monoclonal antibody |
Yes |
Up |
Microfibril scaffold organization |
0.045864587 |
19.5 |
NaN |
|
FBN1 |
| bevacizumab |
Monoclonal antibody |
Yes |
Up |
Osteonectin receptor signaling |
0.00311962 |
4.5 |
NaN |
|
SMOC2;SPARC |
| bevacizumab |
Monoclonal antibody |
Yes |
Up |
Platelet-derived growth factor receptor signaling |
0.025687982 |
14 |
NaN |
|
PDGFRA;PDGFRB |
| bevacizumab |
Monoclonal antibody |
Yes |
Down |
Polyol pathway |
4.48E-05 |
1 |
4 |
Down by cardiotoxic TKIs |
AKR1A1;AKR1B10;SORD |
| bevacizumab |
Monoclonal antibody |
Yes |
Down |
Progesterone receptor signaling |
0.022582922 |
11.5 |
NaN |
|
PGR |
| bevacizumab |
Monoclonal antibody |
Yes |
Up |
Prostaglandin PGF2 alpha receptor signaling |
0.045864587 |
19.5 |
NaN |
|
PTGFR |
| bevacizumab |
Monoclonal antibody |
Yes |
Up |
Retinol metabolism |
0.035340255 |
15.5 |
NaN |
|
ALDH1A2;RDH10 |
| bevacizumab |
Monoclonal antibody |
Yes |
Down |
Roundabout signaling |
0.009898099 |
4.5 |
NaN |
|
ROBO1;ROBO2 |
| bevacizumab |
Monoclonal antibody |
Yes |
Down |
Tenascin receptor signaling |
0.002957925 |
2 |
NaN |
|
TENM1;TNC |
| bevacizumab |
Monoclonal antibody |
Yes |
Down |
Thin myofilament organization |
0.009898099 |
4.5 |
21 |
Down by cardiotoxic TKIs |
LMOD3;TPM2 |
| bevacizumab |
Monoclonal antibody |
Yes |
Up |
Thyroid hormone receptor signaling |
0.00311962 |
4.5 |
10 |
Up by cardiotoxic TKIs |
THRB;TRIP6 |
| bevacizumab |
Monoclonal antibody |
Yes |
Up |
Tight junction organization |
0.001037836 |
2 |
NaN |
|
CLDN11;CLDN6;CRB2;MPP5;MYLK |
| bevacizumab |
Monoclonal antibody |
Yes |
Down |
Tropoelastin synthesis |
0.022582922 |
11.5 |
NaN |
|
ELN |
| bevacizumab |
Monoclonal antibody |
Yes |
Down |
Vasoactive intestinal peptide receptor signaling |
0.044657802 |
15.5 |
NaN |
|
VIPR2 |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Adenylyl cyclase signaling pathway |
0.039728723 |
25 |
NaN |
|
PDE4D;RAPGEF4 |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Aggrecan synthesis |
0.017731122 |
16.5 |
NaN |
|
ACAN |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Albumin mediated blood protein transport |
0.017731122 |
16.5 |
NaN |
|
ALB |
| azacitidine |
Other chemotherapy drug |
No |
Down |
Alternative complement pathway |
0.006449906 |
8 |
NaN |
|
C3;CFH |
| azacitidine |
Other chemotherapy drug |
No |
Down |
Amyloid plaque organization |
0.002488588 |
4.5 |
NaN |
|
APOE;PRNP;VSNL1 |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Biglycan synthesis |
0.017731122 |
16.5 |
NaN |
|
BGN |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Cardiomyocyte depolarization during action potential |
0.017731122 |
16.5 |
NaN |
|
SCN5A |
| azacitidine |
Other chemotherapy drug |
No |
Down |
Cardiomyocyte pacemaker current generation |
0.017146691 |
10 |
NaN |
|
CACNA1D;CACNA1G |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.02474622 |
22 |
NaN |
|
KCNA1;KCNH2 |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Chloride transmembrane transport |
0.021458257 |
21 |
NaN |
|
ANO1;BEST1 |
| azacitidine |
Other chemotherapy drug |
No |
Down |
Cholesterol synthesis |
8.58E-06 |
2 |
NaN |
|
DHCR24;FDPS;HMGCR;HMGCS1;MSMO1;MVD |
| azacitidine |
Other chemotherapy drug |
No |
Down |
Collagen fibril organization by fibril-associated bridges |
6.56E-06 |
1 |
NaN |
|
COL12A1;COL14A1;COL9A1;COL9A3 |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Contractile ring constriction |
0.003020133 |
5 |
NaN |
|
MYH14;MYLK |
| azacitidine |
Other chemotherapy drug |
No |
Down |
Decorin synthesis |
0.026111503 |
11.5 |
NaN |
|
DCN |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Fibrillar collagen core structure organization |
0.012819001 |
12.5 |
NaN |
|
COL1A2;COL3A1 |
| azacitidine |
Other chemotherapy drug |
No |
Down |
Fibrillar collagen core structure organization |
8.45E-05 |
3 |
NaN |
|
COL11A1;COL2A1;COL5A1;COL5A2 |
| azacitidine |
Other chemotherapy drug |
No |
Down |
Glutamate and glutamine metabolism |
0.043842794 |
13 |
NaN |
|
SLC1A1;SLC7A5 |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Glycogen synthesis and glycogenolysis |
0.031886475 |
23 |
NaN |
|
PPP1R3A;PYGM |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Glycolysis and Gluconeogenesis |
0.00748822 |
8 |
NaN |
|
GPI;PGK1;TPI1 |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Granulocyte-colony stimulating factor receptor signaling |
0.010375434 |
11 |
NaN |
|
SOCS3;STAT3 |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Growth differentiation factor receptor signaling |
0.008164533 |
9.5 |
NaN |
|
GDF2;GDF6 |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Inhibin receptor signaling |
0.008164533 |
9.5 |
NaN |
|
INHBA;TGFBR3 |
| azacitidine |
Other chemotherapy drug |
No |
Up |
JAK-STAT signaling pathway |
0.001730476 |
2 |
NaN |
|
SOCS2;SOCS3;STAT3 |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Leptin receptor signaling |
0.00183348 |
3.5 |
NaN |
|
SOCS3;STAT3 |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Microfibril scaffold organization |
0.035149388 |
24 |
NaN |
|
FBN1 |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Mitochondrial fission |
0.018368919 |
20 |
NaN |
|
DNM1;MTFP1 |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Natriuretic peptide receptor signaling |
0.004477398 |
6 |
NaN |
|
NPPA;NPPB |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Osteonectin receptor signaling |
0.00183348 |
3.5 |
NaN |
|
SMOC2;SPARC |
| azacitidine |
Other chemotherapy drug |
No |
Down |
Osteopontin receptor signaling |
0.026111503 |
11.5 |
NaN |
|
SPP1 |
| azacitidine |
Other chemotherapy drug |
No |
Down |
Platelet-derived growth factor receptor signaling |
0.002488588 |
4.5 |
NaN |
|
PDGFRA;RGS5;TNK2 |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Potassium transmembrane transport |
0.000771738 |
1 |
NaN |
|
ATP1A3;KCNE4;KCNH2;KCNK2 |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Progesterone receptor signaling |
0.017731122 |
16.5 |
NaN |
|
PGR |
| azacitidine |
Other chemotherapy drug |
No |
Down |
Proteasomal regulatory particle organization |
0.013083845 |
9 |
NaN |
|
PSMC4;PSMD14 |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Restriction point |
0.012819001 |
12.5 |
NaN |
|
CCND2;CDKN1A |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Roundabout signaling |
0.006195402 |
7 |
NaN |
|
ROBO2;ROBO3 |
| azacitidine |
Other chemotherapy drug |
No |
Down |
Thrombospondin receptor signaling |
0.003937748 |
6 |
NaN |
|
CD47;THBS4 |
| azacitidine |
Other chemotherapy drug |
No |
Up |
Tropoelastin synthesis |
0.017731122 |
16.5 |
NaN |
|
ELN |
| azacitidine |
Other chemotherapy drug |
No |
Down |
WNT-Beta-catenin signaling pathway |
0.006346162 |
7 |
NaN |
|
CTHRC1;FRZB;PAX6;SFRP2;SFRP4;WNT2 |
| axitinib |
Kinase inhibitor |
No |
Up |
Albumin mediated blood protein transport |
0.017819337 |
10.5 |
NaN |
|
ALB |
| axitinib |
Kinase inhibitor |
No |
Down |
Alternative complement pathway |
0.006925405 |
9.5 |
NaN |
|
C3;CFH |
| axitinib |
Kinase inhibitor |
No |
Up |
Antigen presentation via MHC class I molecules |
0.012941091 |
8 |
NaN |
|
HLA-B;HLA-C |
| axitinib |
Kinase inhibitor |
No |
Up |
Axonal intermediate filament dynamics |
0.006255506 |
5 |
NaN |
|
NEFM;NES |
| axitinib |
Kinase inhibitor |
No |
Down |
Bone morphogenetic protein receptor signaling |
0.020689638 |
15 |
NaN |
|
BMP2;BMP7;CHRD |
| axitinib |
Kinase inhibitor |
No |
Down |
Chloride transmembrane transport |
0.046834922 |
18 |
NaN |
|
SLC12A7;SLC26A8 |
| axitinib |
Kinase inhibitor |
No |
Down |
Cholesterol synthesis |
0.001813198 |
5 |
NaN |
|
DHCR7;HMGCS1;MSMO1;MVD |
| axitinib |
Kinase inhibitor |
No |
Down |
Class switch recombination |
0.013817206 |
12 |
NaN |
|
BCL6;IL7R;IRF4 |
| axitinib |
Kinase inhibitor |
No |
Down |
Collagen fibril organization by fibril-associated bridges |
0.010202989 |
11 |
NaN |
|
COL12A1;COL9A2 |
| axitinib |
Kinase inhibitor |
No |
Down |
Contractile ring constriction |
0.006925405 |
9.5 |
NaN |
|
ANLN;MYLK |
| axitinib |
Kinase inhibitor |
No |
Up |
Decorin synthesis |
0.017819337 |
10.5 |
NaN |
|
DCN |
| axitinib |
Kinase inhibitor |
No |
Down |
Desaturation of fatty acids |
0.014030212 |
13.5 |
NaN |
|
FADS2;SCD |
| axitinib |
Kinase inhibitor |
No |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.008563218 |
7 |
NaN |
|
ADAM33;ADAMTS5;ADAMTS6 |
| axitinib |
Kinase inhibitor |
No |
Down |
Extracellular matrix breakdown and membrane shedding by adamalysins |
3.35E-05 |
1 |
NaN |
|
ADAMTS1;ADAMTS12;ADAMTS14;ADAMTS15;ADAMTS2;ADAMTS7 |
| axitinib |
Kinase inhibitor |
No |
Down |
Extracellular matrix breakdown by cathepsins |
0.028496482 |
16 |
NaN |
|
CTSH;CTSV |
| axitinib |
Kinase inhibitor |
No |
Down |
Extracellular matrix breakdown by heparanases and sulfatases |
0.004230807 |
8 |
NaN |
|
SULF1;SULF2 |
| axitinib |
Kinase inhibitor |
No |
Down |
Extracellular matrix breakdown by matrix metalloproteases |
0.001463495 |
4 |
NaN |
|
MMP14;MMP2;MMP3 |
| axitinib |
Kinase inhibitor |
No |
Up |
Extrinsic apoptosis pathway |
0.006255506 |
5 |
NaN |
|
FAS;TNFRSF10A |
| axitinib |
Kinase inhibitor |
No |
Up |
Fibrillar collagen core structure organization |
1.89E-05 |
1 |
NaN |
|
COL11A2;COL1A1;COL1A2;COL3A1 |
| axitinib |
Kinase inhibitor |
No |
Down |
Glutamate and glutamine metabolism |
0.046834922 |
18 |
NaN |
|
SLC1A5;SLC7A5 |
| axitinib |
Kinase inhibitor |
No |
Down |
Glycolysis and Gluconeogenesis |
0.000317571 |
3 |
NaN |
|
LDHA;PCK2;PFKFB3;PFKFB4;PGK1 |
| axitinib |
Kinase inhibitor |
No |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.035322689 |
14.5 |
NaN |
|
JUND |
| axitinib |
Kinase inhibitor |
No |
Down |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.00215396 |
7 |
NaN |
|
A2M;PLAT |
| axitinib |
Kinase inhibitor |
No |
Up |
Natriuretic peptide receptor signaling |
0.004521101 |
3 |
NaN |
|
NPPA;NPPB |
| axitinib |
Kinase inhibitor |
No |
Up |
Non-vesicular phospholipid transport |
0.006255506 |
5 |
NaN |
|
PITPNB;PITPNM1 |
| axitinib |
Kinase inhibitor |
No |
Down |
Non-vesicular phospholipid transport |
0.014030212 |
13.5 |
NaN |
|
PLTP;SCP2 |
| axitinib |
Kinase inhibitor |
No |
Up |
Notch receptor signaling |
0.048646647 |
16 |
NaN |
|
DLK1;NOTCH3 |
| axitinib |
Kinase inhibitor |
No |
Down |
Restriction point |
0.002048978 |
6 |
NaN |
|
CCND1;CDKN1A;PFKFB3 |
| axitinib |
Kinase inhibitor |
No |
Down |
Retinol metabolism |
0.046834922 |
18 |
NaN |
|
ALDH1A3;DHRS3 |
| axitinib |
Kinase inhibitor |
No |
Down |
Serine and glycine metabolism |
0.000149752 |
2 |
NaN |
|
PHGDH;PSAT1;SHMT2;SLC1A5 |
| axitinib |
Kinase inhibitor |
No |
Up |
Thin myofilament organization |
0.000185089 |
2 |
NaN |
|
ACTA1;TNNI3;TPM2 |
| axitinib |
Kinase inhibitor |
No |
Up |
Tropoelastin synthesis |
0.017819337 |
10.5 |
NaN |
|
ELN |
| axitinib |
Kinase inhibitor |
No |
Up |
Versican receptor signaling |
0.035322689 |
14.5 |
NaN |
|
VCAN |
| axitinib |
Kinase inhibitor |
No |
Up |
Versican synthesis |
0.017819337 |
10.5 |
NaN |
|
VCAN |
| axitinib |
Kinase inhibitor |
No |
Up |
Z-disc organization |
0.032179035 |
13 |
NaN |
|
CSRP3;PDLIM3 |
| amiodarone |
Antiarrhythmic |
No |
Down |
Actin polymerization |
0.046827129 |
19 |
NaN |
|
ABRA;ACTA1;ENAH;HSPB1 |
| amiodarone |
Antiarrhythmic |
No |
Up |
Adenylyl cyclase signaling pathway |
0.020631434 |
10 |
NaN |
|
PDE3A;RAPGEF3 |
| amiodarone |
Antiarrhythmic |
No |
Up |
Adherens junction organization |
0.014224113 |
9 |
NaN |
|
ALCAM;CGNL1;RAPGEF3 |
| amiodarone |
Antiarrhythmic |
No |
Up |
Alternative complement pathway |
1.85E-05 |
1 |
NaN |
|
C1S;C3;CFH |
| amiodarone |
Antiarrhythmic |
No |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.012675119 |
8 |
NaN |
|
KCNIP2;KCNJ2 |
| amiodarone |
Antiarrhythmic |
No |
Down |
CCN intercellular signaling protein family receptor signaling |
0.009900042 |
8.5 |
NaN |
|
CTGF;CYR61 |
| amiodarone |
Antiarrhythmic |
No |
Up |
Cellular cholesterol uptake and efflux |
0.010952979 |
6 |
NaN |
|
ABCA1;ABCG1 |
| amiodarone |
Antiarrhythmic |
No |
Up |
Classical complement pathway |
0.003096655 |
5 |
NaN |
|
C1R;C1S |
| amiodarone |
Antiarrhythmic |
No |
Down |
Collagen fibril organization by fibril-associated bridges |
0.014532096 |
13 |
NaN |
|
COL12A1;COL9A2 |
| amiodarone |
Antiarrhythmic |
No |
Down |
Connection of muscle sarcomere to plasma membrane |
0.040004807 |
17 |
NaN |
|
DES;SYNM |
| amiodarone |
Antiarrhythmic |
No |
Up |
Decorin synthesis |
0.01243825 |
7 |
NaN |
|
DCN |
| amiodarone |
Antiarrhythmic |
No |
Down |
Epithelial intermediate filament dynamics |
0.001695869 |
6 |
NaN |
|
KRT19;KRT7;KRT8 |
| amiodarone |
Antiarrhythmic |
No |
Up |
Extracellular matrix breakdown and membrane shedding by adamalysins |
0.035460509 |
13 |
NaN |
|
ADAMTS14;ADAMTS2 |
| amiodarone |
Antiarrhythmic |
No |
Up |
Extracellular matrix breakdown by heparanases and sulfatases |
0.048838754 |
15 |
NaN |
|
SULF1 |
| amiodarone |
Antiarrhythmic |
No |
Up |
Fibrillar collagen core structure organization |
0.000212048 |
3 |
NaN |
|
COL1A1;COL3A1;COL5A2 |
| amiodarone |
Antiarrhythmic |
No |
Down |
Fibrillar collagen core structure organization |
0.040004807 |
17 |
NaN |
|
COL11A1;COL2A1 |
| amiodarone |
Antiarrhythmic |
No |
Down |
Glycogen synthesis and glycogenolysis |
0.013976325 |
11 |
NaN |
|
GYG1;GYS1;PYGB |
| amiodarone |
Antiarrhythmic |
No |
Down |
Glycolysis and Gluconeogenesis |
5.71E-06 |
2 |
NaN |
|
ALDOA;ENO1;HK2;LDHA;PGAM1;PGK1;TPI1 |
| amiodarone |
Antiarrhythmic |
No |
Down |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.0010568 |
4 |
NaN |
|
JAK2;JUND |
| amiodarone |
Antiarrhythmic |
No |
Up |
Hemoglobin and myoglobin synthesis |
0.036855754 |
14 |
NaN |
|
MB |
| amiodarone |
Antiarrhythmic |
No |
Up |
Hepatocyte growth factor receptor signaling |
0.024722873 |
11.5 |
NaN |
|
HGF |
| amiodarone |
Antiarrhythmic |
No |
Up |
Inhibition of amyloid aggregation, amyloid degradation and uptake |
0.000457111 |
4 |
NaN |
|
A2M;MME |
| amiodarone |
Antiarrhythmic |
No |
Down |
Macrophage migration inhibitory factor signaling |
0.009900042 |
8.5 |
NaN |
|
ACKR3;JUND |
| amiodarone |
Antiarrhythmic |
No |
Down |
Microtubule crosslinking and bundling |
0.014532096 |
13 |
NaN |
|
MAP2;MTCL1 |
| amiodarone |
Antiarrhythmic |
No |
Down |
Myofibril formation |
0.040004807 |
17 |
NaN |
|
DES;XIRP1 |
| amiodarone |
Antiarrhythmic |
No |
Down |
Natriuretic peptide receptor signaling |
0.014532096 |
13 |
NaN |
|
NPPA;NPPB |
| amiodarone |
Antiarrhythmic |
No |
Down |
Osteopontin receptor signaling |
0.032551164 |
15 |
NaN |
|
SPP1 |
| amiodarone |
Antiarrhythmic |
No |
Down |
Recycling endosome dynamics |
0.012188594 |
10 |
NaN |
|
RAB11FIP1;RAB11FIP5;RAB15;SNAP23 |
| amiodarone |
Antiarrhythmic |
No |
Down |
Retinol metabolism |
0.007672487 |
7 |
NaN |
|
ALDH1A1;ALDH1A3;STRA6 |
| amiodarone |
Antiarrhythmic |
No |
Up |
Semaphorin signaling |
5.77E-05 |
2 |
NaN |
|
NRP2;PLXNA4;PLXNC1;SEMA6A;SEMA6D |
| amiodarone |
Antiarrhythmic |
No |
Up |
Serotonin inactivation |
0.024722873 |
11.5 |
NaN |
|
MAOA |
| amiodarone |
Antiarrhythmic |
No |
Down |
Thin myofilament organization |
0.001086055 |
5 |
NaN |
|
ACTA1;TNNI3;TPM2 |
| amiodarone |
Antiarrhythmic |
No |
Down |
Thrombospondin receptor signaling |
0.000133563 |
3 |
NaN |
|
CD47;THBS2;THBS4 |
| amiodarone |
Antiarrhythmic |
No |
Down |
Z-disc organization |
3.25E-07 |
1 |
NaN |
|
ACTN2;CSRP3;DES;DYSF;NEXN;PDLIM3;TCAP |
| afatinib |
Kinase inhibitor |
No |
Up |
Actin polymerization |
0.017971346 |
7 |
NaN |
|
ABRA;ACTA1;HSPB1;TMSB10 |
| afatinib |
Kinase inhibitor |
No |
Down |
Albumin mediated blood protein transport |
0.022230064 |
22.5 |
NaN |
|
ALB |
| afatinib |
Kinase inhibitor |
No |
Up |
Axonal intermediate filament dynamics |
0.011202506 |
5 |
NaN |
|
NEFH;NEFM |
| afatinib |
Kinase inhibitor |
No |
Up |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.043457985 |
12 |
NaN |
|
KCNIP2;KCNQ5 |
| afatinib |
Kinase inhibitor |
No |
Down |
Cardiomyocyte repolarization during action potential and hyperpolarization |
0.037567125 |
25 |
NaN |
|
KCNJ2;KCNQ1 |
| afatinib |
Kinase inhibitor |
No |
Up |
CD44-Mediated leukocyte rolling |
0.047587241 |
14.5 |
NaN |
|
CD44 |
| afatinib |
Kinase inhibitor |
No |
Down |
Centrosome maturation |
0.002058279 |
14 |
NaN |
|
AURKA;PLK1;TPX2 |
| afatinib |
Kinase inhibitor |
No |
Down |
Centrosome separation |
2.80E-10 |
1 |
NaN |
|
AURKA;CCNB1;CDK1;ESPL1;KIF11;NEK2;SPAG5 |
| afatinib |
Kinase inhibitor |
No |
Up |
Chaperone-mediated autophagy |
0.047587241 |
14.5 |
NaN |
|
HSPA8 |
| afatinib |
Kinase inhibitor |
No |
Down |
Cholesterol synthesis |
3.39E-06 |
3 |
NaN |
|
DHCR24;DHCR7;HMGCS1;MSMO1;MVD;MVK |
| afatinib |
Kinase inhibitor |
No |
Down |
Cholesterol-sensitive control of SREBP activation |
0.006960163 |
19 |
NaN |
|
INSIG1;SREBF1 |
| afatinib |
Kinase inhibitor |
No |
Down |
Collagen fibril organization by fibril-associated bridges |
0.000206611 |
7.5 |
NaN |
|
COL9A1;COL9A2;COL9A3 |
| afatinib |
Kinase inhibitor |
No |
Down |
Contractile ring constriction |
0.004708979 |
17 |
NaN |
|
ANLN;ECT2 |
| afatinib |
Kinase inhibitor |
No |
Down |
Equatorial RhoA activation |
0.002867401 |
16 |
NaN |
|
ECT2;KIF23 |
| afatinib |
Kinase inhibitor |
No |
Down |
Eukaryotic kinetochore dynamics |
1.07E-07 |
2 |
NaN |
|
BUB1;CENPE;CENPF;CENPI;NDC80;NUF2;SPC24;TTK;ZWINT |
| afatinib |
Kinase inhibitor |
No |
Up |
Extracellular matrix breakdown by matrix metalloproteases |
0.018603478 |
8 |
NaN |
|
MMP12;MMP3 |
| afatinib |
Kinase inhibitor |
No |
Up |
Fibrillar collagen core structure organization |
0.001462167 |
2 |
NaN |
|
COL1A1;COL5A1;COL5A2 |
| afatinib |
Kinase inhibitor |
No |
Down |
Fibrillar collagen core structure organization |
0.001160324 |
10 |
NaN |
|
COL11A1;COL11A2;COL2A1 |
| afatinib |
Kinase inhibitor |
No |
Down |
G2 M transition checkpoint |
0.002058279 |
14 |
NaN |
|
CCNB1;CDC25C;CDK1 |
| afatinib |
Kinase inhibitor |
No |
Down |
GABA metabolism |
0.006960163 |
19 |
NaN |
|
ABAT;SLC6A1 |
| afatinib |
Kinase inhibitor |
No |
Up |
Glycolysis and Gluconeogenesis |
0.01713221 |
6 |
NaN |
|
HK2;LDHA;PFKFB3 |
| afatinib |
Kinase inhibitor |
No |
Up |
Granulocyte macrophage colony-stimulating factor receptor signaling |
0.047587241 |
14.5 |
NaN |
|
JAK2 |
| afatinib |
Kinase inhibitor |
No |
Down |
Hepatocyte growth factor receptor signaling |
0.043967869 |
28 |
NaN |
|
MET |
| afatinib |
Kinase inhibitor |
No |
Down |
Inhibition of apoptosis |
0.002058279 |
14 |
NaN |
|
BIRC5;IFI6;XAF1 |
| afatinib |
Kinase inhibitor |
No |
Down |
Intracellular bridge assembly |
0.001455058 |
11 |
NaN |
|
INCENP;KIF23 |
| afatinib |
Kinase inhibitor |
No |
Down |
Lipogenesis |
0.043967869 |
28 |
NaN |
|
FASN |
| afatinib |
Kinase inhibitor |
No |
Down |
Metaphase to anaphase checkpoint |
7.95E-06 |
5 |
NaN |
|
BUB1;BUB1B;CCNB2;CDC20;CENPE;PTTG1;TTK |
| afatinib |
Kinase inhibitor |
No |
Down |
Methionine cycle |
0.043967869 |
28 |
NaN |
|
BHMT |
| afatinib |
Kinase inhibitor |
No |
Down |
Mitotic H3 phosphorylation and dephosphorylation |
0.000105033 |
6 |
NaN |
|
AURKB;CCNA2;INCENP |
| afatinib |
Kinase inhibitor |
No |
Down |
Mitotic spindle assembly |
5.80E-06 |
4 |
NaN |
|
DLGAP5;NUSAP1;TACC3;TPX2;TTK |
| afatinib |
Kinase inhibitor |
No |
Down |
Mitotic spindle disassembly |
0.022230064 |
22.5 |
NaN |
|
CDK1 |
| afatinib |
Kinase inhibitor |
No |
Up |
Muscarinic receptor signaling |
0.008130369 |
4 |
NaN |
|
RGS4;RGS5 |
| afatinib |
Kinase inhibitor |
No |
Up |
Myofibril formation |
0.022888806 |
9 |
NaN |
|
DES;KLHL41 |
| afatinib |
Kinase inhibitor |
No |
Down |
Natriuretic peptide receptor signaling |
0.006960163 |
19 |
NaN |
|
NPPA;NPPB |
| afatinib |
Kinase inhibitor |
No |
Up |
Platelet-derived growth factor receptor signaling |
0.027536352 |
10 |
NaN |
|
PDGFRA;RGS5 |
| afatinib |
Kinase inhibitor |
No |
Down |
Removal of caspase inhibition |
0.043967869 |
28 |
NaN |
|
XAF1 |
| afatinib |
Kinase inhibitor |
No |
Up |
Retinol metabolism |
0.037839646 |
11 |
NaN |
|
ALDH1A2;ALDH1A3 |
| afatinib |
Kinase inhibitor |
No |
Down |
Serine and glycine metabolism |
0.00156935 |
12 |
NaN |
|
PHGDH;PSAT1;SHMT2 |
| afatinib |
Kinase inhibitor |
No |
Down |
Sister chromatid attachment to mitotic spindle |
0.000492258 |
9 |
NaN |
|
NUF2;TACC3 |
| afatinib |
Kinase inhibitor |
No |
Down |
Sister chromatid segregation |
0.000206611 |
7.5 |
NaN |
|
ESPL1;PTTG1;TOP2A |
| afatinib |
Kinase inhibitor |
No |
Down |
Tropoelastin synthesis |
0.022230064 |
22.5 |
NaN |
|
ELN |
| afatinib |
Kinase inhibitor |
No |
Up |
Vasoactive intestinal peptide receptor signaling |
0.047587241 |
14.5 |
NaN |
|
VIPR2 |
| afatinib |
Kinase inhibitor |
No |
Down |
Versican receptor signaling |
0.043967869 |
28 |
NaN |
|
VCAN |
| afatinib |
Kinase inhibitor |
No |
Down |
Versican synthesis |
0.022230064 |
22.5 |
NaN |
|
VCAN |
| afatinib |
Kinase inhibitor |
No |
Up |
Water transmembrane transport |
0.000707235 |
1 |
NaN |
|
AQP1;AQP3;AQP7 |
| afatinib |
Kinase inhibitor |
No |
Up |
WNT-Beta-catenin signaling pathway |
0.004299451 |
3 |
NaN |
|
APCDD1;DKK2;DKK3;FZD1;FZD2;FZD8 |